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The thesis entitled "Molecular Recognition: Preparation and Identification of 
Inclusion Compounds of Pharmaceutical with Cyclodextrin" is comprised of an 
ntroduction, a general discussion and H NMR spectroscopic study of inclusion 
complexes of five pharmaceutical compounds with (3-cyclodextrin ((3-CD). 
The introduction describes a brief historical background, structures of CDs and its 
derivatives, examples of various industrial applications of CDs inclusion complexes, 
with the main emphasis in the area of pharmaceuticals, chiral recognition by the CDs. 
The general discussion deals with the use of H NMR spectroscopy in the study of 
CD-inclusion complexes. There are five chapters on the study of inclusion complexes 
of pharmaceutical compounds with P-CD. The objective of the study was to 
characterize the structures of the complexes formed in aqueous solution because the 
use of these complexes for pharmaceutical purposes requires the establishment of 
their structures. 
CDs are doughnut shaped molecules composed of glucose units joined through 
a-(l-4) linkage. Three most common, industrially important, a-, (3- and y-CDs are 
composed of 6, 7 and 8 glucose units, respectively. The primary hydroxyl groups (n) 
are located at the narrower rim while wider rim is lined with secondary hydroxyl 
groups (2n). The outer surface of the CDs is highly hydrophilic due to the presence of 
large number of hydroxyl groups while the CD cavity is relatively hydrophobic. 
Considering the presence of 18(a-CD), 21(p-CD) and 24(y-CD) substitutable 
hydroxyl groups and involving cleavage of either 0-H, C-0 or C-C bonds, the 
number of possible derivatives of CDs are unlimited. Functionalization of CDs 
concerns complete or partial functionalization of hydroxy Is. By virtue of their shape 
and hydrophobic nature of cavity, CDs accommodate a variety of hydrophobic 
molecules, or hydrophobic part of the molecules, inside their cavity through non-
covalent interactions to form inclusion complexes. Inclusion of the guest into the CI) 
cavity results in altered physicochemical properties of the guest, like solubility. 
stability and volatility etc., which have found numerous applications in the field oJ 
pharmaceuticals. 
Biological systems are largely constructed from chiral molecules such as L-amino 
acids and D-sugars. In this highly chiral environment it is not surprising that drugs. 
which possess asymmetric center/s, exhibit a high degree of stereoselectivity in their 
interactions with biological macromolecules. It may be highly desirable to have all the 
activity in one enantiomer of the drug so as to avoid the unwanted activity and/or 
toxicity that may reside in the antipode but examples where this has been proven to be 
true are uncommon. The separation of enantiomers and their characterization are. 
therefore, of great importance for the pharmaceutical industry. CDs are chiral 
molecules and exhibit chiral recognition, i.e., they differentiate between enantiomeric 
species, forming diastereomeric complexes. Enantioselectivity of recognition is a 
thermodynamic quantity correlating in some way with the separation factor ot 
enantiomers in separation techniques. It must be noted that among presently applied 
chiral selectors only CDs are effectively used in all enantioseparation techniques. A 
better understanding of the inclusion complex formation and the chiral recognition 
mechanism of CDs is, therefore, a subject of great importance. 
NMR spectroscopy is an important technique to study inclusion complexes. The 
formation of an inclusion complex between a guest and CD results in the chemical 
shift changes in both the host and guest protons. The highfield shift changes in the CD 
cavity protons confirm the penetration of the guest into the CD cavity. The guest 
protons generally show downfield shift changes upon complexation but all the protons 
and not only the part included in the cavity display these changes. Sometmics 
highfield shift changes in the guest proton signals are also observed. Determination ot 
stoichiometry of the complex is required, for any ftirther investigation of the complex, 
which is usually achieved by NMR titrations studies. Nuclear Overhauser Effect 
(NOE) studies are used to fully characterize the inclusion complexes. It gives 
information about the part of the guest included inside the CD cavity, the mode ot 
penetration, i.e. either from narrower or wider rim side, the depth of penetration and 
orientation of the guest. 
'H NMR spectroscopic studies of complexation of venlafaxine hydrochloride, 
triprolidine hydrochloride, D-(-)-chloramphenicol, fluoxetine hydrochloride and 
parecoxib sodium with P-CD were carried out. In all the cases, the chemical shift 
changes in the proton resonances of studied compounds and P-CDs cavity protons 
were observed in the spectra of mixtures of pharmaceutical compounds and P-CD 
compared to pure component. P-CD cavity protons, namely H-3' and H-5', showed 
significant highfield shift changes in the presence of drug while other protons 
generally showed insignificant chemical shift changes. Stoichiometry and overall 
binding constant of the inclusion complexes were determined by reported 'H NMR 
titration methods. The mode of penetration and orientation of the guest molecule into 
the p-CD cavity were established by ROESY spectral data in all the studied cases. 
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P-cyclodextrin Model showing shape of p-cyclodextrin 
Venlafaxine hydrochloride (VEN) forms a 1:1 VEN-P-CD inclusion complex in 
solution, under studied experimental conditions, by the deep penetration of the 
aromatic ring of Venlafaxine hydrochloride into the P-CD cavity from narrower rim 
side. The structure for the VEN-P-CD has been deduced. 
Triprolidine hydrochloride (TRP) has two aromatic rings; a p-tolyl and a pyridyl ring. 
Complexes involving both the rings v^ere found to be present in solution. It was found 
that TRP forms two 1:1 inclusion complexes when the concentration of p-CD was 
less than or equal to that of TRP ([(3-CD] < [TRP]) and as the concentration of P-CD 
further increases, the two 1:1 complexes take up another molecule of P-CD to torm 
1:2 TRP-P-CD complexes. The mode and depth of penetration of the aromatic rings 
were established clearly and structures for all the complexes formed between TRP and 
P-CD were proposed. It was also found that the complexes involving p-tolyl ring 
appeared to be more stable. 
The detailed ' H N M R spectroscopic study of D-(-)-chloramphenicol (CHL) and 
CHL-P-CD mixtures revealed the presence of two tautomeric forms in the solution 
and both of these tautomers were found to be involved in the formation of inclusion 
complexes with p-CD. Thus two 1:1 CHL-P-CD inclusion complexes were identified, 
for keto as well as enol forms, formed by the deep penetration of aromatic ring 
into P-CD cavity from the wider rim side. The structures for complexes formed 
between CHL and P-CD have been proposed. 
Fluoxetine hydrochloride (FHL) has two aromatic rings and both of these rings were 
confirmed to be involved in the inclusion complex formation with P-CD. Two 1:1 
FHL-p-CD diastereomeric inclusion complexes were characterized by the detailed 
' H NMR spectroscopic study. One complex was formed by the deep penetration of 
trifluoromethyl substituted aromatic ring into the P-CD cavity from wider rim side 
while other complex was formed by the shallow penetration of phenyl ring of 
fluoxetine into the P-CD cavity from the wider rim side. 
The detailed ' H N M R spectroscopy study of parecoxib (PRB) and mixtures of parecoxib 
and P-Cf), in aqueous solution confirmed the formation of four different types of 1:1 
inclusion complexes, involving penetration of both the aromatic rings into the (i-C 1) 
cavity from narrower as well as from wider rim sides. The structures for all the probable 
PRB-P-CD complexes, present in solution, have been proposed. 
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J?xm and OBjective 
The objective of the work embodied in this thesis was to study the complexation of various 
pharmaceutical compounds with P-cyclodextrin in aqueous solution. Complexation ot a 
pharmaceutical compound with cyclodextrins, to form a host-guest complex, result in 
altered various physicochemical properties of the guest, like solubility, stability, volatilit\ 
and masking of undesirable properties etc., which are desirable for their use as 
pharmaceuticals. Moreover, these host-guest complexes are considered as new entities and 
are required to be characterized for their approval as a drug. Cyclodextrins are chiral 
molecules and differentiate between enantiomeric species. Enantioselectivity of recognition 
is related in some way to the separation factor of enantiomers in separation techniques. The 
separation of enantiomers of aracemic drug is of great importance to the pharmaceutical 
industry because in a racemic drug one enantionmer is usually unwanted. NMR 
spectroscopy is very useful tool to undertand the mechanism of chiral recognition and a 
better understanding of the subject will help in the use of cyclodextrins as chiral selectors 
in various separation techniques. 
?^T!^?>^!^r!^?^?^!SJ?ESSS!S7!^Sv^5?^5^S?S?!w?I5^^ftS5IS^^ 
CKji^PT^<RjL... 
Introduction 
••••r.^/i7>»i-.»»««»»mt«»^..i»»»mfm»«i»if»ig«»^ 
1.1 CyclhcCej(trin !Htstory 
Supramolecular chemistry, is the discipline which involves all kinds of interactions where 
covalent bonds are not formed between the interacting species. The majority of these 
interactions are of the host-guset type. Among all the potential hosts, the cyclodextrm^ 
(CDs) are the most important. 
In 1891 Villiers isolated a crystalline substance, which later proved to be a cyclodexlrin 
(CD), by digesting starch with Bacillus amylobactor and determined its composition to be 
(C(,Hi(i05)2.3HiO. He named this substance as "cellulosine" simply because it resembled 
cellulose."' Twelve years later, Schardinger observed the same substance and was able tr^  
isolate and eaxmine it, Schardinger was the first to extensively study CDs and for thi--
reason CDs are also referred to as "Schardinger dextrins".^ However, it was not until the 
1930s that Freudenberg and coworkers'*' ^ established the structure of CDs. based parti} on 
their own studies and partly on the observations published by Miekely.'' and others. In 
1950s, the chemical process for the production of CDs was thoroughly investigated b\ 
French and coworkers and the existence of larger CDs was confirmed. Also, during thi^ 
time Cramer et, al. first began to uncover the CDs potential as complex forming agents 
They examined the ability of CDs to complex with a variety of drug moleules. and noteJ 
the stabilization, volatility reduction, and solubility changes that occurred as a result t ' 
complex formation of drugs with CDs. They subsequently obatained a patent in 1953 thai 
coxered practically all of the most important aspects of applications of CDs m druLi 
formulations.'" The number of patents and papers on CDs have increased exponentialh 
since then. In 1981 the first International Symposium on Cyclodextrins was organized 
Since then onward, symposia have been held every second year and presentations haxc 
increased both in quantity and quality. Moreover, while in 1970 the price of 1 Kg of p-Cl) 
was around US$ 2000, and it was available only as a rare fine chamical. li is a relati\el\ 
inexpensive material and an important industrial commodity now in many ways. Also. a-. 
[3- and y-CDs, as well as several of their derivatives are produced industrially and used in 
various chromatographic methods, or are studied as potential drug carriers, stabilizers, 
catalysts, etc. 
Structure of Cylodextrins 
The three most common - a , -p , and y-CDs, consisting of six, seven, and eight 
glucopyranose units, respectively, are linked through a-(l-^4) glycosidic bonds (Fig. ! 
and 2). The internal diameter of the three CDs increases with the number of glucose units 
while the height remains constant at 7.9 A°. The glucose units are in rigid '^ Ci chair 
conformation giving them a toroidal shape with all the secondary hydroxyl groups, 
0(2)-H and 0(3)-H (2n), located on the wider rim while all the primary hydroxyl groups. 
0(6)-H (n), on the narrower rim. The primary hydroxyls on the narrow side of the ca\it\ 
can rotate, thus partially blocking the cavity, in contrast to the secondary hydroxyls. which 
are attached b>' relatively rigid chains and thus can not rotate. 
The interior of the cavity is lined with (from secondary hydroxyl rim inwards) a row of CI 1 
groups (the C-3 carbons), then a row of glycosidic oxygen, and then a row of C-5 CI! 
groups. Intramolecular hydrogen bonds 0(3)-H' 0(2)-H or 0(3) H-0(2) exist between 
the secondary hydroxyl groups of adjacent glucose units, forming a complete secondar\ 
belt in P-CD. This hydrogen bond belt is incomplete in a-CD molecule due to the presence 
of one glucose unit in distorted position. The y-CD has a non-polar and more flexible 
structure. The non-bonding electron pairs, of the glycosidic oxygen atom, are directed 
towards inside of the cavity producing a high electron density and giving the cavity some 
Lewis base character. The interior of the cavity is hydrophobic while the exterior is 
hydrophilic. 
Table 1 gives some of the physical properties of the a-, p- and y-CDs. 
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Fig. 1 Frontier structural representation ofcyclodextrins. 
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Fig. 2 Representation of molecular dimensions ofcyclodextrins. 
Table 1 Some physicochemica! properties of a-, /?- and y-cyclodextrins 
S.N. 
1. 
2. 
3. 
5. 
6. 
Property 
No. glucose units 
Appearance 
Mol. Wt. (anhydrous) 
Solubility (water, %) 
Cavity diameter, A*^  
a 
6 
White crystalline 
powder 
972.85 
14.5 
4.9 
Cyclodextrin 
P 
7 
White crystalline 
Powder 
1134.99 
1.85 
6.2 
Y 
8 
White crvstalline 
powder 
1297.14 
23.2 
7.9 
Cyclodextrin Derivatives/Modified Cyclodextrins 
Today, a number of derivatives of CDs are formed and being used in various ways. Various 
functional groups can covalently be attached to the hydroxyl groups.'^'' The complexation 
behaviour of CDs is altered when the hydroxyl groups are modified. 
Considering the presence of 18(a-CD), 21(P-CD) and 24(y-CD) substitutable hydroxyl 
groups and involving cleavage of either 0-H, C-0 or C-C bonds, the number of possible 
derivatives of CDs are unlimited. All the known CDs derivatives can be classified 
as carriers (solubilizers, stabilizers) for biologically active substances, enzyme 
models, separating agents (for chromatography), catalysts and additives (as 
detergents, viscosity modifiers etc.).'" '^ '"* Actually, methylated CDs (randomly methylated-
f3-CD). hydroxyalkylated-CDs (hydroxypropyl-P-CD and hydroxypropyl-y-CD) and 
branched CDs (glycosyl- and maltosyl-P-CD) are produced due to cost/benefit ratio. 
Complexation with such functionalized CDs can also take place in organic solvents since 
many of the functionalized CDs are soluble in organic solvents. Functionalization of CDs 
can concern complete sets of hydroxyls or partial functionalization. Commercial 
derivatives of cyclodextrins arc shown in Table 2. 
Table 2 Chemical structures of cyclodextrin derivatives. 
H2OR3 
N« 
Compound R i 
Hydrophilic Derivatives 
Methylated cyclodextrins 
3-Mono-O-methylcyclodextrins 
2, 6-Di-O-methylcyclodextrins 
2, 3, 6,-Tri-O-methylcyclodextrins 
Randomly methylated cyclodextrins 
Hydroxyalkylated cyclodextrins 
2-Hydroxyethylcyclodextrins 
2-Hydroxypropylcyclodextrins 
3-Hydroxypropylcyclodextrins 
2, 3-Dihydroxypropylcyclodextrins 
Branched cyclodextrins 
6-0-Glucosylcyclodextrins 
6-0-Maltosylcyclodextrins 
2, 6-0-Dimaltosylcyclodextrins 
H 
CH3 
CH3 
R,,R2,R3 = H( 
R,,R2,R3 = H 
R,,R2,R3 = H 
Ri,R2,R3 = H 
R,,R2,R3 = H 
H 
H 
Maltose 
Hydrophobic Derivatives 
Alkylated cyclodetrins 
2, 6-Di-O-cthylcyclodextrins 
2. 3, 6-Tri-O-ethylcyclodextrins 
Acylated cyclodextrins 
2, 3-Di-O-hexanoylcyclodextrins 
2. 3. 6-Tri-O-acetylcyclodextrins 
2. 3. 6-Tyi-O-propanoylcyclodexIrins 
2. 3, 6-Tri-O-butanoylcyclodextrins 
2. 3, 6-Tri-O-valerylcyclodextrins 
2. 3. 6-Tri-O-hexanoylcyclodextrins 
2, 3, 6-Tri-O-octanoylcyclodextrins 
C2HS 
C2H5 
COC5H,, 
COCH3 
COC2H5 
COC3H7 
COC4H9 
COC5H1, 
COC7H,5 
lonizable Derivatives 
Anionic cyclodextrins 
6-0-fCarboxymethyIjcyclodextrins 
6'0-(Carhoxymethyl)-2,3-di-0-
elhylcyclodextrins 
Cyclodextrin sulfates 
Sulfohulylcyclodextrins 
'N = 6. a-CDs; N = 7. p-CDs; N = 8, y-CDs; N = 
H 
C2H5 
R,,R2, R3 = H 
R|, R2, R3 ~ 11 
 9, 8-CDs 
R2 
CH3 
H 
CH3 
3rCH3 
or CH2CH2OH 
or CH2CH (OH) 
R3 
H 
CH:, 
CH; 
CH3 
or CH2CH2CH2OH 
or CH2CH (OH) CH2OH 
H 
H 
H 
H 
C2H5 
COC5H11 
COCH3 
COC2H5 
COC3H7 
C0C4Hq 
COC5H1, 
COC7H15 
H 
C2H5 
or S03Na 
or (CH2)4S03Na 
Glucose 
Maltose 
Maltose 
C2H-
C2H. 
H 
COCH; 
C0C21K-
COC3II-
COCjIi; 
COCH; 
COC-II;. 
CH2C0().\'a 
CH2C00Ma 
1.2. IncftistriaCjippCicatioTisofCyclhdexprins 
Today in industry, CDs and their derivatives are incorporated into a variety of items. CDs 
ability to form inclusion complexes with a variety of compounds has found usefulness in a 
multitude of areas. CDs are already in use in cosmetics, chewing gum, detergents, shampoo 
and toothpaste and for the formulation of drugs. Due to their nontoxic and non-hazardous 
nature. CDs have found applications in usually all kinds of everyday products. At present 
CDs have general approval for use as food additives in Japan and Hungary and for specific 
applications in France and Denmark. This section will include a broad but brief 
introduction into the different ways CDs and their derivatives are being used today in 
industry due to their ability to accommodate guest molecule in their cavity. The industrial 
applications of CDs have been divided into two parts: general applications and 
pharmaceuticals applications. Fig. 3 shows the structures of some compounds that ha\t' 
been utilized recently for the formation of complexes involving J3-CD derivatives. 
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/. QeneraCjippCications of CycCodexprins 
Solubility 
The solubility of a compound can be altered by complexation with a CD.'^' '^  The guest 
molecule in the cavity of the CD does not come in contact with the solvent. The outer 
surface of the CD interacts with the solvent, which contributes to the solubility of the 
complex and not the portion of the guest included in the CD cavity. Modification of the 
hydroxyl group of the outer surface of the CD markedly affects the solubility properties. 
Substitution of the hydroxyl groups with hydroxypropyl, carboxymethyl, tertiary amine or 
quaternary amine increases water solubility upto 60% or more. On the other hand, 
substitution of -OH groups with aliphatic groups such as hexyl or acetyl results in 
increased solubility in organic solvents. 
Dexamethorphan HBr. is a very bitter pediatric drug, which on complexing with CDs show 
significant differences (P < 0.01) between the plain drug and their P-CD complex, in 
solution/or in solid state, it was also observed that the addition of p-CD resulted in masking 
the bitter taste of dexamethorphan.''' Triterpenes which are water insoluble, such as 
oleanoic acid. Ursolic acid and gederogenin, could be solubilized upto 400 )ag/ml or more 
using CDs.'''' Phenylalanine, tyrosine and tryptophan units of the peptides complex well 
with CDs resulting in the formation of CD-peptide complex. Itraconazole is water insoluble 
and precipitates in the stomach therefore unavailable for absorption. Addition ol 
hydroxypropyl-p-CD prevents precipitation in the stomach, allowing use in an oral dosage 
formation.^" Some plant oils such as uroshiols, cause a rash and irritation when they come 
in contact with skin. Washing can result in spreading of the oils and increased irritation. 
These oils can be removed from skin by complexation with cyclodextrins especialh' y-C D 
and hydroxypropyl-P-CD.^' Large lipids such as ear wax can also be solubilized b> 
complexation with y-CD.'" 
The use of CDs can also increase the efficiency of biodegradation of hydrocarbons. In 
addition to increase the solubility of the hydrocarbons, toxicity is decreased, resulting in an 
increase in microbial and plant root growth. 
CDs have also been used for dying fabrics. Using CDs, more dye was absorbed on tlie 
fabric reducing the amount of dye left in the waste water. The solubility of the dye in water 
also increased and no auxiliaries were needed to slubilize the dye. A 3-fold increase in the 
binding of the fluorescent dye to polyester fiber was achieved using hydrophobic tos\i 
derivatives of p-CD.^'^ 
Viscosity of water-based paints during their manufacture can be controlled using CDs/" 
Thickeners are added to paints to impart desired viscosity properties. By complexing CI) 
with the thickener during the manufacture of the paints, the viscosity is reduced, making 
mixing easier. Viscosity is restored upon addition of paint components which displace the 
thickener from the cavity of the CD to give the paints its desired viscosity properties. 
Process Aids 
CDs have found invaluable roles as processing aids in industry. CD has been used in the 
removal of cholesterol from animal products. ' In one case, aqueous solution of CD was 
stirred with heated lard and tallow from which cholesterol was to be removed. Ihe CD 
forms complex with cholesterol which is insoluble in water or fat. The complex is remo\etl 
by filtration or centrifugation. The CD-cholesterol complex is then suspended in water and 
heated which results in decomposition of complex causing CD to be solubilized in water 
and cholesterol to lloat on the surface. This way upto 80% of cholesterol has been remoxed 
from some treated material and CDs and cholesterol are obtained as pure products. CD 
complexation of cholesterol has also been found useful in reducing dietary cholesterol 
intake.'^ Free fatty acids can also be removed from fats using CDs, improving the frying 
properties of the fat." 
Fruit and vegetable juice were treated with a p-CD polymer to remove polyphenolics 
responsible for enzymatic browning.^^ Naringen and limonene, the bitter components ol' 
citrus fruits, have been removed using a polymer of p-CD. Organic compounds need to 
be solubilized in water for bioconversions and therefore surfactants or solvents are used but 
these can be used in limited quantities because they affect the organism as well. By the use 
of methylated-p-CD. a 6-fold increase in the bioconversion rate of podophyllotoxin was 
achie\ed compared to bioconversion in the absence of CD.' 
Stabilization 
Compounds capable of making complexes with CDs are stabilized as a result ot^  
complexation, " because they cannot interact with other molecules. Moreover, there is 
steric hindrance, which prevents approach by a molecule to the exposed portion of the 
guest at the open cavities. Unsaturated fatty acids, for example in fish oil, are easily 
oxidized resulting in unpleasant taste and odour. These oils can be protected from oxidation 
by complexation with CD."^ Peroxyacids are used as bleaching agents and their thermal 
stability and storage are a matter of concern. Complexation with CDs not only improves 
storage and thermal stability but odour is also reduced and complex is stable without using 
dilutants.^ Nicardipine is sensitive to light and decomposes on exposing to light. Bv 
complexing with CDs, the rate of photodegradation can be reduced by a factor of 10 with 
methyl-P-CD, 8 with hydroxypropyl-p-CD, 6.5 with a-CD, and 5 with y-CD."*' 
Masking of the Guest Effects 
A guest molecule in the CD complex gets isolated, resulting in the masking of its various 
properties.^^' "^  This technique has been used in masking the unwanted flavour in food and 
skin irritation effects. Lotions have been developed in which a fragrant but irritation 
causing component is complexed with CD in order to limit its direct physical contact witli 
skin but still allowing evolution of the desired fragrance. Pilocarpine was administered as a 
prodrug. 0,0'-dipropionyl(l,4-xylenylene)bispilocarpine acid diester with hydrox\prop\i-
P-CD.'** Irritation was reduced as the amount of CD was increased. 
The use of CDs in can coating reduces/eliminates the off taste from can coating. 
Aldehydes and ketones containing 6-18 carbons are implicated in producing tastes similar 
to that of stale beer. Coatings were made with and without CD and extracted with, 
methylene chloride. Aldehydes (amount and kind) were extracted from the coatings which. 
did not contain CDs. demonstrating the ability of CDs to keep the undesirable flaxcr 
constituents out of the contents of the coated can. 
Reduction of Volatility 
Reduction of volatility and controlled release of chemicals are other important applications 
of CDs. Menthol, for example, forms an odourless complex with p-CD which can be dried 
at 100 C while free menthol will be completely volatilized under these conditions. The 
release of fragrance from laundary dryer sheets can be controlled by complexing the 
fragrance with CDs. ' 
Moreover, all the components of the fragrance have different volatility and some of the 
more highly volatile components are easily lost changing the composition of the fragrance. 
However, when these components are complexed with CDs, their volatility is reduced so 
that the character of the fragrance is not changed. CDs can also be used to prevent odour \\\ 
the skin tanning and hair care preparations. A dry powder of CD can be used in products 
such as menstrual products, diapers, tissues, paper towels etc.'*^ making them effecti\c 
scavengers of unwanted odours. Perfumes can also be complexed to CDs to be released 
upon dissolution of the complex and displacement by odiferous compounds. 
Directing of Chemical Reactions 
CDs are also used for the mediation of specific organic reactions. The formation ot 
host/guest complex, not only alter the parameters such as solubility, but inclusion of the 
part of the guest molecule into the CD-cavity offers significant steric shielding. This 
concept has been utilized in many ways for highly selective syntheses. 
2. 6-Naphthalenedicarboxylic acid is an important monomer for liquid crystalline polymer 
synthesis. Synthesis of 2, 6-Naphthalenedicarboxylic acid is difficult due to several 
reactive sites on the naphthalene ring leading to a range of products. It was found that when 
naphthalene was first complexed with CD then the yield of the desired 2, 6-product was 
greatly improved.'^ ^ The host CD sterically shielded the undesirable reaction sites on the 
naphtahalene ring. y-CD was used to accelerate the polymerization of p-styrene sulfonate. 
After 30 minutes of conversion, 89% conversion was obtained with y-CD and 19% with no 
CD, demonstrating an acceleration of the reaction with CD. 
//. ^HarmaceuticaCjippCications of Cyclhdej^trins 
Of all the industrial applications of CDs, a large portion of their uses is de\oted tci 
their applications in the field of pharmaceuticals.'"'- '*'' The most common pharmaceutical 
applications of CDs are to enhance the solubility, stability and bioavailability of drug 
molecules. Each CD has its own ability to form inclusion complexes with specific guests, 
an ability which depends on a proper fit of the guest molecule within the hydrophobic CD 
cavity. At present, some 30 or so drug formulations are approved and marketed worldwide 
as CD complexes, generally natural CD complexes (Table 3). The structures of some of the 
pharmaceutical compounds marketed as CD complexes are shown in Fig. 4. 
The principle advantage of natural CDs are their; 
i. M'ell defined chemical structures yielding many potential sites for chemical 
modification 
ii. easy availability and low cost 
iii. low toxicity and pharmacological activity 
iv. some ^yaler solubility 
\. protection of included drug molecules from hiodegradation 
However, natural CDs have relatively low solubility, both in water and organic solvents 
which limit their uses in pharmaceutical formulations. P--CD, the most common natural 
CD. has 21 hydroxyl groups, i.e. 7 primary and 14 secondary, which are available as 
starting points for structural modifications and so a variety of CD derivatives have been 
prepared so as to extend the physicochemical properties and inclusion capacity of the 
parent host molecule, lypical examples of the pharmaceutically useful (3-CD deri\atives 
are listed in Table 2, classified into hydrophilic, hydrophobic and ionic derivatives. 
Table 3 Cyclodextrin containing pharmaceutical products 
Drug/Cyclodextrin 
Benexate HCl/p-CD 
Cetrizine/p-CD 
Cliloramphenicl/Randomly 
methylated P-CD 
Cisapride/Hydroxypropyl-P-CD 
Clilordiazepoxide/p-CD 
Diphenhydramin, 
Chlortheophyllin/p-CD 
Cefotiam-hexetil/a-CD 
Cephalosporin{ME 1207)/p-CD 
Dexamethasone/p-CD 
Diclofenac-Na/Hydroxypropyl-y-
CD 
PGEi/P-CD 
PGE|/p-CD 
OP-1206/a-CD 
lodine/p-CD 
Nitroglycerine/p-CD 
Tiaprofenic acid/p-CD 
Hydrocortisonc/Hydroxyprpyl-
P-CD 
Itraconazole/Hydroxypropyl-P-
CD 
Piroxicam/p-CD 
Niniesulide/p-CD 
Alprostadil/a-CD 
Nicotine/p-CD 
17p-EstradioI/Randomly 
methylated p-CD 
Indomethacin/Hydroxypropyl-P-
CD 
Omeprazole/p-CD 
Ziprasidonemesylate/Sulfobutylc 
ther-p-CD 
Voriconazole/Sulfobutylether-P" 
CD 
Mitomycin/Hydroxypropyl-P-CD 
Trade Name 
Ulgut 
Lonmiel 
Cetrizine 
Clorocil 
Propulsid 
Transillium 
Stada-Travel 
Pansporin T 
Meiact 
Glymesason 
Voltaren 
Prostarmon E 
Prostavastin 
Caverject 
Opaimoii 
Mena-Gargle 
Nitropen 
Surgamyl 
Dexocort 
Sporanox 
Biexin, Flogene, 
Cicladon 
Nimedex 
Rigidiir 
Nicorette 
Aerodiol 
Indocid 
Omebeta 
Geodon, 
Zeldox 
Vfend 
Mito Extra 
Mitozytrex 
Formulation 
Capsule 
Eye drop solution 
Suppository 
Tablet 
Chewing tablet 
Tablet 
Tablet 
Ointment 
Eye drop soution 
Sublingual tablet 
i. V. solutions and 
infusions 
Tablet 
Solution 
Sublingual tablet 
Tablet 
Solution 
Oral and i. v. 
Solutions 
Tablet 
Suppository 
liquid 
Tablets 
i. V. Solution 
Sublingual tablets 
Nasal Spray 
Eye drop solution 
Tablet 
In solution 
i. V. solution 
i. V. infusion 
Company/Country 
Teikokujapan 
Shionogi, Japan 
Losan Pharma, German\ 
Oftalder, Portugal 
Janseen, Belgium 
Gador, Argentina 
Stada, German) 
Takeda, Japan 
Meiji Seika, Japan 
Fujinaga, Japan 
Novarits, France 
Ono, Japan 
Ono, Japan 
Schwarz, Germany. TSA 
Ono, Japan 
Kyushin, Japan 
Nihon Kayaku,Japan 
Roussel-Maestrelli. ltal\ 
Actavis, Iceland 
Janseen, Belgium and ISA 
Several European countries. 
Ache, Brasil 
Novarits and others. Europe 
Ferring, Denmark 
Pharmacia, Sweden 
Servier, France 
Chauvin, France 
Betafarm, German> 
Pfizer, USA & Europe 
Pfizer, USA 
Novarits, Switzerland 
CI 
H 
NH 
-HN HN ^ NH 
NH 
H3CO 
Chlorhexidine 
V 
N|M^ ^ C H 3 
, 0 . 
CI 
HjCO" 
NO2 Nimesulide 
H,COOH 
Indomethacin 
O 
Naproxen 
CH, 
COOH 
H,N OCH OCH, Cisapride 
Fig. 4 Struct we of some pharmaceutical compounds marketed as CD-complexes. 
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Solubilization of Drugs 
One of the most important applications of the CDs in the field of pharmaceutical sciences 
is to enhance aqueous solubility of drugs tlirough complexation. While the solubility of 
many compounds is not sufficiently increased using unmodified CDs, derivatives can be 
used to increase the water solubility to higher concentrations than can be achieved with 
natural CDs.**^ ' "''' A 30-fold increase in the solubility was reported for tolnaftate with 
hydroxypropyl-p-CD and increased dissolution rate.^ *^  Similarly, a 16-fold increase in the 
water solubility of felodipine and 3-fold increase in the water solubility of amlodipine was 
reported on complexation with methyl-p-CD.^' 
CDs can also be used for reducing the water solubility of drugs. For example, flufenamic 
acid is a non-steroidal anti-inflammatory drug (NSAID) but the use of NSAIDs is limited 
because of their gastrointestinal side effects. Flufenamic acid is water soluble and a watej-
insoluble CD derivative. triacetyl-f3-CD, was used to complex the drug to slow the release 
of the drug.""'" The complexed drug did not have an immediate sharp increase in the plasma 
concentration as did the uncomplexed drug, but had a sustained plasma plateau lasting 6-8 
h. Desirable plasma concentrations were achieved from the complexed drug v\ithout 
reaching high plasma levels which have adverse effects. 
Moreover, the solubility characteristics imparted by CD complexation are stable. The 
dissolution characteristics of glibornuride remained unchanged when it was stored for one 
year in the form of p-CD complex. "' A comparative study of the solubilizing effects o\' 
2-hydroxyethyl-p-CD and 2-hydroxypropyl-p-CD, with different degrees of substitution 
was made on hydrocortisone, digitoxin, diazepam, and indomethacin. The solubilizing 
effect of 2-hydroxyethyl-p-CD with an average degree of substitution of 3.0 was similar to 
that of 2-hydroxypropyl-p-CD with an average degree of subsfitution of 2.5. It was also 
obser\'ed that the degree of subsfitution markedly affected the solubilizing effect: the 
solubility of digitoxin in the presence of 2-hydroxyethyl-p-CD decreased with an increase 
in the average degree of substitution. 3-hydroxyethyl-p-CD was found to have slightly 
higher solubilizing ability while 2, j-dihydroxypropyl-p-CD had a lower solubilizing 
effect as compared to p-CD.^'' Several sulfated CD derivatives have also been studied for 
their complexation behaviour. Because both the CD rims are surrounded by negatively 
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charged groups, CD sulfates interact with positively charged drug molecules such as 
chlorpromazine'^' and gentamicin." The inclusion ability of p-CD sulfate with 
chlorpromazine was weaker as compared to p-CD. The solubilizing ability of CD sulfates 
has not been studied in detail because of their weaker interaction with acidic and neutral 
drugs such as flufenamic acid, flurbiprofen, diazepam and steroids."'' The weaker 
interaction between CD sulfated derivatives and guest may be due to the difficulty in 
approach of the guest to the CD cavity through highly hydrated entrance as well as the 
electrostatic repulsion between negative charges of the host and anionic guest. Tc 
overcome such a drawback with the CD sulfate derivatives, a series of sulfoalkyl ethei' 
derivatives have been used. It was found that sulfobutyl-p-CD is a good solubilizer for 
various poorly water-soluble drugs such as kynostatin, steroids, cinnarizine, indomethacin. 
naproxen and miconazole etc."""' 
Pirodavir. an antiviral drug, has low aqueous olubility (<0.01 mg/ml). The compound is a 
weak base (pK^ 5.8) with high lipophilicity (log P 4.44). lonzation of the compound 
increases the solubility in acidic medium to 2.3 mg/ml at pH 2.4. However, low pH is not 
acceptable for nasal application as this induces irritation. Therefore, hydroxypropyl-P-CD 
has been used to enhance the solubility of pirodavir.^ 
When mono- or di-saccharides are attached to one or two primary hydroxyl groups of CD 
through 2, 6-glycosidic linkage, their water solubility markedly increases: the solubility of 
6-0-glucosyl-p-CD, 6-0-maltosyl-p-CD in water is over 50% (w/v) at 25 ^C.^° The 
complexation ability of branched CDs against hydrophobic guests is comparable to parent 
CDs and decreases only slightly with increase in the glucose number and the degree of 
substitution. However, the solubilizing ability of branched CDs is much greater than that 
of parent CDs. Branched CDs have higher affinity towards steroidal drugs such 
as progesterone, testosterone, dehydricholic acid, digitoxin etc.''°' '^ Due to their high 
solubilizing effect, branched CDs may be useful for parenteral preparations such as 
injections because of their weak hemolytic activity and high bioadaptability. 
The solubility of CDs can significantly be affected by water miscible co-solutes and 
co-solvents. For example, urea is known to increase solubility of a variety of polar and 
non-polar organic solutes in water. The solubilities of p - and y-CD were significantly 
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enhanced in the presence of urea while that of a-CD decreased. Such solubihty changes 
were observed for co-solvents such as alcohols, acetonitrile, dimethyl sulfoxide. dimeth\ 1 
formamide, acetic acid and ethylene glycol etc. "'^ '' 
The co-solubilization method has been found useful for the preparation of solid 
2-hydroxypropylated CD complexes with unstable drugs such as steroids, peptides and 
antibiotics. The synergetic effect of CD derivatives (methylated, hydroxyalkylated. 
carboxymethylated and branched forms) and water soluble polymers (poly\in> 1 
pirroridone, hydroxypropylmethyl cellulose and carboxymethyl cellulose) on the solubilit\ 
of \arious poorly water soluble drugs were studied. It was found that the solubilizing effect 
of 2-hydroxypropyl-P-CD is enhanced on an average by 27% by carboxymethyl cellulose 
49% by polyvinyl pirroridone. "" Table 4 summarizes the solubility enhancement studies 
of variety of pharmaceutical compounds in the presence of CDs. 
Table 4. Examples of CD-enhanced solubility and dissolution of pharmaceutical 
compounds. 
Cyclodextrin Drug (s) Ref. 
p-CD 
a-CD 
Y-CD 
Hydroxy ropyUp-CD 
Dimethyl-p-CD 
Sulfobutylether-P-CD 
Randomly methylated-
p-CD 
Randomly acetylated 
amorphous-p-CD 
74 
74, 80, 83 
84-87,69,71, 
73, 78, 88-91 
Nimesulide, Sulfomethiazole, Lorazepam, 68-82 
Ketoprofen, Griseofulvin, Praziquantel, 
Chlorthalidone, Etodolac, Piroxicam, 
Itraconazole, Ibuprofen, Piribedil, 
Carbamazepine 
Praziquantel 
Praziquantel, Omeprazole, Digoxin 
Albendazole, DY-9760e, ETH~615, 
Levemopamil HCl, Sulfomethiazole, 
Ketoprofen,, Griseofulvin, Itraconazole, 
Carbamazepine Zolpidem, Phenytoin, 
Rofecoxib 
Naproxen, Camptothesin 99,100 
D7- 9760e, Danazol, Fluasterone, 85, 94-96 
Spiranolactone 
ETH-6I5, Tacrolimus 86, 97 
Naproxen 98 
Stabilization of Drugs 
The drugs must retain sufficient stability not only during storage but also in the 
gastrointestinal fluids, since reactions which result in a product that is pharmacological)} 
inactive or less active will reduce the therapeutic effectiveness. The main concern in the 
pharmaceutical field is, therefore, the rate of deceleration. CDs have been used to stabilize 
pharmaceutical compounds. 
Erythropoeten is a glycoprotein hormone which induces an increase in red cell mass, 
Complexed with 2-hydroxypropyI-p-CD, 100% of the activity was maintained for 10 da\s 
compared to only 50% of the activity in the absence of CD. The complexed erythropoeten 
retained 62?/o of the activity after 20 days compared to only 24% in the absence of CD.'°' 
Digoxin, one of the potent cardiac glycosides, is susceptible to hydrolysis in acidic media. 
The acid-catalysed hydrolysis of the glycoside bonds in digoxin is decelerated by the 
addition of CDs. The hydrolysis of the glycosidic linkage connecting the A-ring of digoxin 
and the sugar was completely inhibited by p-CD.'°"^ When the catalytic hydroxyl groups of 
the CD are blocked by substituents, their stabilizing effect is enhanced. The 
P-hydroxyketo-moiety of the E-type prostaglandins is extremely susceptible to 
dehydration under acidic or alkaline conditions. Parent CDs showed a positive catalytic 
effect but the use of methylated-p-CD significantly decelerated the degradation reaction. 
Prostaglandin Ei has been stabilized by 6-0-(carboxymethyl)-0-ethyl-p-CD in a fatt\ 
alcohol propylene glycol ointment, because prostaglandin Ei is most stable in acidic 
conditions.'^'^ Furthermore, sulfobutylether-P-CD can also be used as a stabilizing agent for 
drugs that are subject to base-catalyzed degradation. Carmofur is extremely susceptible 
to base and water catalyzed hydrolysis to 5-fluorouracil, which irritates the gastrointestinal 
tracts. The carmofur can be stabilized by complexing with 6-0-(carboxymethyl)-0-
P-CD.""' An antitumor drug, 0-6-benzylguanine, undergoes hydrolysis under acidic 
conditions to form guanine and benzyl alcohol. The hydrolysis at pU 4.8 was decelerated 
by a factor of 220 by complexing the drug with sulfobutyl-p-CD with an average degree 
of substitution of 4."^^ The results of stability enhancement of pharmaceuticals in the 
presence of CDs are summarized in Table 5. 
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Table 5 CD effect on drug stability. 
Increased Effect 
Photostabilty 
Shelf life with unaffected 
dissolution rates for 4 years 
Thermal stability in solid state 
Stability against intramolecular 
cyclization in solid state 
Stability to acid hydrolysis and 
photodecomposition 
Stability against hydrolysis 
Deacetylation or degradation 
Photoreactivitj' 
Drug 
Promethazine 
DY-9760e 
2~ethylhexyl p-dimethyl 
aminobenzoate 
Glibenclamide 
Diclofenac sodium 
Quinaril 
Doxorubicin 
Acyl ester prodrugs of 
Ganciclovir 
Digoxin 
Rofecoxib 
Camptothesin 
Melphalan, Carmustine 
Paclitaxel 
Spiranolactone 
Flut amide 
Cyclodextrin 
Hydroxypropyl-P" 
CD, 
Dimethyl-p-CD 
Sulfobutylether-P-
CD 
Hydroxypropyl-(3-
CD 
(3-CD 
P-CD 
P-CD, 
Hydroxypropyl-3-
CD 
Hydroxypropyl-p-
CD, 
Hydroxypropyl-y-
CD 
Hydroxypropyl-P" 
CD 
Y-CD 
Hydroxypropyl-P-
CD 
Randomly 
dimethylated-p-CD 
Sulfobutylether -P-
CD, 
Hydroxypropyl-P" 
CD 
y-CD, 
Hydroxypropy!-y-
CD, 
Hydroxypropyl-p-
CD 
Sulfobutylether-a-
CD, 
Sulfobutylether-P-
CD, 
Hydroxypropyl-P" 
CD, y-CD. p-CD 
P-CD 
Ref. 
83 
82 
108 
109 
110 
III 
112 
71 
83 
84 
93 
113 
114 
115 
116 
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Bioavailability Enhancement 
The enhanced water solubiHty of the drug upon complexation with CDs has been found 
resuh in the enhanced bioavailabiHty of the drug."^"'^" The rate and extent 
bioavailabiHty of a poorly water-soluble drug from its CD complex is optimized b\ 
adjusting factors affecting the dissociation equilibria of the complex both in the 
formulation and in the biophase in which the complex is administered. Only a free form of 
the drug, which is in equilibrium with the complexed one in solution, is capable of 
penetrating the lipophilic barriers consisting of either mucosal epithelia or stratified cell 
layers and eventually entering the systemic circulation. Practical formulations usualh 
contain a large quantit)' of pharmaceutical excipients, which may compete with the drug for 
the CD cavity. Moreover, the endogenous substances existing at the absorption site nia\ 
also compete for the CD cavity. The displacement of the drug from the CD ca\ity b\ 
exogenous and endogenous substances is responsible for acceleration of the drug 
absorption. Some recent findings on the enhanced drug absorption by hydrophilic CDs 
administered via different routes are discussed here. 
Oral Drug Delivery 
The commercial viability of the CD-based oral formulations has been established with the 
marketing of more than 10 products.'^^"'^'' Rapidly dissolving complexes of drugs with 
hydrophilic CDs are best suited for sublingual or buccal administration. This type of drug 
delivery not only gives a rapid rise in the systemic drug concentration but also avoids 
intestinal and hepatic first-pass metabolism of the drug. A water soluble complex of 
digoxin with y-CD can be formulated into a sublingual tablet to enhance bioavailability and 
to a\oid acid hydrolysis of the drug by gastric juices.'^^ Other examples are sublingual 
administration of tablets containing complexes of steroids with CDs. 2-hydroxypropyl-P-
CD and (3-CD pohmer supported the absorption of testosterone from the oral ca\ity and 
not from the gastrointestinal tracts. " 
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Rectal Drug Delivery 
The release of drugs from suppository bases is one of the important factors in the rectal 
absorption of the drug.'^ ** In general; hydrophilic CDs enhance the release of poorlv water-
soluble drugs from oleaginous suppository bases. In comparison to parent CDs. the 
methylated CDs are found to significantly enhance the rectal absorption of hydrophobic 
drugs such as flurbiprofen,'^^ carmafur'^^ and biphenylylacetic acid'^° from the oleaginous 
suppository. 2-hydroxypropyl-P-CD was also found particularly useful for the 
enhancement of rectal absorption of the above drugs. The most striking effect of 
2-hydroxypropyl-P-CD was observed for the rectal absorption enhancement of the anti-
inflammatory drug ethyl 4-biphenyIyIacetate, a lipophilic prodrug of biphenylylacetic 
acid. " There is a great clinical need for the development of long-active types of rectal 
preparations for the potent opioid, morphine, in the treatment of intractable chronic pain in 
advanced cancer patients. Some hydrophilic CDs have been found to enhance the rectal 
absorption of morphine from the hollow-type oleaginous suppository in rabbits. 
It has also been reported that the complexation not only enhances the dissolution of 
lipophilic drugs at an interface between the molten base and the surrounding fluid but also 
inhibits the reverse diffusion of the drug into the vehicle. Recently, the absorption of 
human chorionic gonadotropin (hCG) has been found to increase by about four times in 
male rabbits when co-administered with a-CD. 
Ocular Drug Delivery 
One of the pre-requisite for a new vehicle to be used in ophthalmic preparations is that it is 
not irritating to the ocular surface, because irritation causes reflex tearing and blinking, 
which results in a fast washout of the instilled drug. The major problem with eye drops is 
its inability to sustain high local concentrations of drug. The administration of ophthalmic 
drugs in gels and in polymer matrixes has been shown to increase the contact time of the 
drug with cornea, a situation which increases their bioavailability. However, the patient's 
acceptance of such deli\'ery systems is unsatisfactory. The possible advantages in the use ot 
CDs are increase in solubility and/or stability and avoidance of incompatibilities of drugs, 
such as irritation and discomfort. " 
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Hydrophilic CDs. especially randomly methylated-p-CD. 2-hydroxypropyl-p-CD and 
sulfobutyl-p-CD have been shown to be nontoxic to the eye and are well tolerated in 
aqueous eye drop formulations. These hydrophilic CDs do not penetrate tight biological 
barriers such as the eye cornea but enhance the ocular bioavailability of lipophilic drugs b\ 
keeping the drugs in solution and increasing their bioavailability at the surface of the 
corneal barriers.'^ "''"'^ ^ For example, dexamethasone acetate-2-hydroxypropyI-P-CD 
complex can be made as an ophthalmic solution. Recent studies have demonstrated that 
water soluble polymers such as hydroxymethylcellulose polypyrroridone stabilize the 
complex of dexamethasone with 2-hydroxypropyl-P-CD probably through the formation o1 
a ternary complex, a situation which increases the aqueous solubility in eye drops and 
enhances the drug penetration into the aqueous humor in humans.'^^ A combination of 
2-hydroxypropyl-P-CD with hydroxypropyl-methyl-cellulose has also been shown to 
improve the topical delivery of carbonic anhydrase inhibitors to the eyes.'^''" '"^ ^ 
Dermal Drug Delivery 
CDs have a significant safety margin in dermal applications and can be used to optimizing 
the transdermal delivery of drugs intended either for local or systemic use. 
Ilydoxypropyl-P-CD and dimethyl-P-CD are used for lirazole delivery through the dermal 
route by enhancing the transdermal absorption, partitioning and absorption through 
changing the structure of stratum corneum. 
When the hydrophilic ointment containing ethyl 4-biphenylylacetate or its CD complexes 
was applied to the skin of rats, the release of ethyl 4-biphenylylacetate from the ointment 
into the skin was enhanced by heptakis(2,6-di-0-methyl)-p-CD or 2-hydroxypropyl-P-CD. 
while P-CD had no appreciable effect. In addition, the p-CDs assisted the bioconversion oi 
ethyl 4-biphenylylacetate to biphenylylacetic acid in the skin and consequently facilitated 
the delivery of active biphenylylacetic acid to subcutaneous tissues, where its action is 
^ , • 1 145, 146 
most desired. 
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Alleviation of Local and Systemic Toxicity 
The molecular entrapment of a drug into the CD cavity prevents its direct contact with 
biological surface as well as the entry of the drug into the cells of non-targeted tissues and 
thus reducing the local irritation.''^' ^^''' '''^  A complex of diclofenac was compared to a 
commercial preparation, Voltaren. Lysis of red blood cells was used to evaluate cellular 
lysis. The amount of complex needed to lyse the red blood cells was four times higher than 
for diclofenac alone. The results indicated the suitability of the hydroxypropyl-P-CD to 
optimize the ophthalmic application of the drug for improved transcorneal permeability and 
in vivo tolerance based upon the haemolysis studies.'''^ CDs also alleviate muscular tissue 
damage following intramuscular injection of drugs. For example, the intramuscular 
administration of chlorpromazine in the absence as well as presence of p-CD derivatives to 
rabbits showed reduced chlorpromazine-induced muscular damage.'^'' CDs diminish the 
ulcerogenic potency of several acidic anti-inflammatory drugs and mask their disgusting 
smells and tastes when they are administered orally. A similar protection by hydrophilic 
CDs after rectal and ocular administration of drugs was also described. For example. 
2-hydroxypropyl-P-CD significantly reduced the irritation of rectal mucosa in rats caused 
by biphenylylacetic acid both for single and multiple administrations of the complex of 
ethyl 4-biphenylylacetate with 2-hydroxypropyl-p-CD in oleaginous suppositories.'^' 
Systemic Detoxification 
A study has demonstrated that the addition of p-CD to dialysis fluids accelerated the 
removal of phenobarbital by peritoneal dialysis, thereby proving effective in the treatment 
of drug overdose.''^' A retinal-dextran conjugate solubilized by p-CD was reported to be 
less cytotoxic and retained the ability to inhibit the growth of cancer cells.'^^ CDs can be 
used not only as an enabling excipients in pharmaceutical formulations, but also as 
artificial carriers, for either exogenous or endogenous lipophiles, in the body. ^ Some 
natural lipophiles are changed into toxic agents when the organism lacks the ability to 
transport and redistribute them properly by carrier proteins and their receptor systems. 
Furthermore, various exogenous lipophiles enter the body and accumulate in fat tissues. 
Consequently, these exogenous lipophiles may exert toxic action for a very long period. In 
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such cases CDs act as an artificial circulating carrier for the lipophiles in order to 
redistribute them in extracellular space. 
r 
When heptakis(2,6-di-0-methyl)-p-CD was administered parenterally to mice unde 
retinoid induced hypervitaminosis A, the survival rate of poisoned animals was 
significantly improved.'^^ This preliminary result was the impetus for the use of 
2-hydroxypropyl-p-CD to rescue a patient with familial hypervitaminosis A caused by 
overloading retinal esters in the liver.'^^ 
Gentamicin, an aminoglycoside antibiotic, is widely used in the clinical treatment of gram-
negative infections, but its use is sometimes complicated by the development of drug-
induced acute renal failure. CD sulfates, when given intraperitoneally, protected rats 
against renal impairment due to gentamicin. The protection probably occurs through 
interfering with the intracellular events leading from the drug accumulation to 
nephrotoxicity. 
Cyclodextrin Based Delivery Systems 
Due to their multifunctional characteristics, CDs have also been found useful in oral drug 
delivery; peptide and protein delivery, and site-specific delivery. ' ' Drug release 
should be controlled in accordance with the therapeutic purpose and the pharmacological 
properties of active substances. There has been a growing interest in developing the rate- or 
time-controlled type oral preparations, because an appropriate drug release from the dosage 
form is of critical importance in realizing their therapeutic efficacy. Various CD deri\atives 
have been used for controlled drug release in oral preparations. The hydrophilic and 
hydrophobic CDs are useful for immediate release"'*^ and prolonged release'^'' '^ ^ type oral 
formulations, respectively. The delayed release type oral formulation can be obtained b\ 
the use of 6-0-(carboxymethyl)-0-ethyl-P-CD. 
Advances in biotechnology have accelerated the economical, large scale production of 
therapeutically active peptide and protein-based drugs used to combat poorly controlled 
diseases, making them more readily available for therapeutic use. The progress in 
molecular biology, however, has not been matched by the progress in the formulation and 
development of delivery systems for peptide and protein drugs. There are considerable 
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hurdles to be overcome before practical use can be made of therapeutic peptides and 
proteins because of chemical and enzymatic instability, poor absorption through biological 
membranes, rapid plasma clearance and immunogenicity. Many attempts have been made 
to address these problems by chemical modifications or by coadministration of adjuvants to 
eliminate undesirable properties of peptides and proteins. CD complexation is an attracti\e 
alternative to the above approaches.'^'' 
Recently, intensive efforts have been made to design systems able to deliver drugs more 
efficiently to specific organs, tissues, and cells, etc.'"'' "'^ ' "''' The CD complexes are in 
equilibrium with guest and host molecules in water, the degree of the dissociation being 
dependent on the magnitude of the stability constant. This property of the complex is a 
desirable quality, because the complex dissociates to free CD and drug at the absorption 
site, and only the drug in free form enters into systemic circulation. A typical example is 
the application of 2-hydroxypropyl-P-CD to the chemical delivery system developed b\ 
Bodor,"' which was used to deliver the polar drugs targeted on the brain. 
1.3. CfviTaC^cognition 6y Cyclbcfej(trins 
Enantiomerism has always been treated as a rather "special" type of isomerism, probabh 
because the only difference between the enantiomers is the manner in which they interact 
with polarized light. One enantiomer is therefore rarely regarded as an impurit\ when 
present in a sample of the other enantiomer, in contrast to, say, a mixture of two aromatic 
positional isomers or a mixture of E- and Z-alkenes. In fact, this lack of any difference 
other than optical activity, only holds in a truly achiral situation and as soon as an} 
chirality is introduced into the environment of a chiral molecule the enantiomers are 
differentiated. This will clearly be the case when a chiral drug interacts with an enzyme oi 
a receptor, as such biomolecules will typically represent a chiral environment. Furthermore, 
processess such as drug absorption, distribution, excretion and metabolism are all 
potentially subjected to enantioselection. 
It is important to realize that the other enantiomer of a chiral drug, usually present as a 50% 
admixture, as the result of chemical synthesis, may be more than just an ineffective version 
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of its mirror image, and may have dramatically different (and potentially undesirable) 
pharmacological effects in its own right. 
L-Dopa (1), a-dextropropoxyphene (2) and S-(-)-timolol (3) are commercially available 
drugs that are marketed as single enantionmer because the antipode produced unwanted 
side effects. For L-Dopa, it was noted during early development that many of the serious 
side effects, such as granulocytopenia, were due to the D-isomer: the racemate is no longer 
used in humans. ""^  In contrast to flecainide (4) where both enantiomers have been reported 
to have very similar activity,'^^ the isomers of propoxyphene appear to have completely 
different activities. D-propoxyphene has analgesic properties whereas it's optical isomer 
L-propoxyphene has antitussive properties but is devoid of analgesic properties. ^ '^^  
Indacrinone (5) is an interesting drug that has both diuretic and uricosuric activity 
Preclinical and clinical studies showed that R-(-)-5 and its active metabolite are responsible 
for the diuretic activity, whereas S-(-)-5 promotes uric acid excretion. Each enantiomer 
seems to posses very little of the antipode's activity. Similarly, S-(-) enantiomer of (3) was 
selected for development as a P-blocking agent because the R-(+)-3 was found useful for 
the treatment of glaucoma. S-(-)-3 has been reported to cause fatal p-blockade induced 
bronchoconstriction when applied topically to treat glaucoma. It becomes obvious from 
these examples that each enantiomer needs to be evaluated separately before being 
regulated for use as a drug. The separation of enantiomers and their characterization are. 
1 7? 
therefore, of great importance for the pharmaceutical industry. 
28 
OH 
HOOC 
CH3 
C2H5OCO C CHCH2N(CH3)2 
CH, 
O 
OH 
pCHjCHCHjNCCH,), 
\ 
OCH.CF, 
HOOC 
Chiral recognition, also often termed as enantiorecognition, refers to the ability of one 
chiral molecule to recognize the chirality of another molecule. CDs are chiral molecules 
and exhibit chiral recognition, i.e., they differentiate between enantiomeric species, 
forming diastereomeric complexes.' • ' '* The magnitude of the enantiorecognition in 
guest-CD interactions can be characterized by enantioselectivity. Enantioselectivit\' of 
recognition is a thermodynamic quantity correlating in some way with the separation factor 
of enantiomers in separation techniques. 
It must be noted that among presently applied chiral selectors only CDs are effectively used 
in all enantioseparation techniques. ' In fact, widespread industrial applications of CDs are 
primarily due to their two properties: complex formation and their chiral recognition 
ability. A better understanding of the inclusion complex formation and the chirai 
recognition mechanisms of CDs is, therefore, a subject of great importance. The basic 
mechanism of the interactions between CDs and other molecules is known but there arc 
still questions to be answered. The most critical questions in CD chemistry are: 
(i) Is the inclusion complex formation a prerequisite for chiral recognition b} 
CDs? 
(ii) Does any correlation exist between the binding strength and enantiorecognition 
power by CDs? 
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(iii) What sites of the CDs are primarily responsible for binding unci 
enantiorecognition ? 
(iv) What are the major forces responsible for binding, and what factors arc 
responsible for chiral recognition? 
Of all the techniques used to study chiral recognition, chromatographic techniques and 
NMR spectroscopy are the most frequently used methods. In chromatograpy, the separation 
of enantiomers is usually studied while spectroscopic techniques are used to stud\ 
differences in other physicochemical parameters of the diastereomeric complexes involving 
CDs. 
NMR spectroscopic studies have provided some of the most detailed information 
concerning the nature of these interactions and the structure of the diastereomeric 
complexes involved. The most distinct advantage of the NMR spectroscopy is that it allows 
the application of racemic samples or non-racemic mixtures of enantiomers for the 
enantioselective determination of the stoichiometry and equilibrium binding constants ot 
the diastereomeric CD-complexes. Besides, the easier availability of racemic mixtures 
compared to pure enantiomers offers the possibility of competitive binding studies. This 
means that the interaction of one of the enantiomer of a racemic mixture with a chiral 
selector may be studied in the presence of the other enantiomer, which mimics closely the 
real condition in chiral chromatographic separations. 
NMR spectra of enantiomers in an achiral medium are identical because enantiotopic 
groups display same chemical shifts.''^ Enantiodifferentiation in the spectra require the use 
of a chiral medium that converts the mixture of enantiomers into a mixture oi 
diastereoisomeric complexes. The simplest application of the chiral discrimination by CDs 
is an observation of the separation of signals of diastereomeric forms. Such experiments 
enable a simple estimation of optical purity of the guest molecules and rely on evaluation 
of relative signal intensities belonging to respective species. Most of the observations of 
splitting signals due to chiral recognition pertain to ' H spectra. There are very few 
examples describing the effect in '^ C spectra'^'^''^' and other nuclei, '^N,'^^ '^ ^F,'^ ^ and 
31p 184 
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Evidence of chiral recognition is usually the first step for further structural, thermodynamic 
of theoretical studies. Although the chemical shifts of such species are generally different, 
the magnitude of the expected effect is not always large enough to be observed. Moreover, 
it depends on the chemical shift differences between the free and complexed forms of the 
guest, the actual binding constant and finally on the kinefics of host/guest exchange. Hence, 
in order to increase the separation of the signals, an excess of CD is usually used and an 
J Of ^ 1 
analysis of the guest spectra is made. In practice, the observation of the separation of H 
signal due to chiral recognition is easiest and straightforward in the case of relatively strong 
and narrow signals but may be very difficult for complicated multiplets or broad signals. 
The observation of other nuclei provides several advantages, which include a larger 
chemical shift scale and a lack of multiplet structure as in H-coupled spectra. 
•fhe spectra of (±)-pinene (6) complexes'**'' with a-CD in D2O present a typical example ot 
the differentiation in 'H and ''^ C signals due to chiral recognition. The corresponding 
A8 = 5(+) - 5(-) values are given in Table 6. The 'H signal separations were observed for 
almost all protons except H-7 and H-9, whereas, due to their larger chemical shift scale, the 
A§ ('^C) values were larger by atleast 1 order of magnitude. 
H6 
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Tabic 6 Differences hehveen H and '^C complexation induced shifts (CIS) (ppm) of 
enantiomeric guest signals for the con^plexes of enantiomeric a-pinene with a-CD in 
D2O and DMSO. 
Atom 
1 
3 
4a 
4b 
•5 
7a 
7b 
8 
9 
10 
A5CIS 
•H 
-0.04 
-0.05 
-0.02 
0.00 
0.04 
-0.02 
0.01 
-0.02 
0.00 
0.04 
(D2O) 
, 3 ^ 
-0.5 
-0.2 
1.2 
0.3 
-1.3 
-0.3 
-0.4 
0.2 
A5 CIS (DMSO) 
' 'C 
0.01 
-0.01 
0.01 
0.01 
-0.01 
0.00 
-0.02 
-0.02 
The influence of the magnitude of binding constants on the apparent signal separation is 
exemplified by the spectra observed for the same system in DMSO solution. In this case, 
due to greater solubility of free pinene, the binding constant should substantially decrease, 
consequently the differentiation of the ' H signals was too small to be observed and 
the difference in the magnitude of the '^ C chemical shifts were reduced.'^^ Thus, as a result 
the differentiation of the signals of the enantiomeric guest was seen only in the C 
181.188 
Spectrum. 
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Spin-spin couplings, another NMR parameter, can also exhibit enantiodifferentiation. Since 
spin-spin coupHng cannot be directly read out from spectra of tightly coupled spin systems, 
it has seldom been used in chiral recognition studies. Lipkowitz and co-workers'^^ 
determined complexation induced differences in apparent couplings in the range of 
0.01-1 Hz for tryptophan (7) enantiomers complexed by a-CD. The observation of 
enantiodifferentiation of coupling constants is expected to be more reliable for couplings 
involving heteronuclei, owing to their usually larger magnitude. 
'C00~ 
+NH3 
N 
H 
The relaxation rates of nuclei are even more difficult to determine than spin-spin coupling. 
Special experimental techniques and appropriate data reduction have to be applied in order 
to obtain their values.'^ On the other hand; relaxation rates of many magneticalh 
active isotopes can provide valuable information on the dynamics of the system under 
. . 189, 190 
study. 
Few relaxation studies for the complexes of CDs with enantiomeric guests have been 
reported. Interestingly, not all these works exhibit the differentiation of relaxation rates due 
to chiral recognition. The observations of differences in the relaxation rates of CD 
diastereomeric complexes are scarce and all but one is devoted to the studies ol 
longitudinal relaxation rates. The first systematic study of this effect was carried out for 
(7)-CD complexes in D20.'^' Longitudinal relaxation rates for all protons of host and guest 
molecules were determined in free (7) (0.26-2.3 s''), free a-CD (1.4-5.0 s'') and both 
diastereomeric complexes at a host-to-guest ratio of 1:1. The relaxation rates of (7) 
increased on complexation but were smaller than those for a-CD protons. These results 
were interpreted in terms of larger motional freedom of the guest molecules than that of the 
host. According to authors, larger differential changes in relaxation rates of protons of (7) 
in the complex with R-enantiomer, as compared to those with the S-enantiomer complex, 
indicated that the later enantiomer binds less tightly to a-CD. The co-operative effects of 
Coulomb interaction and inclusion were assumed to be essential for chiral recognition of 
anionic phenylacetic acid derivatives by several animated CDs (8, 9).'^^ 
^H2NH3 
N 
( 8 ) N = 6 , R, =R2 = H 
(9)N = 7, R, = R2 = H 
Likewise, the importance of electrostatic interactions for chiral discrimination was pro\'ed 
for complexes of charged, cationic and anionic P-CD with various a-aminoacids.'^' It was 
demonstrated that protonated heptakis(6-amino-6-deoxy)-P-CD favoured the complexation 
with (S)-enantiomers of N-acetylated tryptophan (10), phenylalanine (11), leucine (12), and 
valine (13) in their anionic form while the native a- and P-CD did not. 
Enantiodifferentiation was also found for cations of methyl esters of a-aminoacids 
interacting with the anionic form of heptakis(6-(thioglycolic acid)-6-deoxy)-P-CD where 
the (R)-enantiomers were preferred guests. 
coon 
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Enantiodifferentiation of anionic tetrahelicene (14) by native CDs was studied using 
binding constants and thermodynamic parameters determined by variable temperature M 
NMR titration.'^' The binding constant for the (M)-14 was found to be much higher than 
that for the corresponding (P)-14. However, the 2D ROESY measurements indicated a 
somewhat deeper insertion of the (P)-form into the CD cavity. The results were attributed 
to a domination of enthalpy effects in the process of complexation. 
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(P)-14 (1VI)-14 
The binding constants and enthalpy change (AH) and entropy change (AS) values were 
determined for both the enantiomers of binaphthyl derivatives (15, 16) with native and 
184 heptakis(2,3,6-tri-0-methyl)-P-CD. The results revealed that the complexation is 
entropically driven. They also showed that the entropically driven complxation by the 
permethylated derivative differentiated the enantiomers more effectively. 
15 16 
Several studies. 193. 194 reported the stoichiometry of CD complexes of enantiomers in 
combination with chemical electrophoresis (CE) enantioseparations, but a distinct 
difference in the stoichiometry of the complexes was observed in only few cases. Thus for 
example, Kano and co-workers'^ "^ observed different stoichiometrics for the complexes of 
S- and R-l,r-binaphthyl-2,2'diol (17) with heptakis(2,3,6-tri-0-methyl)-p-CD. The 
stoichiometry of S-guest complex was determined to be 2:1 while for R-guest a 1:1 
stoichiometry was found. 
17 
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An article on the structure determination of CD complexes, using NMR spectroscop> m 
relation to CE, was published by Yamashoji et. al. in 1992.''"^ Subsequently, several studies 
were reported'"^' '"^  in which the authors tried to explain the quantitative differences 
observed in the behaviour of chiral selectors based on the structure with guest molecules. 
All these studies contributed significantly to a better understanding of CD-guest 
interactions. However, at present it is difficult even with very sophisticated powerful NMR 
techniques to define the structure and dynamics of the complexes on a level providing the 
key for the explanation of somefimes very fine quanfitative differences in the 
enantioselective recognition by different cyclodextrins. 
The ' H NMR titration and ROESY studies of inclusion of l-(4-quinolyl) ethanol (18) b> 
per-0-methylated-a-CD evidenced the formafion of equatorial and axial complexes of (R) 
and (S)-enantiomers, respectively.'^^ In addition to the determination of the bindini 
constants for both the enantiomers, the free energy changes (AG) were also determined. 
N 
Axial Equatorial 
18-(per-0-methylated)-a-CD complexes 
The screening of the affinity patterns of a wide range of chiral guests towards CD-type 
chiral selectors using CE revealed that the affinity pattern may change dependeing on the 
type and position of the substituents on the CD rim and on the CD cavity size.' These 
studies help in elucidation of possible structural mechanism of qualitatively differeni 
behavior of the CD type chiral selectors in CE, in particular, for examples in which the 
affinity of the enantionmers is opposite towards given chiral selectors. 
The enantiomers of the anesthetic drug ketamine (19) possesses an opposite affinity pattern 
towards native a- and P-CD.^"' ROESY spectroscopy indicated that there are no dramatic 
differences in the structures of the corresponding intermolecular complexes. The 
enantiomers are just more deeply included in the cavity of P-CD compared to a-CD. 
Similar to this, no clear differences besides the extent of intermolecular inclusion could be 
observed between the structures of complexes of dimethinden (20) and chlorpheniramine 
(21) with p-CD and heptakis(2,3,6-tri-0-methyl)-p-CD although the enantiomer affinity 
patterns were opposite for all three analytes towards these two CDs. 202, 203 
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In other examples, however, significant differences in the structures of intermolecular 
complexes could be observed. The enantiomers of clenbuterol (22) showed opposite 
affinity toward native P-CD and hepakis(2,3-0-diacetyl)-P-CD in CE experiments. The 
splitting of the resonance signals due to complexation induced chemical shifts of the 
protons of the enantiomers was primarily observed for the aromatic protons in the case of 
P-CD and for the protons of the tert-butyl moiety of (22) in the case of heptakis(2,3-0-
diacetyl)-P-CD. These data indicate that the aromatic part of (22) is mainly involved in the 
interaction with p-CD while tert-butyl moiety is involved in the interaction with 
heptakis(2,3-0-diacetyl)-p-CD 203 
22 
The chiral cholinergic drug aminoglutethimide (23) shows opposite affinities in CE 
towards p- and y-CD.^ ""^  The detailed NMR spectroscopic study confirmed the deep 
inclusion of the p-aminophenyl moiety of 23 into the P-CD cavity entering from the wider 
secondary side while the p-aminophenyl ring enters the y-CD cavity from the narrower 
primary side. The glutarimide ring is apparently less involved in the complex formation. 
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However, the involvement of the methyl group in complex formation cannot be completely 
ruled out. 
NH, 
23 
The complexation of antihistamine drug brompheniramine (24) with P-CD and 
heptakis(2,3,6-tri-0-methyl)-P-CD was studied by ID ROESY experiments in solution.^'" 
For the complexes of (+)-24 with both CDs unambiguous conformation was obtained 
indicating the inclusion of the 4-bromophenyl moiety of the drug into the CD cavity, In 
addition, in the case of (+)-24 complex with P-CD, the inclusion of the maleate counter ion 
into the P-CD cavity was also indicated, but this contradicts simple geometric 
considerations and the assumption that the stoichiometry of the complex is 1:1. The 
contradiction was solved by the X-ray crystallographic study performed on the 
monocrystals obtained from a 1:1 aqueous solution of (+)-24 maleate and P-CD. The 
stoichiometry of the complex was found to be not 1:1 but 1:2 and the brompheniramine 
maleate is sandwiched between two molecules of P-CD. The 4-bromophenyl moiet}' of the 
drug enters the cavity of one of the P-CD molecules whereas the cavity of another P-CD 
molecule is occupied by the maleate counter anion. 
Br-
' N 
N \ H 3 
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In a recent study, (27) cationic chiral analytes were resolved by CE using native P-CD and 
heptakis(2-0-methyl-3,6-di-0-sulfato)-p-CD, having both primary and secondary CD rims 
with 14 bulky sulfate substituents. The bulky substituents on both sides of the cavity 
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entrance may hinder inclusion complex formation between chiral analytes and heptakis(2-
0-methyl-3,6-di-0-suIfato)-P-CD. For 12 of 16 chiral analytes resolved with both chiral 
selectors the enantiomer migration order was opposite. Analysis of the structures ol' 
analyte-CD complexes in solution indicated that, in contrast to mainly inclusion i\pc 
complexation between chiral analytes and P-CD, external complexes were formed between 
the chiral analytes and heptakis(2-0-methyl-3,6-di-0-sulfato)-P-CD. ' 
The enantiomers of 23 enantioselectively bind to heptakis(2-0-methyl-3.6-di-()-sulfaUi i-(' 
CD and are resolved with this chiral selector in CE. In addition, significant comple.\aii.)ii 
induced chemical shift differences were observed for the protons of 23 enantiomers i;; 
NMR spectrum of the complex. It was established by ID ROESY experiments that 23 nK-.t 
likely does not form an inclusion complex with heptakis(2-0-methyl-3,6-di-0-sulfato)-!v 
CD. Thus, inclusion formation between CDs and their chiral guests does not seem to be a 
necessary prerequisite for chiral recognition. 
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General Discussion 
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NMR spectroscopy has become the most important tool for the structure elucidation of 
organic compounds, particularly in the solution state. The method is of increasing 
significance for most CD application studies. There are few alternatives to NMR 
spectroscopy in the CD related studies.^°^"^" 
As with many carbohydrates, it is often difficuh to obtain single crystal of CD derivatives 
and then to analyze them by X-ray crystallography, or by neutron diffraction. Other 
techniques such as fluorescence, UV/visible spectroscopy, calorimetry etc. play a major 
role in measuring complexation energetics with CDs but usually provide very indirect and 
qualitative information about inclusion modes and geometries. 
Structure determination is of particular importance for supramolecular host-guest 
complexes, which are the basis of most CD applications in medicine, catalysis, separation 
and sensor technology and also food chemistry. Pharmaceutical uses of CDs for drug 
protection or targeting now legally require structure determination of the administered 
compounds. NMR spectroscopy is also becoming an important tool for in vitro, in future 
perhaps even for in vivo, studies of CD interactions with biological macromolecules such 
as nucleic acids, proteins, or cell membranes. The most obvious incentive to use NMR 
techniques for the investigation of CD complexes is the interest to understand the driving 
forces and binding modes in these non-covalent associations, and then to make optimal use 
of these factors for new applications. It should be remembered that the driving force for CD 
inclusion often is of solvophobic nature and that most CD applications involve action in a 
liquid matrix, which emphasizes again the role of NMR spectroscopy as the most important 
method applicable in solution. 
After the first publication on the use of NMR spectroscopy to study inclusion phenomenon 
by Demarco and Thakkar,^'^ there has been a virtual explosion of such studies. The older 
work was restricted to the observation of few CD protons, mostly at the anomeric centers 
which were sufficiently separated from other strongly coupled signals. The advent of high-
field instruments and in particular 2D methods has completely changed the situation, and 
the possibilities of now available NMR techniques are far from being exploited. Nuclear 
Overhauser Effects (NOEs) have already becomes a major tool in structural studies ot 
complex biomolecules. 
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The spectacular advances of NMR techniques, have led to much more detailed structural 
information of CDs and their complexes. These tasks represent a fascinating challenge for 
the NMR spectroscopist in view of the high complexity of the underlying cycloamylose 'H 
NMR spin systems.^'-'"^'^ These are characterizd by signals which, apart from the anomenc 
proton, absorb in a range of only 0.5 ppm and are strongly coupled. In addition, the 
shielding effects of the CD cavity on the included guest molecules are limited to a few 
tenths of a ppm at most, as a consequence of a host framework being built up entireh of 
single, less polar and polarizable bonds and thus weak shift tensors. 
The aim of the present discussion is not to discuss or even to mention all the work on the 
study of the CD complexes using NMR spectroscopy. Instead we will illustrate the use of 
NMR techniques in the structure elucidation of CD inclusion complexes with some 
representative examples, yet without a special focus on this method. 
Demarco and Thakkar,^'^ first noticed the highfield chemical shift changes in the P-Cl) 
cavity protons, namely H-3' and H-5', in the presence of a variety of aromatic substrates in 
aqueous solution and envisaged from these observations that the aromatic ring is positioned 
in the |3-CD cavity. This observation later became the basis for NMR spectroscopic stud\ 
of the CD inclusion complexes. He used 100 MHz instrument for these studies which is 
actually not suited for this type of work because all the CD protons, except H-T, resonate 
in the 0.5 ppm range and are not easily distinguished. He established the assignment for 
each proton on the basis of analysis of individual splitting patterns and coupling constants 
at 220 MHz, decoupling experiments and expected chemical behaviour i.e. H-3' and H-5'. 
being 1, 3-diaxial to the C] axial oxygen should resonate at lower fields than the H-2" and 
H-4" protons. 
At magnetic fields above 9.4 T, corresponding to 400 MHz for the ' H NMR spectra, the 
dispersion is high enough to locate, in conventional one dimensional spectrum, most of the 
CD protons, eased by high symmetry of the macrocycles. The 'H NMR spectrum of p-CD 
in aqueous solution has already been assigned in detail. It has been established that, on the 
NMR time scale, all the seven glucose units have identical conformations and the molecule 
is highly symmetrical. Furthermore, the magnitude of the vicinal coupling constants J| 2 
through to J4.5 are consistent with the Ci chair form for the glucose units of CDs. 
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It is now well accepted that the signals of the cavity protons move highfield when the guesi 
molecule or a part of it enters the CD cavity. The chemical shift change data obtained from 
H NMR titration experiments can be used to determine stoichiometry, binding constant 
and is thus helpful in the determination of structure of the complex. 
The magnitude of the chemical shift changes for the protons positioned in the CD-cavit} 
217, 218 
while A5H-3- and A8H-5-, increases with an increase in the concentration of the guest 
that for guest protons increases with an increase in the concentration of the CD."'*' The 
magnitude of the A5H-3- and A5H-5' also depends on the nature of the guest. The chemical 
shift changes are high in the case of aromatic guests while these are relatively small if the 
aliphatic guest enters the CD cavity. Salbutamol (25) forms a 1:1 inclusion complex with 
(3-CD whose structure has been confirmed by detailed NMR spectroscopic and molecular 
modeling studies (Fig. 5). It has been established that aliphatic part of the guest enters 
the CD cavity. Fig. 6 shows very small shift changes in the p-CD cavity protons in the 
presence of salbutamol. On the other hand these shift changes are quite large when 
aromatic ring of (IS, 2R)-(+)-ephedrine (26) enters the P-CD cavity. 221 
\ " 3 
HN, 
HO' 
Salbutamol-P-CD complex 
HiC//,,, 
H,C 
,NH 
"OH 
(IS, 2R)-(+)-Ephedrine-|3-CD complex 
Fig. 5 Structures of inclusion complexes of salbutamol and (IS, 2R)-(+)-ephedrine. 
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P-CD 
—r~ 
4,0 
H-3' H-6' 
H-2' H-4' 
H-2' H-4' 
H-2' H-4' 
j . i 3,6 
Fig. 6 Comparative chemical shift changes in the P-CD cavity protons upon inclusion of an 
aromatic guest [A] and an aliphatic guest [B]. The [H]/[G] is same in both cases. 
The CDs generally act as one site ligand and the guest enters the cavity from wider rim 
side. This is always true for a-CD but in the case of (3- and y-CDs, complexes formed by 
the penetration of the guest from narrower rim side have also been reported.^^^ The relati\e 
chemical shift change data for the cavity protons (ASH-S- and A§H-5') is sometimes taken as 
an evidence for the mode of penetration of the guest. It has been suggested that in the cases 
where A5H-3- > A5H-5' the guest entry is from wider side' ^ and vice versa.'^ '^' This statement 
may be true only when the guest is bulky but can not be generalized. 
Kano studied the complexation of pure enantiomers of binaphthyl derivatives with 
various CDs. The chemical shift changes observed for H-3' of heptakis(2, 3, 6-tri-O-
methyl)-P-CD (TMe-p-CD) were quite high compared to those for H-5' (A5H-3' > ASHO) in 
the presence of 1, r-binaphthyl-2,2'-diyl hydrogen phosphate (27). It was established that 
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27 is shallowly bound to the wider side of the TMe-P-CD cavity. The guest being bulk\ 
cannot penetrate deep into the cavity. Moreover, the mode of penetration of the two 
enantiomers was found different (Fig. 7). 
(R)-27-TMe-P-CD complex 
O 
"O 
(S)-27-TMe-(3-CD complex 
Fig. 7 Modes of penetration of two enantiomers of 27 into the P-CD cavity. 
He also studied the complexation of several helical metal complexes with modified CDs, 
A-Ru(phen)3 ion (28) forms a complex with heptakis(6-carboxymethylthio-6-deoxy)-P-
CD (per-COa'-P-CD) (Fig. 8). It has been shown that the guest approaches the cavity from 
narrower rim side and for this complex the chemical shift for H-5' was quite high 
compared to that for H-3' (A6H-5' > A5H-3')-^^'^ These examples show that the relative values 
for A5H-3' and ASH-.V can be used in support of the mode of penetration of guest into the CD 
cavity. 224 
ooc 
28 Model of 28-(per-C02')-P-CD complex 
Fig. 8 Mode of inclusion of 28 into the (per-C02)-fi-CD cavity. 
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Rekharsky." howexer, made a detailed H NMR study of the CD inclusion complexes ol d 
variety of guests and showed that while the magnitude of the chemical shift changes tor 
H-3" and H-5' protons is a quantitative measure of the stability of the complexes, their 
ratios, A6H-5/A6H-3- are related to the depth of penetration of the guest into the CD cavit> 
In all the studied cases, the guest approached the p-CD cavity from wider rim side though 
ASH-5- > A5H-3-- He showed that higher magnitude of ASH-J- and ASH-5- values is due to 
higher stability of the complex. On the other hand, their ratios, A5H.5/A5H-3-, which were 
found as high as 1.2-3.0 for P-CD, indicate a deep penetration of the guest into the host 
cavity. It becomes obvious from these examples that the use of relative magnitude of 
chemical shift changes for cavity protons as an evidence in support of the mode of 
penetration of guest into the CD cavity cannot be generalized (Table 7). In fact the mode of 
penetration can better be determined by NOE experiments. 
Table 7 Chemical shift changes (AS) of H-3 ' and H-5 ' of P-CD protons upon complexation 
Mith selected ligands in buffered aqueous solutions at pD = 7.0 and T = 298.15 K. The 
mode of penetration of the guest into the fi-CD cavity is from wider rim side in all the 
cases. 
Ligand 
Phenethylamine 
L -a-O-Be nzylglycero I 
I -Ben~\ iimidazole 
4-Ben-} ipiperidine 
l-Butylimidazole 
(IS. 2S)-(+)-Pseudoephedrine 
(IS, 2R)-(+)-Ephedrine 
(III 2S)-(-)-Ephedrine 
Hydrocinnamate 
Phenyl- (3-D-glucopyranoside 
3-Phenyl-1 -propylamine 
[G]/[H] 
0.94 
0.59 
0.77 
0.94 
0.95 
0.98 
1.00 
0.97 
0,92 
0.81 
1.03 
H-3' 
0.03 
0.03 
0.09 
0.14 
0.05 
0.07 
0.07 
0.06 
0.04 
0.02 
0.10 
H-5' 
0.06 
0.09 
0.18 
0.22 
0.09 
0.12 
0.12 
0.10 
0.10 
0.05 
0.12 
H-5'/H-3' 
2,0 
3.0 
2.0 
1.6 
1.8 
1.7 
1.7 
1.7 
2.5 
2.5 
1.2 
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The formation of the CD inclusion complex also results in the concomitant chemical shift 
changes for the guest protons and generally all the guest protons, and not only the part 
included in the CD cavity, show downfield shift changes, but sometimes upfield changes 
are also observed. ' These change have mostly been found to be of qualitative significance 
though these may also provide important information regarding the structure of the 
complex. 
Due to lower water solubility of the guest, sometimes it is not possible to use high 
concentration of the guest in the NMR titrations and in such cases the chemical shift 
changes observed for the CD cavity protons may be very insignificant while large chemical 
shift changes are observed for guest protons. The chemical shift change data for guest 
protons can be used for determining stoichiometry and binding constant of the complex but 
whether guest enters the CD cavity or not can only be said on the basis of chemical shift 
changes in the cavity protons. ROESY experiments may be required in such cases lo 
ascertain whether guest has actually entered the CD cavity. 
Nuclear Overhauser Effect (NOE) 
Beside the chemical shift changes, observed for hosts and guests, upon complexation 
relative to unbound state, detection of the through-space dipole-dipole interactions (NOf, 
and/or ROESY) between the CDs and the guests is another important probe of the structure 
of complexes.^^" NOEs have been used for the study of CD complexes in solution since the 
pioneering work of Bergeron and Rowan.^ ^^ Though the advent of high magnetic fields has 
greatly enhanced the dispersion of signals; at the same time, however, the unfavourable 
correlation times of complexes with molecular weights around 10^  lead to a drop of the 
observed NOEs, e.g. from 34% at 90 MHz to 9% at 250 MHz. To obtain sizeable NOEs on 
a 400 or 500 MHz instrument, application of spin-lock techniques such as ROESY are 
required."^" In the ROESY spectra, artifacts which possess phase properties different than 
genuine NOE cross peaks are frequently observed between resonances within a common .1-
coupling network, thus being easily distinguishable. Intermolecularly, as in case of CD 
complexes, these COSY-type peaks are not observed; however, false cross peaks with the 
same phase as genuine interactions may arise from scalar transfer from H-3' and/or H-5". 
the cavity protons being most prone to interact dipolarly with the guest. 
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The use of NOEs in the structure elucidation of CD complexes is exemplified by feu 
representative examples. A typical NOE application is illustrated with a-CD complexes 
with phenol derivatives. Fig. 9 describes different inclusion modes for the cyclodextrins 
complexes with phenol derivatives and, obviously, all three modes should lead to quite 
different NOEs and should be distinguishable this way. 
Mode I Mode II Modem 
Fig. 9 Various possible modes of penetration of phenol derivatives into the CD cavity. 
For Mode 1 with no or little immersion of the phenyl ring into the cavity there is a sizeable 
contact only between the guest H,,, and H-3' of a-CD and one can expect only small ROE 
at Hni upon irradiation of H-3'. For Mode II irradiation at H-3' should lead to ROE of both 
Ho and Hm signals, at H-5' only of the m-proton. In contrast, no effect on the H,,, signal 
upon irradiation of H-5' can be expected for Mode III. The 2D ROESY spectrum of the 
p-iodophenolate with a-CD (Fig. 10) shows only those cross peaks discussed for 
Mode 11 228 
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Fig. 10 Part of the ROESY spectrum showing intermolecular cross peaks between the 
p-iodophenolate and a-CD cavity protons supporting the inclusion Mode II. 
Another interesting example is structure elucidation of a 1:1 complex between benzoic acid 
and p-CD.^'^ ID ROESY experiments were performed to confirm the structure of the 
complex. The NOEs on the CD protons were studied on saturation of various aromatic 
protons. The irradiation of Hp did not show any NOE on the CD cavity protons. However, 
intermolecular NOEs were observed on saturation of Ho, H^, H-3' and H-5'. Almost equal 
NOE values were observed on both the cavity protons when Ho was irradiated, while the 
NOE value for H,„ to H-3' was larger than for Hm and H-5'. These results clearly suggest 
inclusion geometry with the aromatic Hp proton located at the CD equatorial plane, Hp on 
the chiral vertical axis, and Ho at similar distances from both the cavity protons. Both the 
geometries are compatible with this NOE data. However, NOEs on both the cavity protons 
upon saturation of Hm can only be explained when a fast equilibrium exists between the 
two inclusion complexes (Fig. 11). 
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COOH 
Fig. 11 Structures of two 1:1 P-CD-benzoic acid inclusion complexes. 
The use of ROESY in the study of chiral recognition mechanism is exemplified by the 
following example. Chiral recognition of an anionic tetrahelicene (29) has been studied b\ 
native CDs. Fig. 12 shows the ROESY spectra of P-CD-(M)-29 and p-CD-(P)-29 systems 
in D2O which show different connectivities of the cavity protons with the protons of two 
enantiomers. It was interpreted from these results that both C02' groups of 29 are placed 
near the rim of the secondary OH group side of p-CD and ring A of the 29 penetrate the 
p-CD cavity. It was shown that there was somewhat deeper penetration of the ring A of 
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(P)-29 compared to that of (M)-29 into the CD cavity. 
H . H 
"OOC 
(P)-29 (M)-29 
j r i H» M ' H * ICH, 
«* «4i t o r.» 7,« 7.« 20 i.i'i'i |i(ii 
Fig. 12 ROESY spectra of(P)-29-j3-CD and (M)-29-P-CD complexes. 
Stoichiometry and Binding Constant of the Complex 
The most commonly claimed stoichiometric ratio for CD complexes is 1:1 which is usualh 
justified. Nevertheless, other ratios are known, most common of these probably being 2:1 
(H/G) while the ratios 1:2 and 2:2 have also been reported.^"' 
Before any structural or association constant determination is performed, it is always 
essential to determine the stoichiometry of the host-guest complex which is readiK 
achieved from NMR titration data. There are several methods used to determine the 
stoichiometry, namely continuous variation method (Job's plot), molar ratio method and 
several modified Benesi-Hildebrand methods. 
Job's PloP"^ 
The method of continuous variations involves preparing a series of solutions containing 
both the host and guest in varying proportions so that a complete range of mole ratios is 
sampled (0> [H]/[H]+[G] <1) and where the total concentration [H]+[G] is kept constant 
for each solution. The experimentally observed parameter is a host or guest chemical shift 
that is sensitive to complex formation. The data are plotted in the form [H]/[H]+[G]xA5obs 
versus [H]/[H]+[G]. The position of the maximum indicates the stoichiometry of the 
complex (Fig. 13). 
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Fig. 13 A typical Job 's plot for 1:1 inclusion complex. 
The Mole-Ratio Method r231 
In this method a series of solutions is prepared in which the formal concentration of one of 
the components is held constant while that of the other is varied. A plot of the chemical 
shift change (A§) versus mole ratio of the components is then prepared. If the formation 
constant is reasonably favourable, two straight lines of different slopes are obtained; the 
intersection occurs at a mole ratio corresponding to the combining ratio in the complex 
(Fig. 14). 
0.20 
0.18 
0.16 
0.14H 
I. 0.12 
0.10 
0.08 
0.06 
0.04-
0.0 0.5 1.0 1.5 
Molar Ratio 
2.0 
Fig. 14 A typical molar ratio plot showing 1:1 stoichiometry of the complex. 
Modification of Benesi-Hildebrand Method 
The stoichiometry and association constant of the inclusion complex can also be 
determined by any of the following methods. Assuming that the composition of the 
complex is 1:1, the following expression can be written: 
G + H ^ = ^ GH 
The association constant of the complex (ATa) is given by 
[GH] 
K,= [H] [G] 
Where [H], [G] and [GH] are equilibrium concentration of host, guest and complex, 
respectively. Benesi-Hildebrand studied the complexation of iodine with aromatie 
hydrocarbons by UV-visible spectroscopy '^^ ^ and derived the following linear equation 
(equation 1) for the calculation of A'a: 
l /Sobs= l/C^aSmax [ H ] ) + l/8n,ax (D 
where 8obs is the extinction of a layer of solution 1 cm deep containing m moles of h and 
Bmax is the molar extinction coefficient of the complex at the wavelength of maximum 
absorption. NMR version of the Benesi-Hildebrand equation was independently derived b> 
Mathur et. al.^ '^' and Hanna and Ashbaugh '^''* (equation 2). 
l/A5obs = l / (^aA5„,ax [ H ] ) + 1/A5n,ax (2) 
where A5obs = (A§G - ASobs) and ASmax = (SG - SQH)-
A plot of l/A8obs against 1/[H] (often referred to as a double reciprocal plot) should be 
linear for a 1:1 complex, with a slope l/A:aA5max and intercept 1/A5max allowing the 
determination of association constant {K^). This expression is valid when observing one 
species in presence of a large excess of the other species. 
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An alternative solution of Benesi-Hildebrand equation hasJberfh^proDpsed by Foster d|»d 
"yic I V - • • - • • - . • W 
Fyfe (equation 3). ' 
A5obs/[H] = -A:aA5obs + ^aA5 
max 
This is a special form of the more general Scatchard plot?-^^ In the Foster-Fyfe procedure, a 
plot of A6obs/[H] against A8obs (referred as an x-reciprocal plot) should be linear for a 1; 1 
complex. The gradient is equal to -A^ a and the intercept gives ASmax- This modification 
requires an extrapolation to infinitely dilute solution and the A'a is not dependent on the 
extrapolation. 
Another modification of Benesi-Hildebrand equation is Scott equation (equation 4).^'^ 
[H]/A5obs = [ H ] / A 5 , a x + ASn.ax/A'a (4, 
In the Scott procedure, a plot of [H]/A5obs is plotted against [H] (referred to as y-reciprocai 
plot) which should be linear for a 1:1 complex with a slope 1/A5max and intercept ASmax/A"! 
allowing the estimation of association constant {K^. 
The stoichiometry and association constant of the 1:1 tetramethrin and P-CD inclusion 
complex were determined by spectrofluorometry through double reciprocal plot 
(equation 5). ^ 
l/AFob.s= l/(^aAF,™x [H]) + l/AF,,ax ,5) 
where AFobs denotes the change in fluorescence intensity of tetramethrin in the presence of 
P-CD compared to pure tetramethrin and AFmax change in fluorescence intensity of' 
tetramethrin. when all of its molecules are complexed with P-CD, compared to pure 
tetramethrin while other symbols have their usual meaning. The equation is identical to the 
Hanna and Ashbaugh modification (equation 2) except that a different property of the 
complex is studied. 
Now. assuming the complex to be 1:2, the following expression can be written: 
G + 2H - ^ = ^ ^ GH2 
IGH2] 
[H]' [G] 
if [H] » [GH2] » [GH] then the following linear expression (equation 6) is obtained for 
calculating binding constant by fluorospectrometry. 
1 /AFobs = 1 /(^aAFn^ax [ H ] ' ) + 1 /AF^ax (6) 
where symbols have their usual meaning. A plot of 1/AFobs against 1/[H]^  gives a straight 
line for a 1:2 complex. Thus, the NMR version of this equation can be written as: 
l/A5obs= l/(^aA6n.ax [ H ] ' ) + 1/A5,ax (7) 
A plot of 1/ASobs versus 1/[H] should be a straight line for 1:2 complex with a slope 
1/A'a ASmax and intercept l/ASmax allowing the determination of association constant. 
Throughtout the above discussion it is assumed that the guest molecule is the observed 
species. It does not matter which species is observed and the most readily observed and 
responsive molecule would normally be chosen. The data treatment for observed host is 
identical, with host and guest .symbols switched. 
Throughtout discussion the CD protons are numbered as H-1' to H-6'. 
5 b 
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NMR Study of Complexation of P-Cyclodextrin and 
Venlafaxine Hydrochloride 
Venlafaxine hydrochloride (VEN), chemically designated as (R/S)-l-[2-dimethylamino)-l-
(4-methoxyphenyl)ethyl]cyclohexanol hydrochloride and commercially known as 
"'Effexor'. '''"'* ^ is a representative of a new class of antidepressants (Serotonin and 
Norepinephrine Reuptake Inhibitor, SNRI. It is a bicyclic phenylethyl amine and 
chemically unrelated to tricyclic, tetracyclic or other available antidepressant agents.""*' The 
mechanism of the antidepressant action of venlafaxine in human is believed to be 
associated with its potentiation of neurotransmitter activity in the central nervous system 
(CNS). Preclinical studies have shown that venlafaxine and its active metabolite, 0-
desmethylvenlafaxine (ODV), are potent inhibitors of neuronal serotonin and 
norepinephrine reuptake and weak inhibitors of dopamine reuptake. 243, 244 
1 
H.CO 
8,9 
N(CH3)2 
Fig. 15 Structure of Venlafaxine hydrochloride. 
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^RqjeritnentaC 
H NMR spectra (Figs. 16-21) of pure VEN and mixtures of VEN and p-CD were recorded 
on a Bruker Advance DPX 400 MHz spectrometer while COSY spectrum (Fig. 22) was 
recorded on a 800 MHz Bruker instrument, in D2O at 25 °C. The 2D ROESY spectrum 
(Fig. 23) was also obtained on a Bruker Advance DPX 400 MHz spectrometer under spin 
lock condition with a mixing time of 500 ms. Chemical shift values, reported in 5 (ppm). 
were calculated with reference to HDO signal at 4.790. ' H NMR chemical shift change 
data vv'as obtained for p-CD protons, to determine the stoichiometry of the inclusion 
complex, by keeping the concentration of P-CD constant at 20 mM while the concentration 
of venlafaxine hydrochloride was varied from 8 mM to 40 mM. All the spectra consisted of 
only one set of concentration dependent resonances for each proton or group of equivalent 
protons, indicating that reversible exchange between free and bound VEN was rapid on the 
NMR time scale, so distinct peaks for complexed and uncomplexed form of VEN were not 
observed for the free and bind state. 
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Fig. 23 2D ROESY (400 MHz) spectrum of a 1:1 mixture ofVENandjS-CD. 
^suCts and (Discussion 
^HNMR Chemical Shift Change Data of P-CD 
The signals for VEN and 3-CD did not interfere with each other in the spectra of mixtures 
of P-CD and VEN. The P-CD proton signals were easily identified by their characteristic 
shapes and chemical shift values.^'^^ The resonance assignment for all the P-CD protons is 
supported by COSY spectral data (Fig. 24). 
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Kig. 24 A seel ion of COSY spectrum (800 MHz) of the 1:1 mixture of VEN and fJ-CD. 
showing, rci^ion containing:, /j-CD signals. 
11 NMR spectra of mixture of VEN and P-CD displayed significant upfield movements in 
the signals of 11-3' and H-5' located inside the P-CD cavity. Moreover, the other P-CD 
proton signals showed negligible deviations in their chemical shifts in the presence of VHN 
as compared to pure P-CD. Expansions of part of the spectra showing P-CD proton signals 
in the presence as well as in the absence of VEN are shown in Fig. 25, while their chemical 
shift change data is given in Table 8. The dramatic highfield chemical shift changes in the 
P-CD inner cavity protons, H-5' and H-3', are indicative of internalization of VEN into the 
P-CD cavity, resulting in the formation of VEN-P-CD inclusion complex, as reported.''^ 
These upfield shift changes in the inner p-CD cavity protons can only be explained in term 
of ring current effect of aromatic ring entering the host cavity.^ '^ '•^• '^ 
H-6' 
[VEN]/[p-CD]=2.70 
[VEN]/[p-CD]=2.25 
H-6 
[VEN];'[p-CD]=l.97 
H-6 
[VEN]/[p-CD]=l 
[VEN]/[p-CD]=1.03 
y H-2'/H-5' 
H-4' 
H-2'/H-5' 
„ V [P-CD] H-2' H-4' 
3.7 3.6 3.5 
Fig. 25 Partial H NMR (400 MHz) spectra showing signals for the protons of /3-CD. in the 
absence as well as in the presence of VEN. 
6Q 
Table 8 'H NMR (400 MHz) chemical shift change (AS) data for the [i-CD protons m 
presence of VEN in D2O at 25 "C. 
Samples 
A 
B 
C 
D 
E 
[VEN]/[p-CD] 
2.70 
2.25 
1.97 
1.08 
1.03 
H-2' 
0.019 
0.017 
0.010 
0.007 
0.001 
H-3' 
-0.177 
-0.174 
-0.167 
-0.146 
-0.128 
H-4' 
-0.018 
-0.026 
-0.028 
-0.026 
-0.005 
H-5' 
# 
# 
# 
-0.156 
-0.141 
H-6' 
-0.046 
-0,052 
-0.057 
-0.052 
-0.057 
Xegafire values indicate upfield shifts 
Note; # could not be determined due to overlap of H-5 ' signals with H-2' of fi-CD 
^H NMR Spectral Assignment for Venlafaxine 
Hydrochloride Protons 
The spectral assignment for the VEN was made with the help of COSY (Fig. 22) and 
ROESY (Fig. 23) spectral data. ' H NMR spectrum of pure venlafaxine hydrochloride 
exhibited a pair of doublets at 6.998 (J = 8.8 Hz) and 7.289 (J = 8.6 Hz), each integrating 
for two protons. The signal at 7.289 showed through space interaction with H-7 ol" 
methylene protons in the ROESY spectum (Fig. 23), and was therefore assigned to H-3, 5 
while that at 6.998 was ascribed to H-2, 4. The signals at 3.783, integrating for 3 protons, 
and at 2.710, integrating for 6 protons, were assignable to -OCH3 and -N(CH3)2 methyl 
protons, respectively. A pair of doublet of doublets at 3.547 (Ji = 4.0 Hz, h= 13.2 Hz) and 
3.041 (.li = 4.0 Hz, J2 = 12 Hz), for one proton each, was due to H-7a and H-7b protons 
The signal for H-6 appeared as a triplet at 3.688 (J = 12.4 Hz). Cyclohexanol ring protons 
resonances appeared in the region 1.000-1.688 and could not be studied. 
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^H NMR Chemical Shift Change Data of Venlafaxine 
Hydrochloride 
Fig. 26 shows the chemical shift changes in venlafaxine hydrochloride proton signals in the 
presence of p-CD. The aromatic proton signals were not found to be affected by the 
presence of P-CD. The pattern of the spectral region containing venlafaxine hydrochloride 
signals, in the spectra of mixtures of VEN and p-CD, remained more or less unchanged 
because concentration of the P-CD was kept constant. Generally, all the protons ol" the 
guest and not only the part that enters the P-CD cavity, show chemical shift changes upon 
complexation with CDs.' *" 
H-3.5 
H-2.4 
[1-8.9 
|b | 
H-7 
JyJ 
o 
— ] — 1 — I — I — I — 1 / / — I 1 — I 1 — I — I — I ^ / - i — r — 1 — I 1 1 1 — I 1 — 
7.5 7.0 3.0 2.5 1.5 l.O 
Fig. 26 A part of'H NMR spectra showing variation in the signals of VEN protons [aj 
pure VEN [h] VEN-p-CD mixture. 
Stoichiometry of the VEN-fi-CD Complex 
The stoichiometry of VEN-p-CD complex was determined by using Hanna-Ashbaugh 
modification of Benesi-Hildebrand method.^ ^^ In the Hanna-Ashbaugh equation: 
l / A 6 o b s = l / ( ^ a A 5 „ , a x [ G ] o ) + l / A 6 
max 
A5obs is observed chemical shift change, [G]o is the concentration of venlafaxinc 
hydrochloride, and A6max is the chemical shift difference between a pure sample of the 
complex and free component at the saturation and K^ is the binding constant. 
In this method, also called a double reciprocal plot, the chemical shift of H-3' was plotted 
against [VEN] in the form of 1/A5H-3' against 1/[VEN] was plotted, which was found to be 
linear confirming that the stoichiometry of the VEN-P-CD complex is 1:1. The slope of the 
plot is thus equal to l/A'aASmax and the intercept equal to 1/A6max (Fig. 27).^ ^ '^ ^^^ The 
association constant (A^ a) of the complex was determined to be 234 M" . 
0.02 0.04 0.06 0.08 0.10 0.12 0.14 
1/[VEN] mM'' 
Fig. 27 Illustration of the Hanna-Ashbaugh modification of Benesi-Hildebrand method. 
ROESY Spectral Data ofVEN-P-CD Complex 
247 ROESY' experiment was performed on a 1:1 mixture of venlafaxine hydrochloride and 
P-CD. The results are displayed in Fig. 28; NOE cross peaks were observed between H-3' 
and H-5' resonances of P-CD and aromatic ring protons of VEN, while no cross peaks were 
observed between the P-CD cavity protons and aliphatic protons of venlafaxine 
hydrochloride (Fig. 23). thus confirming the penetration of only aromatic ring into the host 
cavity. 
Moreover, the H-3, 5 protons of aromatic ring showed connections with both H-3' and H-5' 
of P-CD cavity protons while H-2, 4 showed cross peaks only with H-3', situated near the 
wider rim of the host cavity. On the basis of these observations, it can be argued that H-2, 4 
of VEN are in the close proximity of H-3' but H-3, 5 of VEN are in close contact of both 
H-3' and H-5' which can be explained if the phenyl ring enters the P-CD cavity from the 
narrower rim side and penetrates deep. The structure proposed for the VEN-P-CD complex 
is shown in (Scheme 1). 
H-3,5 
-7 .0 
H-5\H-3.5 
-7 .2 
-7.4 
3:8 3.6 3 4 
Fig. 28 A section of 2D ROESY spectrum (400 MHz) of the 1:1 mixture ofVENwith /]-CD 
showing cross peaks between aromatic protons and P-CD protons. 
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8,9 
.N(CH3)2 
H3C0 
Venlafaxine hydrochloride P-Cyclodextrin 
H3CO 
8,9 
N(CH3)2 
Scheme 1 The proposed structure for VEN-/3-CD complex. 
ConcCusions 
It can be concluded on the basis of detailed H NMR spectroscopic studies of venlafaxine 
hydrochloride, in the presence as well as in the absence of P-CD, that a 1:1 VEN-P-CD 
inclusion complex is formed in solution under studied experimental conditions by the deep 
penetration of aromatic ring into the host cavity from narrower rim side/ The 
stoichiometry and binding constant were determined using Hanna-Ashbaugh method. The 
structure has been deduced with the help of ROES Y spectral data. 
7^ 
. k b J O i a i M M I t t i a M U m M U J J A A U J ^ a a f a ^ ^ 
CHyKP^^I"^-... 
NMR Study of Complexation of p-Cyclodextrin and 
Triprolidine Hydrochloride 
g^;j*5jjjjj^£gj^jgjjj^;^^^22j£5yj3jj2gjj2^j;g23J22j[[gyji^^ 
Triprolidine hydrochloride (TRP), [l-(p-tolyI)-l-(2-pyridyl)-3-(l-pyrrolidine)prop-l-ene] 
hydrochloride, is a propylamine antihistamine drug.^''^' ^ "^ Antihistamines work by blocking 
the action of histamine at special sites in the skin, nose and blood vessels. Histamine is an 
important part of body's defence mechanism, but sometimes the body releases too much 
histamine and this produces the allergic reaction. This antihistamine is used to relieve 
symptoms of allergies like hay fever, seasonal rhinitis and perennial rhiniti_s^ ^^ i^.^ "^  
9, 
Fig. 29 Structure of Triprolidine hydrochloride. 
11 
^Ej(perimentaC 
All the 'H N M R spectra (Figs. 30-36) of pure TRP and mixtures of TRP and P-CD were 
recorded on a Varian Mercury VX 400 MHz spectrometer in D2O at 25 ^C. Chemical shift 
values are reported in (5) ppm with reference to HDO proton signal at 4.690 ppm. 'H NMR 
chemical shift data for TRP was obtained by keeping the concentration of TRP constant at 
10.3 mM while the concentration of P-CD was varied from 2.9 mM to 26.4 mM. The 
COSY spectrum (Fig. 37) was also recorded on Varian Mercury VX 400 MHz 
spectrometer for a mixture of TRP and p-CD. The 2D ROESY experiment was acquired on 
800 MHz Bruker instrument for a 1:1 mixture of P-CD and TRP (Fig. 38), with a mixing 
time of 500 ms. All the spectra consisted of a single set of concentration dependent 
resonances for each proton or group of equivalent protons, indicating a fast reversible 
exchange between the free and complexed TRP on the NMR time scale. 
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Fig. 37 2D COSY (400 MHz) spectrum of a mixture ofTRP and fi-CD having molar ratio 
f[/}-CDJ/[TRPJ=2.67). 
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^HNMR Chemical Shift Data of/^-CD 
The signals for TRP and P-CD did not interfere with each other in the spectra of mixtures 
of (3-CD and TRP. The P-CD proton signals were easily identified by their characteristic 
shapes and chemical shift values.^ "*^ The assignment for all the P-CD proton signals is full\ 
supported by COSY spectral data (Figs. 37 & 39). 
H-6' 
•I"I I I 1 1 I I I I I r I' r i M 1 1 1 I 1 1 I I ' I I 1 1 I 1 1 I I 1 1 I ' I 
4.'0 3 . 3 3 . 8 3 . 7 3 . 6 3 . 5 3 . 4 3 . 3 3.' 
Fig. 39 An expanded part of COSY spectrum (400 MHz), of a mixture having molar ratio 
[p-CD]/[TRP]=2.67, showing region containing fi-CD signals. 
All the signals for P-CD protons moved towards the higher field in presence of triprolidine 
hydrochloride as shown in Fig. 40. The dramatic highfield chemical shift changes for p-CD 
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protons situated inside the hydrophobic cavity (H-3' and H-5'), demonstrate the realit\ ot 
internalization of TRP into the P-CD cavity,^'^ resulting in the formation of P-CD-TRP 
inclusion complex, as previously reported 218,221 These observed highfield shift changes m 
the inner cavity protons may be due to the anisotropic shielding effect of aromatic ring 
penetrating into the P-CD cavity. H NMR chemical shift change values calculated for 
P-CD protons are listed in Table 9. 
Fig. 40 Partial 'H NMR (400 MHz) spectra showing signals for the protons of P-CD. in ihc 
absence as well as in the presence of TRP. 
QO 
Table 9 'H NMR (400 MHz) chemical shift change (AS) values for the fi-CD protons in 
presence ofTRP in D2O at 25 "C. 
Sample 
A 
B 
C 
D 
E 
F 
[pCDl/[TRPl 
2.67 
2.57 
1.66 
1.25 
0.63 
0.29 
H-2' 
-0.017 
-0.018 
-0.021 
-0.039 
-0.043 
-0.039 
H-3' 
-0.190 
-0.180 
-0.232 
-0.286 
-0.325 
-0.322 
H-4' 
-0.039 
-0.037 
-0.054 
-0.072 
-0.079 
-0.075 
H-5' 
-0.172 
-0.163 
-0.201 
-0.261 
-0.300 
-0.297 
H-6' 
-0.033 
-0.028 
-0.048 
-0.063 
-0.078 
-0.076 
Negative values indicate upfield shifts 
^H NMR Spectral Assignment for Triprolidine 
Hydrochloride Protons 
The resonance assignment of TRP protons was made with the help of COSY experiment 
performed on a mixture of TRP and P-CD (Figs. 37, 41), supporting the assignment of TRP 
protons in the absence of P-CD (Fig. 30). The proton signals for both the TRP aromatic 
rings appeared in the region of 6.957-8.313, totally integrating for nine protons. H NMR 
spectrum of triprolidine hydrochloride, in the absence of P-CD, exhibited a pair of 
doublets, each integrating for two protons. One of the doublets at 6.957 (2H, J = 8.0 Hz) 
was ascribable to H-6, 7 due to shielding effect of methyl group. This doublet was found to 
be exhibiting a cross peak in the COSY spectrum with the other doublet at 7.178 (2H, J = 
7.6 Hz), assigned to H-5, 8 of the p-tolyl ring (Fig. 41). 
A doublet appearing at 8.313 (IH, J = 7.6 Hz), in the lowest field in all the spectra, was 
assignable to H-1, deshielded by nitrogen atom of pyridyl ring, which showed a cross peak 
in the COSY spectrum with a partially merged doublet of doublet of doublet at 7.230 (IH. 
Ji = 2.0 Hz, h = 7.6 Hz, J3 = 6.8 Hz), assigned as H-2 for pyridyl ring (Fig. 41). A doublet 
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of triplet at 7.634 (IH, J| = 2.0 Hz, JT = 6.8 Hz) was found exhibiting cross connections 
with the doublet appearing at 7.126 (IH, J = 7.6 Hz) as well as with H-2. The signal at 
7.634 and 7.126 were assigned to H-3 and H-4, respectively. An inadvertent error was 
detected in the assignment of H-2 and H-3 which has now been corrected.^'''' 
A triplet at 6.493 (IH, J = 7.6 Hz) showed a cross peak with the doublet at 3.873 (2H. J -
7.7 Hz). These signals were assigned to H-10 and H-11, respectively (Fig. 37). A singlet at 
2.430 integrating for three protons was due to methyl group (H-9) while the two remaining 
signals, found to be resonating at 1.886 and 3.293, each integrating for four protons, were 
ascribed to H-13, 14 and H-12, 15, respectively, of pyrrolidine ring. The chemical shift 
change (A5, ppm) values of the various studied protons of TRP are given in Table 10. 
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Fig. 41 An expanded part of COSY spectrum (400 MHz) of a 1:1 mixture of TRP and 
f-CD, showing aromatic region. 
Table 10 'H NMR (400 MHz) chemical shift change (AS) values of the studied protons of 
TRP in the absence as well as in presence of fi-cyclodextrin in D2O at 25 "C. 
Samples 
Protons 
A 
[P-CD]/ 
[TRP] 
=2.67 
B 
[P-CD]/ 
[TRP] 
=2.57 
C 
[P-CD]/ 
[TRP] 
=1.66 
D 
[p-CD]/ 
[TRP] 
=1.25 
E 
[P-CD]/ 
[TRP] 
=0.63 
F 
[p-CD]/ 
[TRP] 
=0.29 
H-1 0.139 0.144 0.117 0.089 0.056 0.026 
H-2 0.011 0.013 0.009 0.004 0.005 0.009 
H-3 0.074 0.066 0.053 0.036 0.022 0.013 
H-4 -0.178 -0.174 -0.165 -0.148 -0.078 -0.026 
H-5,8 0.087 0.087 0.065 0.057 0.031 0.015 
H-6,7 0.104 0.104 0.082 0.065 0.041 0.026 
H-10 0.103 0.100 0.087 0.063 0.037 0.024 
H-11 0.054 0.050 0.040 0.044 0.022 0.021 
Negative values indicate upfield shifts. 
^H NMR Chemical Shift Change Data of Triprolidine 
Hydrochloride 
Prominent changes were observed in the position of signals for most of the protons of TRP 
in presence of P-CD, which increased with the increase in the amount of p-CD (Fig. 42). It 
is generally observed that, all the protons of the guest, and not only the proton/s that are 
included into the P-CD cavity, show downfield shift changes upon complexation with 
^ , p . 255 
CDs. 
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Fig. 42 /I jOar/ o/' / / NMR (400 MHz) spectra showing variation in the signals of TRP 
protons in the absence as well as in the presence of varying amounts of fi-CD. 
Stoichiometry of the TRP-fi-CD Complex 
Scott's plot of chemical shift changes for TRP protons (A5TRP) against [P-CD] in the form 
of [P-CD]/A5TRP verses [P-CD] was found to be a non-linear relationship which indicated 
that the stoichiometry of the complex is not simply 1:1. Therefore, a plot of [P-CD]VA5TRP 
versus [p-CD]^ was plotted by using a 1:2 Scott's equation, which also gave a non-linear 
relationship indicating that the complex stoichiometry is not 1:2 as well. 
The chemical shift changes for TRP protons (ASTRP) were then plotted against 
concentration of P-CD in the form of ASJRP verses [P-CD] (Fig. 43). The plot shows that 
ASTRP increases almost in a linear fashion till 1:1 ratio of the two components but on further 
increasing the concentration of P-CD neither it (A5TRP) increases in a linear fashion (as 
expected for 1:2 TRP-p-CD complex) nor it becomes constant (as expected for 1:1 
stoichiometry). These observations suggest that 1:1 complex/es are dominant till 
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[P-CD] < [TRP] and when [P-CD] > [TRP] the 1:2 TRP-P-CD complex concentration starts 
increasing. 
0.14 
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Fig. 43 Mole ratio plot of the chemical shift changes of TRP aromatic protons during 
titration with P-CD in DiO. 
ROESY Spectral Data of ^CD-TRP Mixture 
ROESY' "^  experiment was performed on a 1:1 mixture of triprolidine hydrochloride and 
P-CD to study the mode and depth of penetration, to confirm whether both the aromatic 
rings were involved in the complexation and to determine clear picture geometr} cii 
complex/es in aqueous solution. In the Fig. 44, intermolecular cross peaks were found 
between both the p-tolyl and pyridyl ring protons of TRP and P-CD cavity protons, 
indicating that both the rings are included in the P-CD cavity. The peaks for p-toiyl ring 
protons were strong compared to pyridyl ring indicating preferential inclusion of p-tol> 1 
rins. 
The spectrum exhibited cross peaks between H-6, 7 of p-tolyl ring with both H-3' and H-5' 
of P-CD. while H-5, 8 showed cross peak with only H-3' of P-CD, situated near the wider 
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rim side. It can be argued on the basis of tliese observations that H-5, 8 of p-tolyl are m 
close proximity of H-3" but H-6, 7 of p-tolyl are close to both the H-3' and H-5' which can 
only be justified if the p-tolyl ring enters the P-CD cavity from wider rim side and 
penetrates deep. 
Moreover, the strong cross peaks were observed for pyridyl ring protons (H-1 and H-3) 
with only H-3' of P-CD, which is located near the wider rim suggesting that pyridyl ring is 
near the wider rim and no cross peak was observed for any of the pyridyl ring proton with 
H-5" of P-CD except H-1 (a very insignificant cross connection), Fig. 44. Therefore, it may 
be concluded that the pyridyl ring is partially inserted into the P-CD cavity from wider rim 
side and the penetration is shallow. The proposed structures for the complexes formed 
between TRP and P-CD in aqueous solution at room temperature are shown in Scheme 2. 
H-5,8 H;6,7 
Fig. 44 A section of 2D ROESY spectrum (800 MHz) showing cross peaks between 
aromatic protons and p-CD protons. 
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Moreover, the signals for H-11 and pyrrolidine ring did not show any cross peak with 
P-CD cavity protons, confirming that this part of TRP is not included into P-CD cavity 
(Fig. 38). 
3 14 
Triprolidinc hydrochloride P-Cyclodextrin 
CH3 
Scheme 2 Supposed representation of the possible inclusion equilibria for triprolidinc 
hydrochloride/p-cyclodextrin system in solution. 
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Concfusions 
It can be concluded on the basis of detailed ' H N M R spectroscopic studies of triprolidine 
hydrochloride, in the absence as well as in the presence of P-CD, that inclusion complexes 
are formed between two in aqueous mediun at room temperature. It was found that the 
stoichiometry of the complexes was neither simply 1:1 not 1:2. Two 1:1 complexes are 
formed involving aromatic rings when the [P-CD] < [TRP] and the complex involving p-
tolyl ring appeared to be more stable because intermolecular croos peaks observed in the 
ROESY spectrum were stronger. It was also found that as the concentration of P-CD 
further increases, the two 1:1 complexes take up another molecule of P-CD to form 1:2 
TRP-P-CD complex. The mode and depth of penetration of the aromatic rings was 
established clearly on the basis of ROESY results and structures for all the complexes 
formed between TRP and P-CD have been proposed.^''* 
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'5*>?^^^s51^K!5^!?!?S7SK!ScS!^ST^^^!5r?!5;^^ 
CH:A^I^^V. ... 
NMR Study of Complexation of fi-Cyclodexthn and 
D-(-)- Chloramphenico I 
i.,.-.,,,.,.,^jm,^r.,inm,,im,~^,,~,.^,,..nm,.m,^ 
D-(-)-Chloramphenicol (CHL), D-threo-(-)-2,2-dichloro-N-[P-hydroxy-a-(hydroxy-
methyl)-p-nitrophenylethyl]acetamide, is produced naturally by streptomyces 
veneziielae. ' It is a broad-spectrum bacteriostatic antibiotic, active against a wide 
variety of gram positive and gram negative organisms including anaerobes, ^^  It exerts its 
antibacterial effect by binding to bacterial ribosomes and inhibiting bacterial protein 
synthesis 259 
CH,OH 
NO. 
Keto Form 
1 
CHCI2 
3 
CH2OH OH 
Fig. 45 Structure of D-(-)-Chlorar}iphenicol. 
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^Ej(perimenta[ 
All the ' H N M R spectra (Figs. 46-51) were recorded on a Bruker DRX-300 MHz 
spectrometer at 25 C in D2O. Chemical shift values are reported in 5 (ppm). The anomeric 
proton H-l' of (3-CD was used as an internal reference. Five samples of mixtures of D-(-)-
chloramphenicol and p-CD were prepared, for obtaining ' H NMR spectra, by keeping the 
concentration of P-CD constant at 20 mM while the concentration of CHL was varied from 
7.05 mM to 24 mM. The molar ratios ([P-CD]/[CHL]) were calculated by direct integration 
of appropriate signals. The COSY (Fig. 52) and 2D ROESY (Fig. 53) spectra were 
acquired on an Inova-600 MHz instrument for a 1:1 mixture of P-CD and CHL. Distinct 
peaks for complexed and uncomplexed form of CHL were not observed in any of the 
spectra indicating a rapid exchange of CHL between free and bind state on the NMR time 
scale. 
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Fig. 52 2D COSY (600 MHz) spectrum of a 1:1 mixture of CHI and p-CD. 
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Fig. 53 2D ROESY (600 MHz) spectrum of a 1:1 mixture ofCHL and P-CD. 
^suCts and (Discussion 
^HNMR Chemical Shift Change Data of fi-CD 
The p-CD cavity proton signals were easily identified by their characteristic shapes and 
chemical shift values.^'*'' ^^ ^ The assignment for all the [3-CD proton signals is fulh 
supported by COSY spectral data (Fig. 52). 
The inner cavity protons of the P-CD, namely H-3' and H-5', showed significant upfield 
shift changes in the presence of CHL. Parts of the spectra showing signals for P-CD 
protons, in the absence as well as in the presence of CHL, are shown in Fig. 54. The 
dramatic highfield chemical shift changes in the P-CD inner cavity protons, H-5' 
(dominant) and H-3' (subordinate), are indicative of internalization of CHL into the P-CD 
cavity, resulting in the formation of CHL-P-CD inclusion complex, as previously 
215, 261 
reported. "' ' Moreover, other P-CD protons showed negligible deviations in thei r 
i i 
chemical shifts in the presence of CHL as compared to pure P-CD. H NMR chemical shift 
change values for all the P-CD protons are given in Table 11. 
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I^-CD]/[CPIL]=1.27 
[^-CD]/[CHL]=1.38 
[/3-CD] [CHL]=1,56 
1/3-CD] [CHL]=1.95 
[/3-CD] [CPIL]=2.3i 
H-6' 
H- H-5 ' I t - ' H-4' \I3-CD] 
1 1 1 1 1 1 I 1 r 
4,0 3.8 3.6 3.4 
Fig. 54 Partial 'H NX4R (300 MHz) spectra showing signals for the protons of (i-CD. in the 
absence as well as in the presence ofCHL. 
Table 11 'H NMR (300 MHz) chemical shift change (Ad) values for the P-CD protons in 
the presence ofCHL in D2O at 25 C. 
Samples 
A 
B 
C 
D 
E 
[|3-CD]/[CHL] 
2.31 
1.95 
1.56 
1.38 
1.27 
H-2' 
0.002 
-0.002 
0.003 
-0.003 
0.004 
H-3' 
-0.041 
-0.045 
-0.054 
-0.061 
-0.071 
H-4' 
0.004 
-0.003 
0.001 
-0.002 
-0.001 
H-5' 
-0.051 
-0.054 
-0.069 
-0.081 
-0.098 
H-6' 
0.000 
-0.001 
-0.002 
-0.002 
0.006 
Negative values indicate upfield shift 
^H NMR Spectral Assignment for D-(-)-Chloramphenicol 
Protons 
l^ he signals for the protons of D-(-)-chloramphenicol and P-CD did not interfere in any of 
the spectra. ' H NMR spectra of D-(-)-chloramphenicol, in the absence as well as in the 
presence of p-CD, clearly exhibited that two tautomeric forms, namely keto and enol. were 
present in solution in the approximate ratio of 3:2, as determined by the integration of 
NMR signals appearing separately for the two tautomers. The presence of two tautomeric 
forms of CHL in the solution was evident from a singlet at 6.267 integrating for 
approximately 0.6 H which could be attributed to -CHCI2. Also, the signals for H-3 of two 
tautomers were observed separately while H-4 signals appeared partly separated. The 
aromatic protons did not show any separation for two isomers. The multiplet centered at 
4.248, integrating for one proton, was ascribed to H-2 because it showed coupling with H-3 
and H-4 signals. Two doublets at 4.483 (J = 7.8 Hz) and 4.696 (J = 7.8 Hz), totallx 
integrating for iwo protons, were assigned to H-3 of keto and enol forms, respectively. The 
signals for H-4 of two isomers were found as two partly merged doublets at 5.254 (J = 3.9 
Hz) and 5.226 (.1 = 3.0 Hz), totally integrating for one proton. The aromatic protons were 
observed as a pair of doublets showing AB pattern. The doublet at 7.663 (J = 8.7 Hz) was 
assigned to H-5, 8 because it showed through space interaction with H-2 in the ROESY 
spectrum. The doublet at 8.273 (J = 9.0 Hz) was, therefore, ascribed to H-6, 7. The 
assignment is also supported by COSY spectral data. 
^H NMR Chemical Shift Change Data of 
D-(-)-Chloramphenicol 
Fig. 55 shows the chemical shift changes for most of the protons of D-(-)-chloramphenicol 
in the presence of p-CD, which increased with the increase in the concentration of (3-CD. 
The H-5, 8 signals for the aromatic protons moved progressively downfield while 
an upfield shift in the H-6, 7 aromatic proton signals was observed, though small in 
magnitude. Generally, all the guest aromatic protons, show downfield shift changes upon 
complexation with P-CD,^ "*^  but when a polar group, present at para-position of the 
aromatic ring, enters the hydrophobic cavity of P-CD it passes through the cavity and 
protrudes out of the smaller rim. In such cases, the aromatic protons ortho to polar group 
exhibit upfield shift while those in meta position move downfield.^ The multiplet for H-2 
proton also exhibited large downfield shift in presence of P-CD while H-3 signals did not 
show any appreciable deviations. The signal for H-4 of keto form also moved downfield 
but no significant change for the same proton of enol form was observed. The observed 
shift changes in the aromatic proton signals, further confirm that the aromatic part of the 
CHL molecule is involved in the formafion of CHL-P-CD inclusion complex. ' The 
chemical shift change (A5) data for studied CHL protons is given in Table 12. 
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Fig. 55 Partial' H NMR (300 MHz) spectra showing signals for the protons of CHL. in 
the absence as well as in the presence of p-CD. 
Table 12 II NMR (300 MHz) chemical shift change (AS) values for the CHL protons in 
: 0, 
the presence of P-CD in DiO at 25 C 
Samples 
A 
B 
C 
n 
E 
[P-CD]/ 
[CHL] 
2.31 
1.95 
1.56 
1.38 
1.27 
H-2 
0.130 
0.128 
0.115 
0.108 
0.086 
Keto 
0.009 
0.006 
0.005 
0.004 
0.003 
H-3 
Enol 
0.023 
0.022 
0.022 
0.021 
0.020 
Keto 
0.161 
0.154 
0.134 
0.123 
0.105 
H-4 
Enol 
0.032 
0.029 
0.026 
0.024 
0.020 
H-5,8 
0.093 
0.086 
0.082 
0.079 
0.078 
H-6,7 
-0.028 
-0.027 
-0.025 
-0.022 
-0.021 
Xegative values indicate upfield shifts 
Stoichiometry of the CHL-/}-CD Complex 
The stoichiometry and overall binding constant {K^) for the CHL-P-CD complex/es were 
determined by the Scott's modification^^^ of Benesi-Hildebrand equation for 1:1 
complex. In the Scott's equation, 
[G]t/A6obs=[G]t/A6„ax+l/A:aA5 
max 
[G]t is the molar concentration of the CHL, A5obs is the observed chemical shift difference 
for a given [G]t concentration, ASmax is the chemical shift difference between a pure sample 
of complex and the free component at the saturation and K^ is binding constant for the 
complex. The ' H N M R chemical shift change data was obtained for p-CD protons in the 
presence of CHL by keeping the concentration of P-CD constant. The plots of ASH-3' and 
ASH-5' against [CHL] in the form of [CHL]t/A6 verses [CHL]t were found to be linear, 
confirming that the stoichiometry of the CHL-P-CD complex/es is 1:1 (Fig. 56). The 
slope of the plot is thus equal to 1/ASmax and the intercept with the vertical axis equal to 
l/AfaA5max, allowing the estimation of A^a- The overall binding constant {K^ was determined 
to be 81 M''. 
360 
320 
I 280-1 
D. 
S 240 
CO 
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^ - 2 0 0 
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12 16 20 24 28 
[CHL] mM 
Fig. 56 Scott's plot of [CHL],/AS verses [CHL], showing 1:1 stoichiometry for CHL-[^-CD 
complex. 
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ROESYSpectral Data ofCHL-p-CD Mixture 
r245 ROESY " experiment was performed on a l.i mixture of D-(-)-chloramphenicol-P-CD 
(Figs. 53 and 57). A set of cross peaks connect both the H-5' and H-3' of P-CD to aromatic 
ring protons of CHL, indicating that aromatic ring is included in the P-CD cavity. The 
presence of strong cross peak between H-5, 8 of aromatic ring with H-3' while relativeh 
weak interaction with H-5' of P-CD, clearly indicate that H-5, 8 protons are near the wider 
rim. Strong intermolecular interactions were observed for H-6, 7 with both H-3' and H-5' 
protons of P-CD, indicating that there is a close proximity between H-6, 7 protons of CHI. 
and P-CD inner cavity protons (H-3' and H-5') as shown in Fig. 57. This can only be 
explained by deep penetration of aromatic ring from wider rim side of the cavity. The fact 
that aromatic ring penetrates deep into the P-CD from the wider rim side is supported b> 
observed highfield shift changes in the H-6, 7 aromatic protons, in the presence of p-CD. 
which may be explained in terms of close proximity of these protons with oxygen atoms of 
nitro group in free state while in complexed state these oxygen atoms (nitro group) ma\ 
form H-bonds with 6'-0H P-CD, thus weakening the interaction between nitro group 
oxygen atoms and H-6. 7. Therefore, the H-5, 8 protons come in sizable contact with only 
H-3' while H-6, 7 are in the vicinity of both H-3' and H-5' of p-CD (Scheme 3). The 
sizeable through space contact between H-6, 7 and H-3' of P-CD can only be explained b> 
deep penetration of aromatic ring. The structures proposed for complexes formed between 
CHL and P-CD in aqueous solution in the concentration range studied, are shown in 
Scheme 3. 
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Fig. 57 Parliul contour plot of the 2D ROESY spectrum ofCHL-P-CD complex. 
HO, I /CI 
n-{-)-Chlorainphcnicol 
Keto I'oiiii 
p-Cyclodextrin 
D-(-)-Chloramphcnicol-P-CD 
K,eto Form 
D-(-)-Chlorampheiiicol 
Hiiol I'orm 
NO, 
D-(-)-Chloramplienicol-p-CD 
Eiiol Form 
Scheme 3 A plausible inclusion equilibria proposed for CHL-fJ-CD complex. 
Condusions 
The detailed H NMR spectroscopic study of D-(-)-cliloramphenicol and mixtures o\ 
n-(-)-chloramphcnicol with P-CD in aqueous solution at 25 C, revealed the formation o\ 
1 :t tiuht fitting inclusion complexes, in which the aromatic rings are penetrating deep from 
the wider rim side of the hydrophobic cavity. The proposed structures for complexes formed 
between CHL and P-CD, are shown in Scheme 3.""'' 
\p:^^% 17 
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CKA^PT^^Vl.... 
NMR Study of Complexation of P-Cy do dextrin and 
Fluoxetine Hydrochloride 
Fluoxetine hydrochloride (FHL, a psychotropic drug) is chemically designated as 
(±)-N-methyl-3-phenyl-3-[(a, a, a-trifluoro-p-tolyl)oxy]propylamine hydrochloride."'''' "'"" 
FHL, commercially known as "Prozac", is an antidepressant, antiobsessional and 
antibulimic drug. It is a potent and selective inhibitor of serotonin uptake.^ ^^ The uptake 
inhibition by fluoxetine enhances serotonergic function. As a consequence the serotonin 
receptors are desensitized or down regulated after long-term fluoxetine administration. 
Fluoxetine does not appear to cause down regulation of post synaptic beta-adrenergic 
receptors or a decrease in beta-adrenergic-stimulated cyclic adenosine monophosphate 
generation, as do other antidepressant medications. " ^ 
Fig. 58 Structure of Fluoxetine hydrochloride. 
119 
^EjqperimentaC 
H NMR spectra (Figs. 59-64) of pure FHL and mixtures of FHL and P-CD were recorded 
on a 500 MHz Bruker instrument in D2O at 25°C, without adding any external reference. 
Chemical shift values are reported in 5 (ppm) with reference to anomeric proton H-l" of 
P-CD. Five samples of mixtures of FHL and P-CD were prepared for obtaining 'H NMR 
spectra, by keeping the concentration of the FHL constant at 20 mM while the 
concentration of P-CD was varied from 8 mM to 28 mM. The molar ratios ([P-CD]/[FHL|) 
were calculated by direct integration of appropriate signals. The COSY spectrum of 1:1 
FHL-P-CD mixture (Fig. 65) was recorded on a 300 MHz Bruker instrument while 2D 
ROESY (Fig. 66) experiment was carried out on a 500 MHz Bruker instrument for a 
mixture of P-CD and FHL, having a molar ratio [P-CD]/[FHL] = 0.45, with a mixing time 
of 225 ms. Distinct peaks for complexed and uncomplexed forms of FHL were not 
observed in any of the spectrum indicating a rapid exchange of FHL between free and bind 
state on the NMR time scale. 
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^suCts and (Discussion 
^HNMR Chemical Shift Change Data of P-CD 
The signals for FHL and P-CD did not interfere with each other in the mixtures of P-CD 
and FHL. The P-CD proton signals were easily identified by their characteristic shapes and 
chemical shift values. ^^ (similar to Chapter-Ill & IV). 
The H-5' and H-3' proton signals, situated inside the p-CD cavity, exhibited significant 
highfield shifts in presence of FHL; the H-5' shifts being dominant while H-3' shifts as 
subordinate. The H-2' proton signal of P-CD also moved significantly downfield in 
presence of FHL. Though signals for H-4' and H-6' also displayed downfield shifts, these 
were not very significant. The highfield shift changes in the P-CD inner cavity protons 
(H-3' and H-5'), confirmed the inclusion of the FHL into the P-CD cavity resulting in the 
formation of FHL-P-CD inclusion complex, as reported previously. ' The pattern of 
the spectral region containing P-CD signals, in the absence as well as in the presence of 
FHL is shown in Fig. 67. 
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Fig. 67 Partial 'H NMR (500 MHz) spectra shoM'mg signals for the protons of /)-CD, in 
the absence as well as in the presence ofFHL. 
^H NMR Spectral Assignment for Fluoxetine 
Hydrochloride Protons 
'H NMR spectrum of pure FHL exhibited a set of protons signals in the aromatic region, 
totally integrating for nine protons. A pair of doublets, each integrating for two protons and 
showing A2B2 pattern, was found to be a part of the same aromatic ring (-CF3 substituted 
ring), on the basis of cross peaks observed between these doublets (Fig. 65). The doublet at 
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7.573 (2H, J = 8.8 Hz) was assigned to H-1, 4 which should appear downfield due to 
deshielding effect of-CFs group. This imphes that the doublet at 7.091 (2H, J = 8.8 Hz) 
was due to H-2, 3 protons of-CFs substituted ring. A triplet at 7.393 (IH, J = 7.2 Hz) was 
ascribable to H-8 while the remaining four phenyl ring protons appeared merged in the 
region 7.430-7.505. A singlet at 2.779 for three protons was due to N-CH3. A doublet of 
doublet at 5.618 (IH, Ji =- 4.2 Hz, J2 = 8.2 Hz) was ascribed to benzylic proton (H-5) 
because h exhibited through space coupling with H-11, as shown in the ROESY spectrum 
of mixture of FHL and P-CD. A pair of multiplets centered at 2.364 and 2.463, each 
integrating for one proton, was assigned to methylenic protons (H-11) while signals for 
other methylenic protons (H-12) were found to be resonating, as a pair of multiplets. 
centered at 3.261 and 3.346. 
^H NMR Chemical Shift Change Data of Fluoxetine 
Hydrochloride 
Contrary to the highfield shift changes experienced by the protons situated inside the 
cyclodextrin cavity, all the protons of the guest molecule, and not only the proton included 
in the P-CD cavity, show downfield shift changes upon complexation.^''^ The downfield 
shift changes in the guest molecule have been attributed to, besides the shielding effect by 
the cavity, other factors like changes in the microenvironment and guest conformational 
changes upon complexation.^"' Prominent changes in the nature and position of signals for 
most of the protons of fluoxetine hydrochloride were observed in the presence of P-CD. 
which increased with the increase in the concentration of P-CD (Fig. 68). The signals for 
the phenyl ring protons moved downfield and became complex making their assignment 
impossible. The signals for H-2, 3 of trifluoromethyl substituted aromatic ring exhibited 
downfield shift changes with the increase in the concentration of P-CD and signals for two 
diastereomers started separating. A very significant upfield shift was observed in the H-1, 4 
proton signal in the presence of P-CD. Kano et. al.^ ^^ reported that in the presence of an 
electron withdrawing group at para-position of the aromatic ring, the protons ortho to polar 
group exhibit upfield shift while those in meta-position move downfield and penetration of 
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-) I o _ 
the ring (bearing a polar group) takes place from the wider rim side.' The peaks for H-5 
proton of the two diastereomers also separated in the presence of P-CD. Downfield shift 
changes were also observed in the signals for two methylenic groups of the FHL in 
presence of P-CD. Therefore, the observed chemical shift changes in the signals of FHL. 
clearly suggest that FHL is involved in the formation of FHL-P-CD inclusion complex."' 
"•"' 'H N M R chemical shift change (A6) values for various studied protons of the FHL 
molecule are given in Table 13. 
^miT-'H-iA 
[p-CD]/[FHL]-1.40 
[p-CD]/[FHL]=1.05 
[p-CD]/[FHL]=0.88 
H-Ph 
H-1,4 
[p-CD]/[FHL]=0.45 ^ ^ 
H-1,4 ' 
[P-CD]/[FHL]=0.40 rr-^ 
[FHL] H-1,4 H-Ph H-2,3 H-5 M jMJl,, MA 
—1 r 
7.6 
- ' /—r 
7.5 7.4 7.1 5.6 
Fig. 68 Partial 'H NMR (500 MHz) spectra showing signals for the protons of FHL. in 
the alxscncc as well as in the presence of (i-CD. 
Table 13 H NMR (500 MHz) chemical shift change (AS) values for various protons of 
the FHL in the presence of fi-CD in D2O at 25 C. 
Samples [p-CD]/ H-1,4 H-2,3 H-5 H-lla H-llb H-12a H-12b H-13 
[FHL] 
-0.021 0.131 0.093 0.005 0.040 0.050 
-0.019 0.119 0.088 0.060 0.047 0.042 
-0.018 0.112 0.082 0.041 0.038 0.041 
-0.013 0.050 0.035 0.022 0.016 0.010 
0.056 -0.003 -0.016 0.025 0.013 0.104 0.005 0.010 
A 
B 
C 
D 
E 
1.40 
1.05 
0.88 
0.45 
0.40 
-0.138 
-0.115 
-0.102 
-0.060 
-
0.047 
0.040 
0.038 
0.016 
: 
Negative values indicate upfield shifts 
Stoichiometry of the FHL-p-CD Complex 
To determine the stoichiometry of the FHL-p-CD complex, the variation in the chemical 
shift of H-1, 4 with increasing concentration of P-CD was studied. A plot of chemical shift 
changes in the form of A6H-I,4 verses [p-CD] was plotted (Fig. 69),^ ^^ which showed that 
the chemical shift changes of guest aromatic protons (H-1, 4) increase in a linear fashion up 
to 1:1 complex ratio and started saturating as the concentration of P-CD was further 
increased indicating 1:1 stoichiometry for FHL-p-CD complex in solution but there is some 
element of uncertainity. 
To confirm the stoichiometry of the FHL-p-CD complex, Scott's modification^^^ of 
Benesi-Hildebrand method^^^ was then used. In the Scott's equation for 1:1 complex: 
[CD]t/A5obs= [CD]t/A6„ax + l/^aA6 max 
[CD], is the molar concentration of the CDs, ASobs is the observed chemical shift difference 
for a given [CD], concentration, A5max is the chemical shift difference between a pure 
sample of complex and the free component at the saturation, K^ is the binding constant. The 
chemical shift changes for H-1, 4 were plotted against the concentration of P-CD, in the 
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form of [P-CD]/A5H-I,4 versus [P-CD] which gave a straight line (Fig. 70) confirming the 
1:1 stoichiometry for the p-CD-fluoxetine hydrochloride complex. The overall association 
constant {K^ of the complex/es was determined to be 71 M"'. 
0.14 
0.12 
I. 0.10 
? 0.08 
0.06-
0.04 
H-1,4 
0.8 1.2 1.6 2.0 2.4 2.8 
-2 [p-CD]xlO (M) 
Fig. 69 A plot of the chemical shift changes of H-1, 4 protons of FHL molecule during 
titration with P-CD in D2O, indicates a presence of 1:1 FHL-P-CD complex. 
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6 0 
U 
I 
CD. 
[p-CD]xlO (M) 
Fig. 70 A Scott's plot of [/^-CDJ/ASH.IJ versus [P-CD] showing 1:1 stoichiometry for (i-
CD-FHL complex. 
ROESY Spectral Data ofFHL-p-CD Complex 
In order to have an insight into the mode and depth of penetration, to confirm 
whether both the aromatic rings were involved in the complexation and to determine a 
detailed structure of complex/es, ROESY "^^ experiment was performed on a mixture of 
FHL and p-CD. The cross peaks were observed between both the aromatic ring protons of 
FHL molecule with P-CD inner cavity protons (H-3' and H-5'), confirming that both the 
aromatic rings are involved in complexation with P-CD (Fig. 71). 
The ROESY spectrum exhibited cross peaks between H-2, 3 of trifluoromethyl substituted 
aromatic ring with both H-3' and H-5' of P-CD, while H-1, 4 of FHL showed cross peak 
with only H-5' of P-CD, situated near the narrow rim. It can be argued on the basis of these 
observations in the ROESY spectrum that H-1, 4 of FHL are in the close proximity of H-5' 
but H-2, 3 of FHL are close to both the H-3' and H-5' which can only be explained if the 
CF3 substituted ring enters the P-CD cavity from the wider rim side and penetrates deep so 
that the CF3 group protrudes outside the narrower rim of p-CD cavity as shown in Mode-I 
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(Scheme 4). This is furtlier supported by the highfield shift changes in the H-1, 4 signals in 
the presence of P-CD 216,263 
A single cross peak was observed for phenyl ring protons with H-3' of P-CD (Fig. 71). 
which is located near the wider rim suggesting that phenyl ring is near the wider rim and 
since no cross peak was observed with any of the phenyl ring protons with H-5', it can be 
concluded that phenyl ring is partially inserted into the P-CD cavity and the penetration is 
shallow (Mode II). The proposed structures for the complexes formed between FHL 
and P-CD in aqueous medium at room temperature are shown in Scheme 4. 
H-1,4 
(ppm) 
H-5'/H-I,4 H-5'/H-2,3 
0 
H-3'/H-Ph ^^3'^-2.3 
-3.5 
1—I—I—r 
7.5 
-4.5 
7.0 
Fig. 71 Partial contour plot of the 2D ROESY spectrum ofFHL-P-CD at 500 MHz in D2O 
at 25 "C. 
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3 4 
13 
NHCH3 
Fluoxetine Hydrochloride 
13 
NHCH3 
Mode I Mode II 
Scheme 4 Plausible structures proposed for two 1:1 FHL-P-CD inclusion complex. 
ConcCiisions 
The detailed NMR spectroscopic study of fluoxetine and mixtures of fluoxetine and P-CD. 
in aqueous solution at room temperature, revealed the existence of two 1:1 diastereomeric 
inclusion complexes. One complex was formed by the deep penetration of trifluoromethyl 
substituted aromatic ring into the P-CD cavity from wider rim side while other complex 
was formed by the shallow penetration of phenyl ring of fluoxetine into the P-CD cavity 
from the wider rim side.^ ^^ 
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cnyKPT^^i^iL... 
NMR Study of Complexation of p-Cyclodextrin and 
Parecoxib Sodium 
Parecoxib (parecoxib sodium, PRB) is commercially known as "Dynstat" and is chemically 
designated as N-{[4-(5-methyl-3-phenylisoxazol-4-yl)phenyl]sulfonyl} propanamide.^^'''^^^ 
Several new cycIo-oxygenase-2 (COX-2) specific inhibitors, known as "Coxibs", have 
been tested in acute pain. These drugs specifically inhibit only one of the two 
cyclooxygenase isoforms inhibited by older non-steroidal anti-inflammatory drugs 
(NSAIDs). Parecoxib is a water soluble sulphonamide based pro-drug that undergoes 
complete and rapid biotransformation to valdecoxib, a potent and selective inhibitor of 
COX-2.^ '^ ^ Traditionally oral NSAIDs are used to treat mild to moderate acute pain. This is 
problematic, however, when the patients are unable to take oral medication or are nauseous 
and vomiting. Parecoxib (PRB) is a selective non-steroidal anti-inflammatory drug, which 
has been developed with the aim of producing pain control comparable of traditional 
NSAIDs, with a reduced risk of serious adverse gastrointestinal and antiplatelet effects. 
Moreover, it is also the first selective COX-2 inhibitor administered as intramuscular or 
intravenous injection for short-term management of post-operative pain 270,271 
H,C-
Fig. 72 Structure of Parecoxib sodium. 
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^EjqperimentaC 
AH the 'H N M R spectra (Figs. 73-77) of pure PRB and mixtures of PRB and |3-CD were 
recorded on a Bruker 400 MHz instrument in D2O at 25 °C, without using any external 
reference. Chemical shift values, reported in 5 (ppm), were calculated with reference to 
HDO proton signal at 4.790. 'H NMR chemical shift change data was obtained for PRB 
protons, to determine the stoichiometry of the inclusion complex, by keeping the 
concentration of the PRB constant at 10 mM while the concentration of P-CD was varied 
from 3.90 mM to 13.7 mM. The molar ratios ([p-CD]/[PRB]) were calculated by direct 
integration of appropriate signals. The COSY (Fig. 78) and 2D ROESY (Fig. 79) spectra 
were recorded on an 800 MHz Bruker instrument for a mixture of PRB and P-CD, having 
[P-CD]/[PRB] molar ratio as 0.625, at 25 ''C in D2O. Distinct peaks for complexed and 
uncomplexed form of PRB were not observed indicating rapid exchange of PRB between 
free and bind state on the NMR time scale. 
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^suCts and (Discussion 
^H NMR Chemical Shift Data of P-CD 
The signals for PRB and (3-CD did not interfere with each other in the spectra of mixtures 
of P-CD and PRB. The assignment of all the P-CD proton signals was made with the help 
of their characteristic shapes and chemical shift values, '^*'' and was further confirmed by 
COSY spectral data (Fig. 78). 
All the P-CD proton signals displayed chemical shift changes in the presence of parecoxib. 
Fig. 80 shows the spectral region containing P-CD protons for pure p-CD as well as 
mixture of P-CD and PRB. Significant chemical shift changes for the protons positioned 
inside the cavity, namely H-3' and H-5', and the protons located near the narrower rim 
(H-6') were observed in the presence of PRB. The protons situated near the wider rim. 
H-2' and H-4', showed only insignificant deviations in the presence of PRB. Moreover, the 
chemical shift change for H-5' were found to be more dominant as compared to H-3'. The 
observed shift changes in the P-CD cavity protons, and the concomitant chemical shift 
changes in the PRB proton signals, in the spectra of mixtures of p-CD and PRB, compared 
to pure components, are clear indication of inclusion of some part of the guest into the 
P-CD cavity and thus confirming the formation of P-CD-PRB inclusion complex/es.''''' 
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H-2' ^H-4'^ 
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Fig. 80 Parts of'H NMR spectra of fi-CD (400 MHz), showing the changes in chemical 
shift for P-CD protons on interaction with parecoxib. 
^H NMR Spectral Assignment for Parecoxib Protons 
The assignment of signals of the parecoxib, in the absence as well as in the presence of 
P-CD, was very straight forward. The aliphatic region of the spectra exhibited a singlet for 
three protons, a triplet for three protons and a quartet for two protons which were easily 
assigned. The aromatic region of the spectra integrated for nine protons which were due to 
the protons of the two aromatic rings. The protons of the para-disubstituted ring were 
observed as a pair of doublets, interacting with each other in the COSY spectrum (Fig. 81). 
showing A2B2 pattern which were ascribed to H-3, 5 and H-4, 6 protons, respectively. The 
H-3, 5 signal is being deshielded by sulphonyl group. The protons of the phenyl ring were 
observed as a triplet for one proton (H-10) which appeared in the lower field and the 
signals for the remaining four protons appeared merged together and could not be 
distinguished. 
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Fig. SI A section of COSY spectrum (800 MHz) showing aromatic signals ofPRB. 
^HNMR Chemical Shift Change Data ofParecoxib 
Prominent changes in the nature and position of signals for most of the protons of 
parecoxib were observed in the presence of P-CD, which increased with the increasing 
concentration of P-CD. The chemical shift changes for ahphatic protons were also observed 
but these were found not to be affected by the change in the concentration of P-CD. The 
observed chemical shift changes in the aromatic signals of PRB, therefore, clearly suggest 
that aromatic rings of PRB are involved in the formation of PRB-P-CD inclusion 
complex/es.^'^' ^'^^ Part of spectra exhibiting aromatic proton signals of parecoxib, in the 
absence as well as in the presence of P-CD, are shown in Fig. 82 while chemical shift 
change (A6) data for parecoxib protons is given in Table 14. 
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Fig. 82 Partial 400 MHz 'H NMR spectra for parecoxib in the absence and presence of 
0^. jj-cyclodextrin, in D2O at 25 C. 
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Table 14 'H NMR (400 MHz) chemical shift (S, ppm) data for PRB and chemical shift 
change (AS) values for the studied protons of PRB in the presence of fi-CD in D2O at 
25 "C. 
Protons 
H-3,5 
H-10 
H-4,6 
H-7 
H-2 
H-1 
[PRB] 
7.721 
7.403 
7.274 
2.387 
2.089 
0.911 
[P-CD]/ 
[PRB] 
=1.15 
0.116 
0.071 
0.043 
0.048 
0.063 
0.058 
[p-CD]/ 
[PRB] 
=1.10 
0.110 
0.071 
0.046 
0.049 
0.060 
0.055 
[P-CD]/ 
[PRB] 
=0.88 
0.100 
0.068 
0.050 
0.049 
0.062 
0.056 
[P-CD]/ 
[PRB] 
=0.42 
0.076 
0.034 
0.003 
0.023 
0.067 
0.060 
Stoichiometry of the PRB-P-CD Complex 
The determination of stoichiometry of the complex is the first step for any structural studies 
of the inclusion complexes, which was determined by using Hanna-Ashbaugh modification 
of Benesi-Hildebrand method.^ ^^ In the Hanna-Ashbaugh equation: 
l / A 5 o b s = l / ^ a A § m a x [ C D ] o + l / A S 
max 
A5obs is the observed chemical shift change for a given [CD]o concentration, ASmax is the 
chemical shift change between a pure sample of complex and the free component, A.'a is the 
binding constant and [CD]o is the initial concentration of the host. 
A double reciprocal plot was obtained for H-3, 5 by plotting A5H-3, 5 against [P-CD]o in the 
form of 1/AS versus l/[p-CD]o which gave a straight line, with the slope 
l/^ aA6n,ax = 26.50938 mM ppm'' and intercept l/ASmax = 6.30737 ppm"' (Fig. 83),"^- ^^^ 
152 
confirming the 1:1 stoichiometry for the PRB-p-CD complex. The overall binding constant 
(Ka) of the complex/es was determined to be 238 M"'. 
14.0-
13.0-
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f 11.0-
<! 
- 10.0-
9.00-
^ nn 
o.UU^ 1 
0.08 
1 ' 1 • 
0.12 0.16 
l/[(3-CD]omM"' 
/ H - 3 , 5 
1 ' 1 ' 
0.20 0.24 
Fig. 83 Illustration of the Hanna-Ashbaugh modification of Benesi-Hildebrand method fi)r 
1:1 PRB-P-CD complex. 
ROESY Spectral Data ofPRB-fi-CD Complex 
In order to have an insight into the mode and depth of penetration, to ascertain the 
involvement of both the aromatic rings in the complexation and to determine a detailed 
structure of complex/es, ROESY,^^ '^ ^^"^  experiment (Fig. 79) was performed on a mixture 
of parecoxib and P-CD. The cross peaks were observed between all the proton signals of 
the two aromatic rings of PRB molecule with P-CD inner cavity protons (H-3' and H-5'), 
confirming that two aromatic rings are involved in complexation with p-CD. Moreover, the 
intensities of all the cross peaks between P-CD cavity protons and PRB aromatic ring 
protons were almost same (Fig. 84). 
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Fig. 84 A partial 800 MHz 2D ROESY spectrum of mixture of parecoxib and [i-CD 
f[/]-CDJ/[PRBJ=0.625, in D2O at 25 "C with mixing time of 500 ms. 
Thus, taking into account the 1:1 stoichiometry of the complex/es, it can be argued that 
several complexes are present in the solution. There are two probable modes of entry for 
each aromatic ring into the P-CD cavity and none of these can alone explain the identical 
intensities of intermolecular cross peaks. It seems more appropriate to assume that two 1:1 
complexes involving each aromatic ring and differing in the mode of penetration are 
present in solution. Thus, it can be inferred that four 1:1 P-CD-PRB inclusion complexes 
are formed in solution at room temperature. The proposed structures of all the four 1;1 
PRB-P-CD inclusion complexes formed between PRB and p-CD in aqueous medium at 
room temperature are shown in Scheme 5. 
.54 
1 2 
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Scheme 5 Supposed representation of all the four possible mode of penetrations for 1:1 
inclusion complexes formed between PRB and /3-CD system in solution. 
ConcCusions 
The detailed H NMR spectroscopic study of parecoxib and mixtures of parecoxib and 
(3-CD, in aqueous solution at room temperature, confirmed the presence of four 1:1 P-CD-
PRB inclusion complex, involving the penetration of two aromatic rings into the p-CD 
cavity from narrower as well as from wider rim sides, as evidenced by ROESY 
spectrum. 272 
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SHORT COMMUNICATIONS 
30 mill) (Pliarmakopca I'olska I9')3). ll is iiucicsiiiig ihal 
an increasing proportion of xylitol in model tablets is ac-
companied by an increase in measurable tablet diameter 
during storage. Average values of disintegration time of 
model tablets are specified in Table 2. This property, re-
sulting from so called "crystallographic memory" of the 
xyliio! structure, described by the approximation equation, 
should be taken into consideration during design of packa-
ging (blisters) not only to reduce losses during blistering 
but also to pro\ ide the required practical stability of a pre-
paration. 
Experimental 
1. Excipients 
.Si)rbil()l: .Neosorb P 60 W (Roquette-Lustcmi. France; Xyliiol: Xylisorb 
300 (Roquettc-Leslrem, Francci: HNdioxypropylmethyl cellulo.se (HPMC): 
I'iKiniiacdal 904 (France); Oiba.sic calcium phosphate - CaHPO.i • 2 H;0 
(Calcium imho pho.sphale p.a.) POCH Glivvice (Poland), C-72-04 Buden-
heim; Magnesium stearate 
2. Instruments and methods 
"ILXACT.A, 2["' numerical (ableKing machine with computet control which 
etiahlcs monitrning of the compression process at prr)grammed itiorph(»lo-
eical parameters of a model lablel. •"ri'RBl'I.A type 'r2("' inr\er with 
standaid glass containers V .lOdm' in which tablet leed (po\^der) Ii>r 
direct Itibleiting u ;is mtide. Hieclronic micrometer pixtduceii by Mittitoyo 
( I ' K i Lid; Patent FP OO.S.^ om. Measurement ol morphologictil vtihics of 
a taliiei (d - 2r. hi utis made with an accuracy ol 1-O.Ol mm. Hardness 
tester; .Schleuninger Type T 2 C i .Switzerland i and ERWFK.A type TB -
•M i(rerni;in\). FRVV'FK.A mslrumeni to determine tablet disintegration 
time 
The product lor direct labletting «as prepared in a TURBL'I.AT2C mi.\er 
by inning NeoMirb P6I)W. Xylisorb ?(»). HPMC and CaHPO.i 2 H;0 lor 
1.'^  mm. The coinparative particle size at the mixed coinpiinenis was main-
tained in a lorrnulalion, Atier introducing the magnesium siearate the com-
ponents were mixed m alternaling planes tor 5 min al a speed ol" 20i7>m. 
The compression process was earned out in an "EXACTA 21" tabletung 
machine using computer oplimizatton ot the morphological parameters of 
ntodel tablets. 
The dit'ferent types of model tablets were produced in quantities ot 4 .5 -
.5.0 thotisand units. 
Tests were inade ,according to the requireinents of FP V (Pharmakopea 
Ptilska 199,"^ ). The results obtained for each of the four model types, which 
are characterized by different contents of xvhtol. were estimated statisti-
cally. 
The evaluation of hardness of the model tablets was inade with a Schleuni-
gcr T 2 C hardness tester ex tempore and after the first (12 inonths) and 
second (24 months) yeai of storage. The measurements were made for 
20 tablets selected al randoin and were analysed statistically. 
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A NMR spectroscopic study of mixtures of varying rati-
os of roxatidine acetate hydrochloride (RAH) and p-cy-
clodextrin (P-CD) in D2O revealed the formation of a 
1 :1 inclusion compound. The aromatic ring of RAH se-
lectively penetrates the p-CD cavity in preference to 
the piperidine ring. 
Cyclodextrins (CDsj hold a variety of guests into their h\-
drophobic cavities (.Steed and Atwood 2000; VVimmcr 
etal. 2003) and serve as useful models for studying topo-
chemistry and catalytic mechanism of enzymes (Bender 
1988). CDs are widely used in pharmaceutical applications 
as a \ehicle for drug delivery of pooriy water-soluble 
drugs (Aithal and Shrinivas 1996; Frdmming and Szejtli 
1994). Extensive studies on inclusion complexes of various 
medicinally useful compounds with p-CD have been re-
ported (Aithal and Shrinivas 1996; Fromming and Szejtii 
1994; Menard etal. 1990). We report, herein, our results 
on the study of the inclusion complex of roxatidine acetate 
hydrochloride (RAH), a potent anti-ulcer drug (Murdoch 
1991), with P-CD in solution by NMR spectroscopy. 
The ' H NMR spectra were recorded for five samples with 
1RAH]/[P-CD] molar ratios varying from 0.77 to 4.55 as 
determined by direct integration of the NMR signals. The 
anomeric proton (H-1) of P-CD was used as internal refer-
ence throughout this work. 
The signals for RAH and p-CD protons did not interfere 
with each other in any spectrum. The signals for aromatic 
protons of the RAH molecule appeared as a singlet (H-6'), 
a doublet (J = 8.1 Hz H-2',4') and a triplet (J = 8.0 Hz H-
3') in all the cases except in the spectrum of the pure drug 
in which the doublet for H-2',4' and H-6' singlet were 
found partly overlapping. 
The induced chemical shift change (A6i) for p-CD pro-
tons were calculated relative to reported 'H NMR data 
(Schneider etal. 1998). Each sample spectrum denoted 
largest A6i for the H-3 and H-5 protons of the P-CD. The 
other P-CD's protons showed either much smaller or neg-
ligible deviations. The A6i data for various protons of P-
CD in the presence of varying amount of RAH is given in 
the Table. In the presence of RAH, the peaks for H-3 and 
H-5 protons of the P-CD moved progressively upfield 
with the increase of concentration of RAH. The Fig. 
shows the part of the NMR spectra of samples A to E, 
containing signals for protons of P-CD, NMR spectra of 
samples A and B were recorded on a 200 MHz spectro-
meter while those of samples C, D & E were obtained on 
a 300 MHz instrumenl. The spectra of samples A and B 
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Table: 'H NMR chemical shift chanjjes (Afij) of (5-CD and RAH protons upon complexation 
S.mipl 
A 
B 
C 
D 
E 
[< i | / | i i | 
0.77 
1.19 
1.96 
3.50 
4.55 
i;-c'>cKKifMi 
H^: 
0.0141 
0.0107 
0.0060 
0.0)40 
0.0170 
" 
Hi 
-0.0176 
-0.0276 
-0.0495 
-0.0985 
-0.1455 
H^4 
0.0093 
0.0079 
0.0095 
0.0145 
0.0185 
H-5 
-0.0182 
-0.0281 
-0.0505 
-0.0995 
-0.1535 
H-6 
-0.0075 
-0.0095 
-0.0135 
-0.0135 
-0.0255 
.^ A, (H-5)/ 
A.I, lH-.1l 
1.03 
1.01 
1.02 
1.01 
1.05 
Ri).\;tliditic ;RC 
H-2'.4' 
0.0214 
0.0155 
0.0100 
0.0070 
0.0050 
•lie hidrochlondc 
H-.V 
0.0302 
0.0220 
0.0120 
0.0082 
0.0041 
H-6 
-0.0388 
-0.0322 
-0.0130 
-0.0087 
-0.0037 
Ni:i;.,u\>.- values mdicales uplk-ld shift. 
are very much alike due to small change in [RAH]/[|3-CDJ 
molar ratio but the shift of signals for H-3 and H-5 pro-
tons is obvious. The .shift of signals for H-3 and H-5 pro-
tons in the spectra C. D and E is very prominent. 
The penetration of the less polar portion of the guest 
molecule into the \]-CD cavity from the wider side com-
prises the most common mode of complexation. Since 
the H-3 and H-5 protons are positioned inside the cavity, 
the inclusion of guest into the P-CD cavity causes major 
upfield shifts of these protons. This is attributed to the 
ring current of the aromatic ring of the guest molecule 
that is included in the cavity (Komiyama and Hirai 
198()a. 1980b). On the other hand, most of the guest 
protons show downfield shift changes but the Abi values 
for guest protons are much smaller in magnitude com-
pared to host protons. Rekharsky etal. (1995) have de-
monstrated that the magnitude of the uptkld shifts of 
H-3 and H-5 protons of CDs. A<M(H-3) and A6i(H-5). 
and their relative ratios A6i(H-5)/Ahi(H-3), can be used, 
respectively, as a quantitative measure of the stability of 
complex and the depth of inclusion of ligand into the 
cavity. 
The obser\ed high field shifts in the H-3 and H-5 peaks 
of (>CD in the presence of varying amount of RAH thus 
clearly indicate the insertion of the aromatic ring of the 
RAH into the (3-CD cavity. Moreover, the magnitude of 
the shifts for H-3 and H-5 protons of (i-CD increased as a 
function of an increasing ratio of [RAH]/[P-CD1 giving a 
slightly curved line for A6i(H-3) vs [RAH1/[P-Cb] plot. 
A modified Hildebrand-Benesi plot (Benesi and Hilde-
brand 1949: Qi etal. 1991) of chemical shift change data 
for H-3 of p-CD in the form of (fRAH]/[P-CD])/A6i(H-3) 
vs [RAHJ/[P-CDJ gave excellent linear fits supporting the 
i : 1 complex formation. As expected, all the protons ol 
the RAH. except the aromatic proton (H-6'). shoued 
downfield shifts on complexation. The A6i data for aro-
inatic protons of RAH in the presence of varying amounts 
of P-CD is given in the Table. There was no significant 
change observed in the chemical shift values of protons of 
RAH molecule in the spectra of samples C, D and E. This 
is in good agreement with the ecirlier observation that w ith 
the increase of concentration of guest, the A6i values tor 
guest protons decrease (Rekharsky etal. 1995). This phe-
nomenon indicated, in analogy to many previously re-
ported cases (Bergeron and Rowan 1976; Komiyama and 
Hirai 1980a, 1980b), that the phenyl ring of the RAH is 
selectively inserted into the p-CD cavity driven primariK 
by hydrophobic interactions. 
^ 
3.25 
l-ig.: Typical 'H NMR .speclra al a variciy of guest to ho.st |G)/|H] ratios for the complexation of Roxatidine Acetate Hydrochloride [RAH] wiih fi-cyc\o-
dextrin in D:0. Note the large upfield shifts of H-3 and H-5 in sharp contrast to the small shift changes observed for H-2, H-4 and H-6 
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The A6i values for H-2 and H-4 of (3-CD and H-6' aro-
matic proton of RAH need special attention. Normally the 
signal for all the P-CD protons show upfield shifts (if any) 
while all the guest protons show downfield shifts. The 
downfield shifts of H-2 and H-4 of P-CD and upfield shift 
of H-6' of RAH may be attributed to their interaction 
through solvent. The ratios A6i(H-5)/A6i(H-3) were calcu-
lated for all the samples. The relatively smaller values 
(1.01-1.05) for Abi(H-5)/A6i(H-3) ratios compared to 
those reported for other comple.xes (1.2-3.0) suggest that 
the penetration of the aromatic ring in the f5-CD cavity is 
not deep which is expected due to the presence of two 
bulky groups in the meta position of aromatic ring. 
Finally, the 'HNMR spectroscopic study of RAH in the 
presence of P-CD shows that a 1 : 1 RAH-P-CD complex 
is formed in solution which is in rapid equilibrium with 
free P-CD and RAH since the spectra consisted of mainly 
one set of resonances. Moreover, the aromatic ring of the 
RAH selectively penetrates into the P-CD cavity dri\en by 
hydrophobic interactions 
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The new triterpenoid taraxerol-3-p-O-tndecyl ether was 
isolated from the aerial part of Derris triofoliata. The 
structure was established on the basis of spectral data. 
The genus Derris (Leguminous family) is widely spread 
in southeast Asia. It is employed for pest control in horti-
culture, agriculture and in poultry (Gupta etal. 19 )^91, 
Some species are also used in folk medicine (Sekine et al. 
1999; Mahidol etal. 1997). D. triofoliata, a woody clim-
ber growing in the coastal forest throughout south east 
Asia, is used for poisoning fish by local people. The 
whole plant is also used as a stimulant, antispasmodic, 
and counter-irritant (Ramachandran etal. 1986). Previous 
investigations of leaves of Derris trifoliata have yielded 
hydrocarbons, wax esters (Misra etal. 1987). sterols, 
amyrin, lupeol (Ghosh etal, 1985), and two tlavonol gly-
cosides: rhamnetin-3-O-P-neohesperidoside and querceiin-
3-(9-P-ncohesperidoside (Ramachandran etal, 1986), We 
have investigated the chemical constituents of the aerial 
parts of D. triofoliata, and report here the isolation and 
characterization of a new etherified triterpenoid. 
Compound 1, prismy ciystalline (CHCI3—CH3OH), was 
formulated as C43H76O from ESI-MS (m/z 64?" (M ^ kl , 
631 IM-fNa] ' ) , Its 'H and '^C NMR .spectra showed 
great similarity to that of taraxerol (Sakurai etal, 1987). 
In 'H NMR, eight tertiary methyls at 6 1,09 (3H, s), 0.98 
(3H, s), 0,95 (3H, s), 0,93 (3 H, s), 0,91 (6H, s), 0,82 
(3 H, s) and 0,80 (3H, s) were typical for triterpene; an 
oxymethine proton at b 3,20 (1 H. dd, J = 11,0, 4,6 Hz, 
H-3) was observed; a downfield one proton double doub-
let centered at 6 5,53 (J = 11,3, 3,2 Hz, H-15) indicated 
the presence of an olefmic bond, and was assigned to the 
olefinic proton at C-15 of the taraxerane skeleton (Tala-
patra et al, 1981); Two geminal methylene protons at 5 
1.92 (1 H. dd, J = 14,7, 2,9 Hz, H-16a) and 2,03 (! H, m, 
H-16b) could be discerned in the 'H NMR spectra; Che-
mical shifts for one oxymethine carbon at 6 79,08 {€-^1 
olctinic carbons al h 138.10 (C-14) and 116.88 (C-15) 
were all observed. Thus, the carbocyclic nucleus of com-
pound 1 proved to be that of a typical taraxerol. Addi-
tional signals as one oxymethylene carbon at 6 63.11. one 
terminal methyl carbon at 6 14.11. multiple methylene 
carbon signals al 6 29.34 ^ 29.70 indicated that the hy-
dixixyl of taraxol was substituted by a long alkane. And 
CO rono.-iv c 
Available online at www.sciencedirect.com 
S C I E N C E 1/1) D I R E C T ' = N C E ^ I 
ELSEVIER il. KAR.MACO 59 (2004) 835-838 
Article original 
IL FARMACO 
u'ww.el.sevjer.com/locate/farmaj 
NMR spectroscopy of inclusion complex of D-(-)-chloramphenicol 
with P-cyclodextrin in aqueous solution 
Syed Mashhood Ali *, Fahmeena Asmat, Arti Maheshwari 
Department af Cliemislry. Ali/farh Muslim University. Aligiirh-202002 UP. India 
Received 4 March 2004; accepted 12 May 2004 
Available online 19 August 2004 
Abstract 
'HNMR spectroscopic study in D,0 of mixtures of D-(-)-chloramphenicol (guest), present in two tautomeric forms in solution, and 
P-cyclodextrin (host) revealed the formation of 1:1 inclusion complex in which aroinatic ring of the guest is tightly held by the host ca\it\. 
There seems no discrimination between the aromatic rings of two tautomers by the host. 
'0 2004 KIscvier SAS. All rights reserved. 
KcvM-iirils: 'IIN.MR; IncliiMon complexes; (i-('\clode,\iriii; D-f-j-CliloiMniphenicol 
1. Introduction 
Cyclodcxtrins (CDs) are among the most widely used 
hosts for their ability to bind organic tnolecules in aqueous 
solution and in the crystalline state by non-covalent interac-
tions [ 11. The internal diameter of their torus shaped cavity 
and size of the guest molecule are of primary significance for 
the formation of inclusion complexes. The ability of CDs to 
hold a \ai-iety of guests into their hydrophobic cavity has 
tendered them very useful models for studying lopochemis-
iry and catalytic mechanism of enzymes [2\. Inclusion com-
pounds have diffcrcni physico-chemical properties, stich as 
altered solubility, reduced volatility, reduced/enhanced sta-
bility, niodilied chemical rcacli\il\ and altered bio-
availability as compared to free molecule, and that is why 
CDs are widely used in pharmaceutical applications as a 
vehicle for drug delivery of poorly water-soluble drugs 13,41. 
NMR spectroscopy is the most reliable technique [5], of all, 
for the study of inclusion phenomenon because both the host 
and guest molecules are observed simultaneously. NMR 
studies of CD-complexes in solution generally show rapid 
exchange of guest molecule between the hosts resulting in 
averaged shifts and no distinct species on the NMR time-
seak. However, valuable information regarding the inclusion 
•^  Corresponding author 
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of the guest into the CD-cavity, their stoichiometry and 
stability can be extracted thiough treatment of the data from 
simple ' H N M R experiments through the variation of the 
chemical shifts for different protons [6-81. Extensive studies 
on the inclusion complexes of pharmaceutical compounds 
with P-CD have been reported |3.4,9]. In continuation with 
our work on the complexation behaviour of pharmaceuticals 
with P-CD [101. we report here our results on the study of 
inclusion complex of D-(-)-chloramphenicot, an antibacterial 
drug having a wide spectrum of activity against gram positive 
and gram negative cocci and bacilli (including anaerobes) 
1111. with P-CD in solution by NMR spectroscopy. 
2. Results 
' HNMR spectra were recorded on a 300 MH/, instrument 
at 25 °C for tive samples with |H1/[G] molar ratios ranging 
from 2.31 to 1.27 which were determined by direct integra-
tion of the NMR signals. The anomeric proton (H-l)of P-CD 
was used as internal reference throughout this work. The use 
of this proton signal as a reference is justihed because the 
water signal is too wide; H-3. H-5 signals show largest 
chemical shift changes on complexation; H-2, H-4 signals 
may also be affected though situated outside the cavity. The 
location of anomeric proton ensures the smallest (if any) 
induced shift. 
The signals for the protons of the drug and P-CD did not 
interfere with each other in any of the spectrum. 'HNMR 
X3^ S. Mashhoocl All el ,il. / IL FARMACO ?'^ l2l>()4) HJ5-SJ,S 
spectrum of each sample denoted largest chemical shift 
changes (Af)) for H-3 and H-5 protons of the P-CD while the 
other protons of the (]-CD showed negligible deviations in 
the presence ol'guest. The chemical shift change {AS) data 
for \arious protons of the |3-CD in the presence of varying 
amounts of drug is given in Table 1. Part of the NMR spectra 
of samples A-E containing signals for the protons of P-CD is 
shown in Fig. I. The progressive upheld shift in the signals 
i'or H-3 and H-5 protons of |3-CD with the increase in the 
concentration of guest, is quite prominent. 
A cursory examination of the signals for drug protons, in 
the absence as well as in the presence of (3-CD, clearly 
indicates that two tautomeric forms, namely keto and enol, 
are present in solution in the approximate ratio of 3:2, as 
determined by the integration of NMR signals appearing 
separately for the two tautomers. 
S'CHpOH 0 
Co 
l> . ( - ) -C h lor a 111 p h o n i c oi 
The presence of two tautomers of drug molecule was 
evident from the signal for H-l' proton which integrated for 
two-third of a proton. Moreover, the signals for H-3'and H-4' 
protons appeared separately for the two tautomers while 
aroinatic protons were observed together as a pair of doublets 
having AB pattern, hi the presence of P-CD, signal for 
H-.'^',8' aroinatic protons of drug moved progressively down-
lield with the increase in the concentration of P-Ci3 while an 
upheld shilf in the H-6',7' aromatic protons signal was ob-
served, though small in magnitude. The multiplet for H-2' 
proton also exhibited large downheld shift in the presence of 
P-CD while H-3' signal did not show any appreciable devia-
tion. The signal for H-4' of keto form also moved downfield 
but no siynilicani change lor the same proton oi enol form 
was obser\ed. Table 2 shows the chemical shift change (Ad) 
data for the D-(-)-chloramphenicol protons and part of the 
NMR spectra showing the chemical shift changes for various 
protons of the drug in the presence as well as absence of 
P-CD is given in Fig. 2. 
Tabic I 
'l-iN.Ml^ Clicmical sliill changes (AcSi ot' |i-c>cli>dexlrin protons in Ihe presence of D-(-)-cliloramphcnicol 
38 3.6 3.i 
Fig, 1, Pari of 'HNMR spectra (300 MHz) containing signals for (i-('l) 
prolon in the presence of D-t-l-chloramphenicol lA-Ei and 'HNMR 
(.M)()MH/lspeclriim()r(!-CD, 
3. Discussion 
P-Cyclodextrin is a truncated right cylindrical cone 
shaped inolecule, 7.9 x 10^ ** cm high, with a hollow tapered 
cavity whose top and bottom dimensions are 6.5 x KV'* and 
6.0 X 10 ** cm [12]. The inost likely mode of complexation ol 
the guest involves insertion of the less polar portion into the 
cavity of the P-CD from the wider side resulting in major 
upfield shifts in the signals for H-3 and H-5 protons of P-CI3. 
since these are positioned inside the cavity. This is attributed 
Sample 
B 
C 
1) 
li 
|H| / |G| 
2,.M 
1 ,').S 
1,.S6 
1 3X 
1,27 
H 2 
(1.0(12 
-0,1)02 
0,00,1 
-n.iVB 
(1.004 
-0,041 
-0,045 
-0.0.S4 
-0,061 
-0,071 
H-4 
0,004 
-0.00.1 
0.001 
-0,002 
-0,001 
H 5 
-O.O.S 1 
-0.054 
-0,069 
-0,0X1 
-0,09,S 
H-6 
0,000 
-0.001 
-0,002 
-0,002 
0.006 
H-5/H-,1 
1.24 
1,20 
1.27 
1 ..\1 
1.40 
Neeaiive \aliies nidicale liisli held shifr 
.V. Mcisliluxid Mi CI ,il. / IL I'MiMXCO >^> i200-li SJ_^-S_l,\ 
)-i - i ^ c l i l o i ; i i i i ; ) l i e n i c o l 
7.5 5,5 4.5 
l-ig. 2, Pan ot 'HNMR specira I.MK) MH/1 comainins signals Inr l>4-)-
chhtranifiheiiiciil ptolons in Ihc presence (A-F:) and absence of* [^-CD. 
to the ring current of the aromatic ring olthc guest molecule 
that is inckided into the cavity |1-1I4|. The other (3-CD 
protons located outside the cavity show either no or negli-
gible changes in their chemical shifts upon complexation. On 
the other hand, signals for most of the guest protons show 
downfield shift changes upon complexation with P-CD but 
the inagnitude of the shifts is much smaller compared to 
p-CD protons. In a detailed ihermodynainie and NMR spec-
troscopic study of the interaction of CDs with a variety of 
model substrates, Rekharsky et al. 115] demonstrated that the 
<.o(-
11],1GJ 
magnitude of the upheld shifts in the signals for H-5 and H-,^  
protons of CDs, Af)(H-.')) and Af)(H-3). and their relative 
ratios, Ar)(H-5)/A(HH-3), can be used as a quantitatiNc mea-
sure of the stability of the complex and the depth of inclusion 
of the guest into the cavity, respectively. 
It can be argued, in analogy to earlier reports (15-1 7|. that 
the observed highlield shifts in the signals for H-.^  (domi-
nant) and H-3 (subordinate) protons are clearly indicative of 
the penetration of the aromatic ring into the [J-CD ca\ii\ 
from the wider side, and the formation of a tight-htting 
complex between the guest and [}-CD as evidenced b\- high 
A(5(H-5) and Af>( H-.3) values. Also, the values (1.20-1.40) for 
A()(H-5)/A()(H-3) ratios (Table 1) are suggestive o( deep 
insertion t)f the aromatic ring of the guest into the host ca\ it\ 
115|. The stoichiometry of the complex v>.as determined b\ 
plotting Ad(H-5) and Af5(H-3j vs. IH|/|G| which gave 
slightly curved lines. However, a modihed Benesi and Hilde-
brand (18| plot of chenucal shift changes for H-3 and H-5 
protons in the form of (|H|/lG|)/Af)(H-3 or 5) vs. IH1/|G1 
gave excellent linear tits (Fig. 3) supporting 1:1 complex-
ation. There seems no discrimination by the host belv\'een the 
two tautomeric forms of the guest as the signals for aromatic 
protons of both the tautomers appear together as a pair of 
doublets in the presence as well as in the absence of host. The 
chemical shift changes that take place in the signals for 
aromatic protons, upon complexation with ji-CD. also give 
valuable information regarding the depth of penetration be-
side the values for Ar5(H-5)/A(!)(H-3) ratios. All the aromatic 
Table 2 
'HNMR chemical shift changes (A6) for various protons of D-(-)-chloramphenicol in the presence of p-CD 
•Sample 
A 
B 
C 
D 
E 
Negative vi 
(H1/(G| 
23] 
1.95 
1.56 
1.38 
1.27 
lues indicate h gh field 
H-2' 
0.130 
0.128 
0.115 
0.108 
0.086 
shift. 
H-3' 
Keto 
0.009 
0.006 
0.005 
(1.004 
0.f)()3 
Enol 
0.023 
0.022 
0.022 
0,021 
0,020 
l^-4'_ 
Kcto 
0.161 
0.154 
0.134 
0.123 
0.105 
H-5'.8' 
Enol 
0.032 
0.029 
0.026 
0.024 
0.020 
0.093 
0.086 
0.082 
0.079 
0.078 
H-6',7' 
-0.028 
-0.027 
-0.025 
-0.022 
-0.021 
X3S .S: MashhoodAli el al^ /IL FARMACO 59 12004) HJ5-8Mi 
pioloiis ol llic phenyl ring show dovvnficid shifl upon com- l*^ '! 
picxulion |16|, but when u pcilur group, present at paru-
position of the aromatic ring, enters the hydrophobic cavity 
of P-CD it passes through the cavity and protrudes out of the p, 
smaller rim. In such cases, the aromatic protons oriho to 
polar group exhibit upheld shift while those in meta position 
move downheld \\9\. The chemical shift chanaes in the 
( S i 
aromatic protons ot the guest, in our case, also point to the 
nitro group protruding out of the smaller rim and exposed to 
solvent. The diiference in the chemical shift changes for H-4' |9| 
proton of keto and enol forms of the guest molecule may be 
due to different en\ ironment but is not clearly understood. 
Finally, the ' H N M R spectroscopic study, in solution of 
i)-(-)-chloramphenicol with varving amounts of (]-CD re-
\ealed the formation of a 1:1 tight fitting inclusion complex |i i 
formed by the inclusion of the aromatic ring into the hydro-
phobic ca\ it> of the R-CD. There is no evidence of discrimi-
' . . I P 
nation by the host between the two tautomeric lorms ot the 
' U i e s t . M^ 
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.Abstract 
A proton magnetic resonance spectroscopic study in D^O of mixtures of fluoxetine hydrochloride (guest) with |3-cyciodextrin (host) 
revealed the existence of two different equilibria for 1:1 inclusion complexes in which -CF , substituted ring of the guest is more tiahtiv held 
by the host ca\iiy. The structures of the two complexes have been proposed which are supported by 2DR0ESY spectral data. The dissociation 
constant was also determined. 
O 200.5 Elsevier SAS. All rights reserved. 
Kexmnxls: Inclusion complexes. P-Cvclodextnn; Fluoxetine hydrochloride; 'H NMR; ROHSY 
1. Introduction 
Cyciodexlrins (CDs) arc polymeric carbohydrates (cyclic 
oligomers) differing from one another in number ofglueopy-
ranose units in their structure and are referred as u-. (3- and 
y-CD having 6-8 units, respectively 111. Due to formation of 
(;.-I,4-glyc()sidic linkage. CDs are doughnut shtiped mol-
ecules, possessing hollow cavities which can accommodate a 
variety of guests in aqueous solution and in the crystalline 
state by non-covalenl interactions [2]. The presence of 
hydroxyl groups on the exterior surface of CDs make them 
fairly polar while the interior of the cavity is relatively non-
polar, The slightly hydrophobic character of the inner cavity 
provides a driving force for host-guest complexation with 
similarly apolar guest molecules. The study of inclusion com-
plexes of pharmaceuticals with CDs have received consider-
able attention due to altered physical and chemical properties 
of the included guest molecules {?<]. Several drugs are already 
approved and marketed m CD-eomplexed form and ctwsid-
ering the strict requirements for approval of a new chemical 
entiiy, the study of inclusion complexes of drug molecules 
with CDs has become a subject of greal inleiest |4 | . 
In continuation of our work on the NMR spectroscopic 
studies of P-CD-complexes of pharmaceutical compounds 
" Corresponding author. 
E-mail address: smashhoodali(!!'yahoo.com (,S.M. Ali). 
0014-827X/S - see front matter © 2005 Elsevier SAS. All rights reserved. 
doi:10.IOI6/J.faniiac.2005.0.V()0.^ 
|5.6|. we report here our results on the study of inclusion 
complex of racemic fluoxetine hydrochloride (G) with P-CD 
(H), Fluoxetine hydrochloride, commercially known as 
•Prozac'. is an antidepressant, antiobsessional and antibu-
limic drug. It is a potent and selective inhibitor of serotonin 
uptake. This uptake inhibition by fluoxetine hydrochloride 
enhances serotonergic function. As a consequence the sero-
tonin receptors are desensitized or down regulated after long-
term fluoxetine hydrochloride administration. If does not 
appear to cause down regulation of post synaptic beta-
adrenergic receptors or a decrease in beta-adrenergic-
stimulated cyclic adenosine monophosphate generation as do 
other antidepressant medications [7], 
2. Results 
All the NMR spectra were recorded on a 500 MHz Bruker 
instrument at 25 °C in 0 , 0 , The H-l' signal of P-CD is used 
as a reference throughout this work [8] and chemical shift 
values arc reported in ppm, ' H NMR spectra for live mix-
tures of fluoxetine hydrochloride and P-CD. having |HJ/|G) 
molar ratios ranging from 0,40-1,40. us determined by the 
integration of appropriate signals, were recorded. The amount 
of guest was kept constant (1 x 10"* mmol) while amount of 
P-CD was varied. These samples were then dissolved in 0,5 ml 
DjO, ROESY (500 MHz) experiment was performed on a 
44() S.M Ml ri ill. / II Faniuuti Ml I2(IU5) 445-4-19 
[H>IG>=1.40 
Fig. 1 
sample having |H]/|G| molar ratio as 0.45 vviili a mixing time 
of 225 ms at 25 'C. All the spectra contained one .set otfeso-
nances suggesting a last equilibrium between free and the 
comple.xed state, on the NMR time scale. 
The signals for the protons of fluoxetine hydrochk)ride and 
p C D did not interfere in any ol'the spectra. 'H NMR spectra 
of fluoxetine hydrochloride, in the absence of (i-CD. exhib-
ited a pair of doublets, each integrating for two protons and 
showing A.B . pattern, at 7.091 (./ = 8.y5 H/) and 1.51^ 
(J = ^ .15 H/,) which were assignable to H-2..i and H-1.4. 
respectively, of the trilluoromethyl substituted aromatic ring. 
The signal for H-8 of phenyl ring appeared as a triplet at 7.393 
{J = 7.20 Hz) while signals for remaining phenyl ring pro-
tons appeared merged in the region 7.430-7.505. A singlet at 
2.779 for three protons was due to N-CH,. A doublet of dou-
blet ( i | = i , = 4.25 Hz) at 5.618 was ascribable to benzyhc 
proton (H-5). A pair of multiplets centered at 2.364 and 2.463. 
each integrating for one proton, was assigned to methylenic 
protons (H-11) while signals for methylenic H-12 were found 
resonating as a pair of multiplets centered at 3.261 and 3.346. 
Prominent changes in the nature and position of signals 
for most of the protons of fluoxetine hydrochloride were 
observed in the presence of P-CD which increased with the 
increase in the concentration of P-CD. The signals for the 
phenyl ring protons moved downfield and became complex 
making it difficuil (o calculate chemical shift change values 
in the presence of P-CD. The signals for H-2.3 of trifluorom-
ethyl substituted aromatic ring exhibited downfield shifts with 
the increase in the concentration of P-CD and signals for two 
enantiomers started separating. A very significant upfield shift 
was observed in the H-1.4 proton signal in the presence of 
P-CD. The peaks for H-5 proton of the two enantiomers also 
separated in the presence of P-CD. Downfield shift changes 
were also observed in the signals for two methylenic groups 
of the drug in the presence of P-CD. Part of spectra contain-
ing studied signals of fluoxetine hydrochloride are shown in 
Fig. 1 while chemical shift change values for \arious protons 
of the guest are given in Table 1. 
In all the spectra of mixtures of fluoxetine hydrochloride 
and P-CD, the signals for H-5' and H-3'. situated inside ihc 
P-CD cavity, exhibited high held shifts compared to pure 
P-CD; the H-5' shifts being dominant while H-3' shifts as 
subordinate. The signal for the H-2' proton moved signifi-
cantly dovvntield in the presence of fluoxetine hydrochloride. 
Though signals H-4' and H-6' also displayed downheld shifts. 
these were not very significant. The chemical shift change 
(A()) xalues for p C D protons are given in Table 2. The pal-
tern o( the spectral region containing P-CD signals, in the 
spectra of mixtures of fluoxetine hydrochloride and P-CD. 
Table 1 
'H N M R (.SOO M H z ) ctiemicaf sfiil't ctiange (Ac)) vafues for various protons of (luoxetine tiydrochloride in the presence of P-CD in D-,0 at 2.'i °C 
.Sample 
A 
B 
C 
I) 
1-; 
|H|/fG] 
1.40 
1 i)^ 
0.88 
04.S 
0 4 0 
H-1.4 
-0.1.^8 
-0.1 Ls 
-0.102 
0.060 
-0.0.S6 
H-2.? 
0.047 
0.040 
0.0.^8 
0016 
-0.003 
H-.s 
-0.021 
-0.019 
-0.018 
-0.01.3 
-0.016 
H-l la 
0.1.31 
0.119 
0.112 
O.O.M) 
().02.S 
H - l l b 
0.09.3 
0.088 
0.082 
0.03.'^ 
0.013 
H-12a 
O.OO.'i 
0 .060 
0.041 
0.022 
0 .104 
H-12b 
0 .040 
0.047 
0 .038 
0 .016 
o.oo.s 
H-13 
O.O.'^ O 
0.042 
0.041 
0.010 
0.010 
Negal i \o \a l i ics Hiclicalc iiplickl sliili 
l a b l c 2 
H NMR (.SOO M H z l chemical shift change (.^l>> data for [i-CD protons in ihe presence of liuoKetine hydrochlor ide in D , 0 at 2,5 "C 
S.impI 
A 
B 
c: 
1) 
i : 
c mi/iGi 
1.40 
1.0.s 
0.88 
0.4.S 
0.40 
11-2' 
0.0.S4 
0.0.S7 
().0.S7 
0.().S9 
O.O.^ i? 
H-y 
-0.038 
-0.048 
-O.O.SO 
-0.0.S6 
-0.0,S9 
H-4' 
0.022 
0.023 
0.021 
0.022 
0.020 
H .S-
-0.291 
-0.310 
-0.308 
-0,319 
-0.3I,S 
H-6' 
0.028 
0.020 
0.017 
0.009 
0.009 
Af)H-,s7ArfH-3' 
7.66 
6.46 
6.16 
,•1,70 
,'i.,34 
Negative values indicate uplieid shilt . 
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more or less remained unchanged because concentration of 
line guest was kept constant. 
3. Discussipn 
CDs have played major role in the development of su-
pramolecular chemistry. Most of the CD related studies 
involve structural elucidation of the inclusion complex besides 
the energetics of the complex formation. The results of these 
studies suggest that the mode of complexation of the guest 
with CDs. involve insertion of the less polar (non-polar) por-
tion of the guest into the CD cavity. They act as one site ligand 
meaning that the penetration mostly takes place from the 
wider rim side of cavity. Though these observations are mainly 
based on the studies of a-CD complexes but have mostly been 
found true for P-CD complexes. In the case of larger CDs the 
entry of guest may take place from either side, as in the case 
of-/-CDll|. 
NMR spectroscopy has proved to be the most useful tech-
nique for the study of (3-CD inclusion complexes because of 
its sensitivity [9|, The host-guest interactions are clearly 
rellected in changes on various NMR spectral parameters. 
The structure of an inclusion complex is determined by an 
energetic balance between the maximal inclusion of non-
polar portion of guest into the P-CD cavity and optimal mutual 
orientations of host and guest to permit interactions of polar 
portions of the guest with P-CD or solvent. 
Demarko and Thakkar first observed the variations in 
chemical shifts of H-.'^ ' and H-5' of P-CD in the presence of 
various substrates and inferred that inclusion in cavity has 
taken place since these protons are situated inside the cavity 
110|. This type of evidence has since been widely collected. 
The development of new NMR techniques has further.con-
tributed to better understanding of structures of CD com-
plexes 11 I j. A typical structural inference is that if only H-.^' 
signal undergoes a shift in the presence of a substrate then 
caviiv penetration is shallow, a deep penetration results in 
H-5'shift also [12]. The magnitude of shift changes for H-3' 
and H-5' have been shown to be related to the stability of 
inclusion complex; higher values of M^y and Af)^. '^ mean-
ing higher stability of the complex. Moreover, the ratio for 
the induced shift changes for these protons. Ar^ ,, v/Ad,, ,-has 
been corrclalcd lo ibc ilcplb of inclusion of the gucsl inio llie 
CD cavity jl.^j. 
Contrary lo the upheld shift changes experienced by the 
protons situated inside the CD cavity, all the protons of the 
gucsl. generally, show downlield shift changes on complex-
ation and not only the proton/s included in the CD cavity 
which has been attributed, besides the shielding effect by the 
cavity, to other factors like changes in the microenvironment 
and guest conformational changes upon complexation. The 
downlield shift changes in protons (^^ the guest are smaller in 
magnitude compared to CD protons and have mostly been 
neglected though these may be useful, using advanced NMR 
techniques, in identification of the part of the gucsl thai is 
nicludcd in the CD cavity j I 11. 
a. 
< 
0 l o -
o.DS-
[H]^10•'(M) 
Fi". 
Remarkable upheld shift variations observed in the reso-
nances of H-3' and H-5' of P-CD in the presence of fluoxet-
ine hydrochloride clearly indicate the inclusion of aromatic 
part of the guest into the CD cavity due to hydrophobic inter-
action, in analogy lo earlier studies [5,6.10]. As expected, 
most of the guest protons exhibited concomitant downtield 
shifts which increased with increasing [H]. exhibiimg type ot 
saturation curvature (Fig. 2). A modified Hildebrand-Benes\ 
plot of H-1.4 of trilluoromelhyl substituted aromatic ring in 
the form of [H]/Af) vs. [H] gave excellent linear fils (Fig. 3) 
which supports 1:1 complex formation [14]. The higher mag-
nitude for t^dy^.y compared to l^S^y values may be due to 
either the penetration of aromatic guest from the narrow rim 
of P-CD [15] or deep penetration of the guest from wider 
side [I3|. The observations that protons belonging to both 
the aromatic rings exhibit shift changes (though the chemical 
O.g 1.2 1.6 2.0 2.4 
[H]xlO-^(M) 
28 
l-i" ^. 
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shift changes of phenyl ring could not be calculated because 
of their complexity), taking into account the 1:1 stoichiom-
elry of the complex, indicates that two equilibria may exist in 
solution. The separation of signals of H-5 of two enanti-
omers in the presence of P-CD (Fig. 1), may be attributed to 
the fact that diastereomeric complexes formed from two enan-
tiomers are structurally different from each other. 
To have an insight into the mode and depth of penetration, 
confirm the existence of multi-equilibria in solution and 
detailed structure of complex/es. ROESY experiment was per-
formed on a mixture of fluoxetine hydrochloride-P-CD. The 
presence of strong cross peaks between H-2,.^ and H-1.4 of 
tritluoromethyl substituted aromatic ring with H-,V and H-5' 
of P-CD and relatively weak cross peaks between H-,V of 
p-CD and phenyl rmg protons of guest (Fig. 4), confirmed 
the presence of two equilibria in solution. .Several topologies 
may arise for each aromatic ring because entry may occur 
through either the larger or smaller rim of P-CD and the pen-
etration may be either shallow or deep. The 2DR0ESY spec-
trum confirms binding mode-I for CFi,-substituicd ring with 
P-CD in which the guest enters from wider rim and pen-
etrates deep so that the -CF, group protrudes outside the cav-
ity and interacts with 6'-OH. This assumption is supported 
by the fact that H-1.4 showed upheld shifts in the presence of 
P-CD. which may be explained in terms of close proximity 
o[ these protons with fluorine in free state while in com-
plcxed state these F atoms may form H-bonds with 6'-OH, 
thus weakening the interaction between F and H-1,4. In this 
mode, these H-1,4 come m si/able contact with only H-5' 
while H-2..'^  of guest are in the proximity of both H-3' and 
H-5' of P-CD, The cross peaks between phenyl ring protons 
with only H-,'^ ' of P-CD, which is near the wider rim. support 
the mode-II of various probable topologies meaning the pen-
7.5-
7,0-
Fluoxetinc Hydrochloride 
P-Cyclodexlrin 
NHCHj 
Mode 11 
•Scheme 1, 
eiration of the phenyl ring is also from wider side but only a 
part of the ring enters the cavity. The deep penetration would 
bring some of the phenyl protons near the H-5', A schematic 
representation of the inclusion equilibria is shown in Scheme 
I. The dissociation constant. K^ of the complex was calcu-
lated to be 1.4 X 10 "^' M by a least-square Htting procedure 
from the plots (Figs. 2 and .3) [14.16]. 
In conclusion. 'H NMR and 2DR0ESY .spectro.scopy of 
mixtures of fluoxetine hydrochloride and P-CD in D;C) at 
25 °C revealed the existence of two 1:1 diastereomeric inclu-
sion complexes formed by the penetration of aromatic rmgs 
of guest into the P-CD cavity from wider rim side and that 
CF,-substituted ring penetrates deep while inclusion of phe-
nyl ring is shallow. The dissociation constant. A',, for the com-
plex was determined. 
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Spectroscopic Study on Interaction of ^-Cyclodextrin with 
Triprolidine Hydrochloride 
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The complexation of triprolidine hydrochloride (TRP) and /?-cyclodextrin (yS-CD) in deuterium oxide was inves-
tigated by 400 MHz ' H N M R spectroscopy The 800 MHz 2D ROESY data revealed that two 1 : 1 and one 2 : 1 
/5-CD-TRP inclusion complexes were formed. Both aromatic moieties (p-tolyl and pyridyl ring) has entered into the 
/9-CD cavity, confirming the existence of two different equilibria for 1 : I inclusion complexes in which p-tolyl ring 
of the guest is more tightly held by the host cavity. The ROE intermolecular interactions provided the plausible 
structures of these 1 .' 1 and 2 '• 1 stoichiometric inclusion complexes of/?-CD-triprolidine hydrochloride in solu-
tion. 
Keywords host-guest complex, jg-cyclodextrin, triprolidine hydrochloride, 'H NMR, ROESY 
Introduction 
Cyclodextrins (CDs) are cyclic oligomers, differing 
from one another in the number of £)-glucopyranose 
units, and most typical are a-, /]- and y-CD. CDs can 
form doughnut shaped molecule by forming a-l,4-gly-
cosidic linkage with glucopyranose units. Such a tor-
oidal structure has a hydrophilic surface, making it wa-
ter soluble, whereas the cavity is composed of methine 
hydrogens, giving it a hydrophobic character. As a 
consequence, CDs can accommodate, into their cavities, 
other hydrophobic molecules^ of appropriate dimensions 
and shapes in aqueous solution and in the crystalline 
state by non-covalent interaction. ' 
In the area of pharmaceuticals, cyclodextrins have 
mainly been used as complexing agents to increase 
solubility, bio-availability, stability and to decrease the 
volatility of poorly water soluble drugs.'*' In addition, 
they can be used to reduce or eliminate unpleasant 
smells or tastes, prevent drug-drug or drug-additive in-
teractions.* That stimulated a great deal of research to-
ward the synthesis of new host-guest complexes and the 
structural characterization of the supramolecular ad-
ducts in terms of geometry and conformational prefer-
ences via a variety of physical methods. Of all the tech-
niques available for obtaining proofs of host-guest com-
plexation, NMR is the most reliable technique.^'* Inter-
molecular proximity and orientation of the guests were 
investigated with the aid of 2D rotating frame experi-
ments [ROESY]. Dipolar interactions between the guest 
protons and ^-CD inner cavity protons (H-3' and H-5') 
were observed while the guest molecule was included 
into the ^-CD cavity. The relative intensities of these 
dipolar correlations in 2D ROESY spectrum provide a 
simple recipe for predicting the structure of complexes. 
In continuation of our work on the spectroscopic 
studies of yff-CD-complexes of pharmaceutical com-
pounds, ' we report here our results on the inclusion 
complexation of yS-CD and triprolidine hydrochloride in 
aqueous solution. Triprolidine [l-(/i-tolyl)-l-(2-pyridyl)-
3-(l-pyrrolidine)prop-l-ene] is a propylamine antihis-
tamine drug. Antihistamines work by blocking the ac-
tion of histamine at special sites in the skin, nose and 
blood vessels. It is an important part of body's defence 
mechanism. But sometimes the body releases too much 
histamine and this produces the allergic reaction. 
Triprolidine hydrochloride is used to relieve symptoms 
of allergies like hay fever, seasonal rhinitis and peren-
nial rhinitis 12,13 
Experimental 
All ' H NMR experiments were carried out in D2O, 
on a Varian Mercury VX 400 MHz spectrometer at 25 
°C. The HDO peak at S 4.690 was used as a reference 
throughout this work and chemical shift values were 
reported in 3. ' H NMR spectra for six samples having 
[H]/[G] molar ratios ranging from 0.29—2.67, as de-
termined by the integration of appropriate signals were 
recorded. Signal assignments were made with the aid of 
COSY spectrum of a mixture of triprolidine hydrochlo-
ride and y9-CD. ROESY experiments were performed on 
a 1 : I mixture of triprolidine and ^-CD on a 800 MHz 
Bruker instrument with a mixing time of 0.5 s. 
Results and discussion 
' H NMR spectra of triprolidine hydrochloride (G), in 
the absence ofy9-CD (H), exhibited a pair of doublets at 
S 6.957 ( J = 8 HZ) and 7.178 ( /=7 .6 Hz) each integrat-
E-niail: smashhoodali@yahoo.com 
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ing for two protons, which were assignable to H-6,7 and 
H-5,8, respectively, of the/7-tolyl ring. Two doublets at 
d 7.126 and 8.313 (J] =72 = 7.6 Hz), each integrating for 
one proton, were assigned to H-4 and H-1 of pyridyl 
ring, respectively. The signals for H-2 and H-3 of 
pyridyl ring were observed as triplets at S 7.634 (7=6.8 
Hz) and 7.230 ( J=6 .4 Hz), each integrating for one 
proton. The signal for H-10 also appeared as a triplet at 
6 6.343 (J=7.6 Hz), integrating for one proton. A 
singlet at S 2.168 for three protons was due to methyl 
group (H-9), while signals for pyrrolidine ring were 
found resonating as a pair of multiplets centered at S 
1.833 (H-13,14) and 2.230 (H-12,15). A doublet for two 
protons was observed at S 3.783 (7=7.7 Hz) which was 
ascribable to H-11. The chemical shift change data for 
various protons of triprolidine hydrochloride are shown 
in Table 1. 
Generally, all the guest protons, not only the part that 
enters the /9-CD cavity, show downfield shift changes 
upon complexation with P-CD. Figure 1 shows part of 
NMR spectra of TRP in the presence of increasing 
amount of/?-CD. The chemical shift forp-tolyl ring and 
pyridyl ring protons (except H-4) exhibits a pronounced 
downfield movement. This upfield shift variation in the 
-A. 
JV. 
_A_ 
_ A A ^ 
1H|/1(1| 2 67 
-It-J^ 
-A. 
(HJ/(Ci 2,57 
|H)/IG|-1,66 
H|/|C1 I 
A ih 
[H]lia]'0.2<> 
[0] 
H-5.S. , H-6,7 
8,4 7,6 7.4 
5 
7.2 7.0 
Figure 1 Partial 400 MHz H NMR spectra for triprolidine 
hydrochloride in the absence and presence of ^-cyclodextrin in 
0 , 0 at 25 'C. 
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H-4 signals can be attributed to interaction with hydro-
philic external part of they9-CD." Signals for H-11 pro-
tons remain as a doublet through out the spectra and the 
presence of the chiral /?-CD places these protons as di-
astereotopic. 
The spectral changes for yS-CD are more pronounced 
in the presence of triprolidine hydrochloride (see Figure 
2). The entire signals for y5-CD protons move towards 
the higher field with increasing the amount of guest 
molecule. The chemical shift change values for ^-CD 
protons are listed in Table 2. These high field shift 
changes in the /?-CD cavity protons can only be ex-
plained in terms of anisotropic shielding effect of aro-
matic ring penetrating into the fi-CD cavity."" In par-
ticular, the largest differences in the chemical shifts for 
the jS-CD protons are always observed for the protons 
situated inside the hydrophobic cavity (H-3' and H-5'), 
demonstrating the reality of inclusion processes.' 
- 1 1 1" I III 
3.8 3.7 3.6 3.5 3.4 
IHHCl] 2,6 
|HWC]-2,57 
|H)/[01 1,66 
|H)/ |G).L2 
(H|/1G] 0,63 
(Hl/lGl 0,29 
Figure 2 A part of 'H NMR spectra of ^-cyclodextrin (400 
MHz), showing the changes in chemical shift for ^-cyclodextrin 
protons by interaction with triprolidine hydrochloride. 
Table 1 'H NMR (400 MHz) chemical shift (S) data for triprolidine hydrochloride (G) and chemical shift change (AS) values for the 
studied protons of triprolidine hydrochloride in the presence of/J-cyclodextrin (H) in D2O at 25 'C 
Proton 
H-l 
H-2 
H-3 
H-4 
H-5,8 
H-6,7 
H-IO 
H-11 
H-12,15 
H-13,I4 
[G] 
8.313 
7.634 
7.230 
7.126 
7,178 
6,957 
6.343 
3.783 
2.230 
1.833 
[H]/[G] = 2.67 
0.139 
0.011 
0.074 
-0 .178 
0.087 
0.104 
0.103 
0.054 
0,022 
0.053 
[H]/[G] = 2.57 
0.144 
0.013 
0.066 
-0 .174 
0.087 
0.104 
0.100 
0.050 
0.027 
0.056 
[H1/[G] = 1.66 
0.117 
0.009 
0.053 
-0.165 
0.065 
0.082 
0.087 
0.040 
0.015 
0.041 
[H]/[G]=1.25 
0.089 
0.004 
0.036 
-0 .148 
0.057 
0.065 
0.063 
0.044 
0.002 
0.029 
[H]/[G] = 0.63 
0.056 
0.005 
0.022 
-0 .078 
0.031 
0.041 
0.037 
0.022 
0.000 
0.020 
[H1/[G] = 0.29 
0.026 
0.009 
0.013 
-0.026 
0.015 
0.026 
0.024 
0.021 
0.005 
0.009 
Negative values indicate upfield shifts. 
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Table 2 'H N M R (400 
drochloride (G) in DiO at 
[H][G] 
2.67 
2.57 
1.66 
1.25 
0.63 
0.29 
MHz) chemical shift change (Ad) values for the fi-
25 'C 
H-2' 
-0.017 
-0.018 
-0.021 
-0.039 
-0.043 
-0.039 
H-3' 
-0 .190 
-0 .180 
-0 .232 
-0 .286 
-0 .325 
-0 .322 
H-4' 
-0 .039 
-0 .037 
-0.054 
-0 .072 
-0 .079 
-0 .075 
Chin. J. Chem. 
cyclodextrin (H) protons 
H-5' 
-0 .172 
-0 .163 
-0.201 
-0 .261 
-0 .300 
-0 .297 
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in the presence 
H-6' 
-0 .033 
-0 .028 
-0 .048 
-0 .063 
-0 .078 
-0 .076 
of Iriprolidine hv-
A(5H.5'/AdH-V 
0.905 
0.906 
0.866 
0.913 
0.923 
0.922 
Negative values indicate upfield shifts. 
Downfield shift changes for the TRP signals are 
lower in magnitude as compared to /?-CD protons and 
have mostly been neglected though these may be useful, 
using advanced NMR techniques, in identification of the 
part of the guest that is included in the host cavity. A 
typical structural inference is that if only H-3' signal 
undergoes a shift in the presence of guest molecule then 
cavity penetration is shallow, a deep penetration results 
in H-5'shift also.'^ The presence of TRP resulted in up-
field shift movements in the resonances of both H-3' and 
H-5' offi-CD. The observation that protons belonging to 
both jD-tolyl and pyridyl rings show chemical shift dif-
ferences upon inclusion, suggest that multiple equilibria 
may exist in solution. 1 : 1 and 2 : 1 Stoichiometry in 
solution is determined by molar ratio method (see 
Figure 3), shows quick shielding of the guest aromatic 
protons at the beginning of the titration withy9-CD and a 
flattening of the slope of the titration curve, for 
triprolidine hydrochloride aromatic protons on titration 
with fl-CD, at a molar ratio of around 1.25 (clearer in 
H-5,8 titration curve). This suggests a prevailing 2 : 1 
host-guest stoichiometry, although participation of some 
1 : 1 complex stoichiometry is very likely, since the 
change in chemical shifts continues well after the 
[H]/[G] molar ratio reaches 1.25. 
0.14 
0 10-
0.06 
0.50 1.00 1.50 
[H]/[G] 
2.00 2.50 
Fi};iii-e 3 A plot of chemical shift change (AS) of guest aromatic 
protons agamst [H]/[G]. 
To have an insight into the mode and depth of pene-
tration, confirm the existence of multi-equilibria in so-
lution and detailed structure of complexes, ROESY ex-
periment was performed on the 1 M mixture of 
triprolidine hydrochloride and f]-CD. A set of strong 
cross peaks connecting H-5' and H-3' of/i-CD to H-6,7 
and H-5,8 of p-tolyl ring and relatively weak cross 
peaks connecting H-1 and H-2 protons of pyridyl ring 
with H-3' only of/9-CD (see Figure 4) confirmed the 
presence of two equilibria for 1 '. 1 TRP-y6-CD complex 
in solution. A set of cross peaks for p-to\y\ methyl pro-
tons were observed with H-2', 3', 4', 5' and H-6' of/?-CD 
(not shown in Figure 4). Furthermore, the change in 
chemical shifts of H-3' (A^„ax=-0.322) and H-5' 
(A(5n,ax—~0.297) of^-CD do not conclusively indicate 
which side of the ;ff-CD cavity is involved in complex 
formation, because no significant differences were de-
tected by 'H NMR chemical shift data. Due to these 
observations, several topologies may arise for each 
aromatic ring because entry may occur through either 
the wider or narrower side of ^ -CD and penetration may 
be either shallow or deep. The binding mode for p-tolyl 
ring with yS-CD is confirmed by 2D ROESY spectrum 
i.e., guest enters from the wider side and methyl group 
is near the narrow rim of the cavity, which is now in 
proximity of H-5' and H-6' of fi-CD. The cross peak 
between pyridyl ring protons (H-1 and H-2) with H-3' of 
/9-CD near the wider rim suggest the penetration of this 
ring also from the wider rim side but only a part of the 
L ^ A„.„ /fl Jl 
}.-* 
— s — ^ . V — I * r r 1— 
»,!> T4 7,: "TO 6K r\6 
Figure 4 A partial 800 MHz 2DR0ESY spectrum of 
triprolidine hydrochloride-/;-CD (1 i 1) inclusion complex ni 
D2O at 25 "C with mixing time of 0.5 s, indicating the dipolar 
contacts between protons of the triprolidine hydrochloride and 
protons of/?-CD. 
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pyridyl ring enters the cavity. The deep penetration 
would bring some of the pyridyl ring protons near the 
H-5'. Except these findings a very insignificant/and ab-
sence of dipolar interactions for guest protons with H-6' 
of y?-CD strongly support the penetration of both rings 
from the wider rim. Moreover, the signals for H-11 
and pyrrolidine ring did not show any cross peak with 
yff-CD cavity protons, confirming that this part of TRP is 
not included into /?-CD cavity. From the overall discus-
sion it is confirmed that TRP forming two 1 : 1 di-
astereomeric inclusion complexes with y5-CD (see 
Scheme 1). However, the larger volume of the cross 
peak area for /)-tolyl ring confirms that the 1 '• 1 
TRP-^-CD complex involving inclusion of this ring is 
more stable. The equilibria for 2 ! 1 stoichiometry can 
also be presumed that, at higher y5-CD concentrations, 
the 1 ! 1 complexes may take up a second yff-CD mole-
cule for including other aromatic ring (p-tolyl or 
pyridyl)" (Scheme 1). 
Scheme 1 Supposed representation of the possible inclusion 
equilibria for triprolidine hydrochloride/^ -cyclodextrin system in 
solution 
9CH 
3 
ii 
1 
11 12 
, ^= 14 
tnprolidine hydrochloride 
/J-cyclodextrin 
Conclusions 
This work has demonstrated that triprolidine hydro-
chloride can bind to /i-CD to form two 1 : 1 di-
astereomenc complexes and one 2 '. 1 complex in D2O 
as conrlrmed by 'H N M R and 2D ROESY spectroscopic 
studies. Inclusion of guest aromatic part takes place 
from wider rim side into the host cavity, p-lo\y\ ring 
ALl&ASM.AT 
penetrate deep and methyl group is near the narrow side 
of /?-CD cavity, while inclusion of pyridyl ring is shal-
low. Indeed, 2 : 1 triprolidine hydrochloride-j6-CD 
complex in aqueous solution would exist only at rather 
high concentration of yff-CD. On the basis of the inter-
molecular interactions the geometry of the su-
pramolecular system in solution has been hypothesized. 
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A detailed spectroscopic study ('H NMR, COSY, ROESY) of complexation of venlafaxine hydrochloride 
(VEN) with /^cyclodextrin (^OD) was carried out in solution. The stoichiometry of the complex was 
determined to be 1 :1 and penetration of aromatic ring into >5-Cyclodextrin cavity was confirmed from primary 
rim side, with the help of ROESY spectral data. The structure of the venlafaxine hydrochloride-y^CD complex 
has been proposed. The association constant was determined to be 234 M"'. 
Key Words : /3-Cyclodextrin, Venlafaxine hydrochloride. Inclusion complexes, 'H NMR titration, ROESY 
Introduction 
Venlafaxine hydrochloride (VEN), commercially known 
as "Eflexor" is a representative of a new class of anti-
depressants. It is a bicyclic phenylethyl amine and chemi-
cally unrelated to tricyclic, tetracyclic or other available anti-
depressant agents and designated as (R/S)-l-[2-dimethyl 
amino)-l-(4-mcthoxy phenyl)ethyl]cyclohexanol hydro-
chloride. This medication is used to treat anxiety. It acts by 
inhibiting selectively the uptake of serotonin and noradre-
naline but shows no affinity for neurotransmitter receptors. 
Its solubility in water is 572 mg/mL.' 
CDs can be visualized as toroidal, hollow, truncated cones 
having highly hydrophilic surface and relatively hydro-
phobic cavity." By virtue of their shape and nature of cavity, 
CDs admit hydrophobic moieties into their cavity to form 
host-gue.st complexes. CDs have aroused considerable 
interest in the phanuaceutical field because of their potential 
to fomi complexes with a variety of drug molecules.^  Com-
plexation of phanuaceutical compounds with CDs leads to 
alteration of physical, chemical and biological properties of 
guest molecules. The main advantages in the pharmaceutical 
use of CDs are the increase in solubility, improved stability 
of light and oxygen senshive drugs.'' 
NMR spectroscopy,' is one of the most sensitive methods 
for studying the inclusion phenomena, allowing one to 
detennine not only the stoichiometry and stability of com-
plexes but also the spatial relationships between hydrogen 
atoms of the CDs and the incorporated molecule. Although 
there are several tecliniques to predict the geometry of CD 
inclusion complexes,* rotating frame NOE (ROE)' is the 
most reliable technique. 
In continuation of our work on the preparation and 
stnicture elucidation of /5-cyclodextrin inclusion complexes 
with phanuaceutical compounds,*' we report here our 
results on the detailed NMR spectroscopic study of J3-CD-
venlafaxine hydrochloride inclusion complex in aqueous 
medium. 
Experimental Section 
'H NMR and 2D ROESY experiments were performed on 
a Bruker Advance DPX 400 MHz spectrometer while 
COSY spectrum was recorded on a 800 MHz Bruker instru-
ment, in D2O at 25 "C. The 2D ROESY experiment was 
carried out under spin lock condition with a mixing time 500 
ms. Chemical shift values, reported in (J(ppm), were calcu-
lated with reference to HDO signal at 4.790. 'H NMR 
spectra for five samples of mixture of venlafaxine hydro-
chloride and /?-CD were recorded keeping the concentration 
of /?-CD constant at 20 mM while the concentration of 
venlafaxine hydrochloride was varied from 8 mM to 40 mM. 
Distinct peaks for complexed and uncomplexed form of 
VEN were not observed indicating rapid exchange of VEN 
between free and bind state on the NMR scale. 
Results and Discussion 
'H NMR' spectra of venlafaxine hydrochloride, in the 
absence of >S-CD, exhibited a pair of doublets at 6.998 (J = 
8.8 Hz) and 7.289 (/ = 8.6 Hz), each integrating for two 
protons. The signal at 7.289 exhibited through space inter-
action with H-7 of methylene protons and was therefore 
assigned to H-3, 5 while that at 6.998 was ascribed to H-2,4. 
The signals at 3.783, integrating for 3 protons, and at 2.710, 
integrating for 6 protons, were assignable to -OCH3 and 
-N(CH3)2 methyl groups, respectively. A pair of doublet of 
doublets at 3.547 (Ji = 4.0 Hz, J2 = 13.2 Hz) and 3.041 (J, = 
4.0 Hz, J2 = 12 Hz), for one proton each, was due to H-7a 
and H-7b protons. The signal for H-6 appeared as a triplet at 
3.688 (J= 12.4 Hz). Cyclohexanol ring protons resonances 
appeared in the region 1.000-1.688 and could not be 
determined. 
An unambiguous resonance assignment for /9-CD protons 
was made with the help of COSY spectrum (Figure 1). 'H 
NMR spectra of mixture of venlafaxine hydrochloride and 
y?-CD displayed significant upfield movements in the signals 
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Figure 1. A section of COSY spectrum (800 MHz) of the 1 : 1 
mixture of venlafaxine hydrocliloride with /3-CD, in DnO at 25 °C 
with 500 ms mixing time. 
[A] 
[B] 
H-6' 
H-5' y^ ^A^ 
[D] 
[El 
__y-Mu<I^ 
p.Q^D Jfcj; H-4' 
3.6 
T 
Figure 2. Partial 'H NMR (400 MHz) spectra showing signals for 
the protons of /?-cyclodextnn, in the absence as well as in the 
presence of venlafaxine hydrochloride. 
of 11-3' and H-5' located inside the fi-CY) cavity. Expansions 
of part of the spectra showing /?-CD protons in the presence 
as well as in the absence of venlafaxine hydrochloride are 
shown in Figure 2, while their chemical shilt change data is 
given in Table 1. These upfield shift changes in the inner yS-
C'D cavity protons can only be explained iji term of ring 
current effect of aromatic ring entering the host cavity and 
thus confirms the formation of VEN-/5-CD complex.'" '" The 
higher magnimde for Ac^i-s' compared to hS[\.y values may 
Syed Mashhood AH et al. 
Table 1. 'H NMR (400 MHz) chemical shift change (A^ values for 
the /5<;yclodextrin (H) protons in the presence of venlafaxine 
hydrochloride (G) in D2O at 25 °C. [H] was kept constant at 20 mM 
Sample 
A 
B 
C 
D 
E 
[G]mM 
40.0 
31.8 
25.4 
12.6 
8.00 
H-2' 
0.019 
0.017 
0.010 
0.007 
0.001 
H-3' 
-0.177 
-0.174 
-0.167 
-0.146 
-0.128 
H-4' 
-0.018 
-0.026 
-O.028 
-0.026 
-0.005 
H-5' 
# 
# 
U 
-0.156 
-0.14L 
H-6' 
-0.046 
-0.052 
-0.057 
-0.052 
-0.057 
Negative values indicate upfield shitts. Note; # could not be determined 
due to overlap of 11-5' signals with II-2' of/S-CD 
[a] 
Jul ,, 
H-2,4 
JJ 
[b] 
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Figure 3. A part of 'H NMR spectra showing variation in the 
signals of venlafaxine hydrochloride protons [a] venlafaxine 
hydrochloride alone [b] VEN-/5-CD mixture. 
be due to the penetration of aromatic guest from narrow rim 
of/?-CD.'^ 
Figure 3 shows the chemical shift changes in venlafaxine 
hydrochloride proton signals in the presence of >S-CD. The 
pattern of the spectral region containing venlafaxme hydro-
chloride signals, in the spectra of mixtures of venlafaxine 
hydrochloride and fi-CD, remained more or less unchanged 
because concentration of the host was kept constant during 
titration. Generally, all the protons of the guest and not onK 
the part that enters the /?-CD cavity, show chemical shift 
changes upon complexation with CDs. 
The association constant (A'a) of the complex was 
determined to be 234 M^' by using the Benesi-Hildebrand 
(Hanna-Ashbaugh) treatment. ' ' 
\/AS= l/(:^aAA,ax[G]o)+ 1/A5mx 
A plot of l /AJagainst l/[G]o, as a double reciprocal plot «as 
found to be linear, confirming 1 : 1 Venlafaxine hydro-
chloride-/?-CD complex stoichiometry, with a slope 1/ 
AfbAAimand intercept l/A^mx (Figure 4).'^-'" 
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Figure 4. Illustralion of the Benesi-Hildebrand Data Treatment. 
The data from Table are plotted as a double reciprocal plot. A least 
squares fitting of this data gives 1/Adimx = 5.10105 ppm'' and 1/ 
K-,A4U.X = 21.76794 mM ppm"'. Hence the Benesi-Hildebrand 
treatment gives K^ = 234 M"'. 
(ppm) 
H-2,4 
H-:i5 
I H-3',H-2.4 
H-.r,H-3,5 
0 0 tl-5M[-3,5 
77 36 
-70 
-7,2 
J-7 4 
Fifjurt 5. A section of 2D ROESY speclnim (400 MHz) of the 1 : 1 
mixture of venlafaxine hydrochloride with /3-CD (H), in DiO at 25 
"C under spin lock condition with mixing time 500 ms, showing 
cro.'is peaks between aromatic protons and /J-CD protons. 
In order to clearly establish the strucnire of the VEN-y^ 
CD inclusion complex, ROESY experiment was performed 
on 1 : 1 mixture of venlafaxine hydrochJoride and /i-CD. 
The results are displayed in Figure 5; a set of intermolecular 
interactions is observed between H-3' and H-5' resonances of 
/3-CD and aromatic ring protons, thus confirming the 
penetration of only aromatic ring into the host cavity. No 
cross peaks between the /f-CD cavity protons and aliphatic 
8,9 
^N(C11,) , 
1^ 
3 6 
2/^Sy--^^ 
^ > \ ^ 5 14 
' " l O 
4 13 
Venlafaxine hvdrochloride P-Cyclodextrin 
H,C 
Figure 6. A plausible structure proposed for venlafaxine 
hydrochloride-/?-CD complex. 
protons of venlafaxine hydrochloride were observed. More-
over, the H-3, 5 protons of aromatic ring showed connec-
tions with H-3' and H-5' oi/3-CD while H-2, 4 showed cross 
peaks only with H-3' suggesting the penetration of aromatic 
ring from primary rim of /?-CD cavity. The structure 
proposed for the venlafaxine hydrochloride-/(?-CD complex 
is shown in Figure 6. 
Conclusion 
The detailed NMR spectroscopy study of venlafaxine 
hydrochloride in the presence as well absence of /J-CD in 
solution confirmed the formation of 1 : 1 inclusion complex, 
resulting by the penetration of aromatic ring into the /3-CD 
cavity from narrow rim side as evidenced by ROESY 
spectrum. The association constant {K^) of the complex was 
determined to be 234 M"'. 
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COMPLEXATION OF ENALAPRIL MALEATE WITH p-CYCLODEXTRIN: NMR SPECTROSCOPIC STUDY IN 
SOLUTION 
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A (Jclailed NMR ('H , COSY, ROESY) .spectro.scopic .study of complexation of enalapril maleatc with p-cyclixlexlrin was carried out. 
The 'H NMR spectrum of enalapril maleate confirmed the existence of cis-trans equilibrium in solution, piKsibly due to hindered 
roljlion along the amide bond. The ci.s-trans ratio remained almost the same in the presence of p-cyclodexuin but in one ease it wa^  
I'oimd .significantly different which suggests a catalytic role of P-cyclodextrin in the isomerization. 'H NMR titration studies confirmed 
the fonnation of an enalapril-P-cyclodextrin inclusion complex as evidenced by chemical shift variations in the proton resonances of 
both the host and the guest. The stoichiometry of the complex was determined to be 2:1 (guest: host). The mixie of penetration of the 
guest uito the P-cyclodextrin cavity as well as the structure of the complex were established using ROESY spectroscopy. 
Keywords: enalapril maleate; P-cyclodextrin; NMR spectroscopy. 
INTRODUCTION 
Enalapril maleate and its analogs are highly effective 
aniihypcricnsivc agents which act as angiotensin converting enzyme 
(ACE) inhibitors. ACE inhibitors prevent conversion of angiotensin 
1 lo 11 and act to widen the blood vessels resulting in easier pumping 
of blood by the heart. They are, Ihercfore, used for the treatment of 
hypertension, congestive heart failure and to alleviate strain on heart 
damaged by heart attack'-. The solubility of enalapril maleate in 
water is poor bul it is highly soluble in methanol. 
The study of inclusion complex of pharmaceuticals with 
cyclodcxlrins (CDs) is a subject of great interest. Stjch studies 
involve siruciure determination of the complex besides the 
energetics of the complex formation. CDs are doughnut shaped 
molecules composed of 6, 7 or 8 a-D-glueose units, linked through 
o;-l.4 bonds, called a. f> and y-CD, respectively. The primary 
hydroxyl groups are located at the narrow rim while wider rim is 
lined with secondary hydroxyl groups. The exterior of the CDs is 
fairly hydrophilie due to the presence of hydroxyl groups while 
CD cavity is relatively hydrophobic. By virtue of their shtipe and 
hydrophobic nature of cavity, CDs accommodate a variety of 
liydn>phobic molecules, or part of it, inside their cavity through 
non-covalcnt interaclions to form inclusion complexes'. 
Inclusion of the guest into the CD cavity results in altered 
physico-chemical properties of the guest like water .solubility, 
bioavailabilly. stability and volatility etc-". The majority of drug 
molecules arc poorly water soluble and their biological absorption 
is. consequently, slow and far from being complete. Most drug 
molecules are ideal guests for CDs because their polarity, sizx 
:iiul siructuic enable Ihcm to penetrate into the cavity. Moreover, 
ihc inclusion complexes of pharmaceutical compounds with CDs 
have several desirable properties. This is the reason why major 
(lorlion (if CD rclalcd studies is dedicated lo pharmaceutical 
• '^-nuill: sinasiiiioodali(gJvaho(.).ct)in 
applications. A variety of techniques are u.sed, for charaeteri7ation 
of inclusion coinplexes in terms of geometry and configurational 
preferences, of which solid state and high resolution KMR 
spectroscopy are tnost important\ 
The formation of inclusion complex results in the shift changes 
in resonances of both the CDs and the guest protons'. The magni-
tude of A 5 is a critical function of position of proton in the molecule. 
size of CD cavity as well as host/guest ratio. In general, the inclusion 
of an aromatic ligand into the CD cavity causes major upfield shifts 
in the H-3' and H-5" of CD, situated inside the eaviiy, which is 
attributed to the ring current effect of the aromatic ring. The protons 
located outside cavity show negligible or trivial changes. Conirary 
to the upfield shift changes experienced by the CD protons, situated 
inside the cavity as a result of complexation, all the guest protons. 
and not only those included inside the CD cavity, generally show 
downfield shift changes upon complexation. This has been 
attributed, besides the shielding effect of the cavity, lo other faciors 
like changes in the microenvironment or conformational changes' 
The preferred mode of penetration of guest into the cavity is iroiii 
vv'ider rim side bul complexes in which the entry of the guest lakes 
place from nanower rim side are also known*. 
Siinple 'H NMR titration studies between CDs and the guest 
confirmed the formation of inclusion complex. Moreover, valuable 
information regarding mode of penetration of guest into CD cavity. 
i.e. from narrower or wider rim side, stoichiometry and stability of the 
complex can be obtained by the treatment of 'H NMR titration data' 
Advanced 2D NMR techniques like NOESY and ROESY prove vciy 
helpful in unambiguous assignment of structure of the complex. 
In continuation of our work on the NMR studies of inclusion 
complexes of pharmaceutical compounds with P-CD'"", we report 
herein our results on the study of complexation of enalapril malctitc 
with P-CD in solution by NMR spectroscopy. 
EXPFKIMKNTAL PART 
Enalapril maleate was obtained from Nebula Health Care Ltd. 
India, while P-CD was obtained from Cercster, Belgium, and these 
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were used witliout further purification. 'H NMR spectra were 
recorded on a JEOL 400 MHz instrument in D,0 at 25 "C. The 'H 
NMR measurements were carried out with 4 s relaxation delay. 
0.73275969 Hz resolution and 16384 data points. 2D ROESY 
measurements were inade with the experimental conditions as 
follows: scans 32, acquisition time 0.1470 s, pulse delay 2.3530 s 
and data points 512. The concentration of p-CD was kept constant 
at 10 niM while the concentration of enalapril maleatc was varied 
from 11.4 to 52.6 inM. The H/G molar ratios were calculated by 
direct integration of appropriate signals. The chemical shift values, 
reported in 5 (ppm). were calculated with reference to HDO peak 
at 4.7846. 
RESULTS .\ND DISCUSSION 
Two diaslereomeric forms, (,S.SS)- and (RSS)-. of enalapril 
maleaic. chemically known as I-lN-|(S)-l-cthoxycarbonyl-3-
lJheiiylpi'opyl]-L-alanyl-L-proline maleale, are known of which 
only (S.SS)-diastereoiiier is used as drug". 'H NMR spectra of 
enalapril maleate (SSS-diastereomer), in the absence as well as 
III the presence of (3-CD, showed that two geometrical isomers 
are in equilibnuin in solution, Cis-trans isomerism is possible 
111 ihe case of enalapril maleale due to hindered rotation along 
amide bond''. The spectral assignment for the iriajor (A) and 
minor (B) isomers was made with the help of COSY spectrum. 
The chemical shift data of the studied protons for pure enalapril 
maleale and enalapril maleate-P-CD mixtures is given in Table 
1. The signals for the protons of three methylenic groups, for 
two isomers, at C-8, 17, 18 were found resonating as multiplets 
centered at 2.2700 (3H^+4H,^). 1.9600 (3H^+IH^) and 1.7200 
(IH ). The signal for H -19 was observed resonating at 3.5328 
in the case of pure enalapril maleate. In the presence of P CD, 
this signal merged with P-CD protons and, therefore, its chemical 
shift changes could not be determined. The structures for the 
two isomers could be established by comparative study of the 
H-13, 14 and 16 signals. The inajor isomer was assigned structure 
(A) since H-13 and 14, being in close proxitnity of oxygen of -
COOH group should appear downfield compared to signals for 
the same protons of the minor isomer (B) which is in good 
agreement with earlier observation". As expected, the signal 
for H-16 for major isomer (A) appears relatively upfield 
compared to that of minor isomer 
- i c o n 
A: I;nalapril in<ile!ilc (Miijcr) B: linalapril in.ilratc (Mn 
As expected, changes in the shapes as well as chemical shifts 
of enalapril maleate protons were observed in the presence of p-
CD. All the protons, except H-11, exhibited downfield shift changes 
The highfield shift in the H-l I signal may be due to hydrogen 
bonding between the hydrogen of the rim hydroxy! and -COOC.IT 
group. The signal for H-l 1, which appeared as a quartet al 4.2321 
in the spectrum of pure enalapril maleate, became complex in the 
presence of P-CD making it diiTicult to calculate chemical shift 
changes. The A5 values for all the studied protons of the enalapril 
maleate are given in Table I. 
Table I. 'H NMf^  (400 MHz) Chemical shift (5, ppm) data for Enalapril maleatc (G) and chemical shift change (A5) values for the studied 
protons of Enalapril maleatc in the presence of P-cyclodextrin (H) in D,0 
Proton [G] [H]/[G]=0.875 
0,0092 
0.0183 
0.0302 
0.0275 
0,0700 
0.0300 
0.0530 
0.0608 
# 
0.0360 
0.(M36 
0.0130 
0.0250 
0.0140 
IH)/IG]=0.750 
0.0110 
0.0202 
0.0284 
0.0257 
0.0620 
0.0200 
0.0476 
0,0517 
0.0290 
0.0333 
0.0300 
0.0100 
0.0200 
0,0140 
[H]/[G]=0.560 
0.0110 
0.0202 
0.0247 
0.0232 
0.0500 
0.0150 
0.0421 
0.0462 
0.0250 
0.0296 
0.0280 
0.0080 
0.0150 
0.0100 
[H]/[G]=0.335 
0.0128 
0.0202 
0.0229 
0.0211 
0.0450 
0.0100 
0.0312 
0.0388 
0.0220 
0.0280 
0.0262 
0.0050 
0.0120 
0.0090 
[H]/[G]=0.190 
0.0092 
0.0147 
0.0174 
0.0156 
0.0350 
0.0020 
0.0310 
0.0278 
0.0170 
0.0220 
0.0230 
0.0015 
0.0080 
0.0040 
H,-I2 
H„-I2 
H„-I4 
H^-14 
H.,r7 
H„-I9 
H„-9 
H,-9 
H„-I3 
H,-I3 
H^-16 
ll„-16 
H,„-2,4,6 
H.,,-3,5 
1.2490 
1.2490 
1.4910 
1.5368 
2.7600 
3.4000 
3.8700 
3.9100 
4.0380 
4.2620 
4.3800 
4.4200 
7.2550 
7.3360 
#could not be determined. 
Tabic 2. 'H N.MR (400 MHz) cheinical shift change (A5) values for p-cyclodextrin protons in the presence of Enalapril maleate in D,0 
A/B' 
73:27 
60:40 
61:39 
S')-4] 
64:36 
fHl/fGl 
0.875 
0.750 
0.560 
().33.'i 
0.190 
H-r 
-0.0055 
-0.0073 
-0.0091 
-0.0128 
-0.0201 
H-2' 
O.OWG 
0.0064 
0.0046 
0.0046 
0.0037 
H-3' 
-0.0402 
-0.0403 
-0.0439 
-0.0567 
-0.0751 
H-4' 
-0.0019 
-0.0037 
-0.0055 
-0.0092 
-0.0147 
H-5' 
-0.0730 
-0.0738 
-0.0798 
-0.0998 
-0.1428 
H-6' 
•0.0073 
-0.0091 
-0.012S 
-0.0183 
-0.0311 
#cis / nans ratio of enalapril maleale. Negative values indicate high field shift. 
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,^.^. "-<^' [H]/[G) = 
A [H]/[G] = 
A (H]/[G1 = 
(\ (H1/1G] = 
A [Hl/[61 = 
H-3- " - « ' . , [Hi 
1 1 1 1 ••• 
3.9 38 
0.190 _ H-4' 
0.335 
0.560 
0.750 
0.875 
1 
37 
_/OA_MJ, 
J\P\J^Ay^ 
_MJ^KJ^ 
y^>vVU 
H-2' 
^ H-4' 
1 1 < 1 
3.6 3.5 
/•Vgnrc /. f'liriiiil 'H ,\'.MR {4011 MHzl .\i>eclia .Ji«in/i,!; sifiimis for the protons 
of ji-CI) (Hj in lite ahseua' as well as in the pri'sence of varying amounts of 
rnalapril nmleatf IGf Note the lari;e upfield shifts of H-.Vand H-5' in sharp 
((intr<i.\t to the .\t//all shift chan.i^es oh.serxcd for H-2 '. H'4' and H'6' 
'H N'MR bpectra of |3-CD in the presence of enalapril maleale 
displayed significant iiighlleld shift changes in the signal for H-3' 
and li"5' while the peaks lor other protons showed negligible A8. 
The A8 data for all the P-CD protons compared to pure p-CD has 
been given in Table 2, The progressive upfield shift of H-3' and H-
.5' resonances in the presence of varying amounts of enalapril 
maleate are shown in Figure 1 which shows the part of the 'H NMR 
spectra containing (.i-CD signals. 
0,06 
^0.12 
H-5' 
0 2 0,1 0 6 oe 
[(t~CU]/ (Enalapril maleate] 
1,0 
The upfield shifts observed for the signals of H-3' and H-5\ 
situated inside the (3-CD cavity, and concomitant downficid shift 
changes for enalapril maleate protons in the 'H NMR spectra of 
mixtures of enalapril maleate and P-CD are a clear indication of 
complexation between enalapril maleate and P-CD, in analogy to 
previous studies'''. Furthermore, the magnitude of shift changes 
of these P-CD protons increased with the increase in the 
concentration of enalapril inaleate. The stoichiomctry of the 
complex was determined by mole ratio method'''. The plot &&f,, 
vs H/G (Figure 2) shows flattening of the slop of the curve at a 
molar ratio of around 0.5 suggesting a 1:2 stoichiomctry for the 
P-CD-enalapril maleale complex. 
uL lL.IL.,_...,.,...i 
H-17(IS>'H-3'-^-
II.3,5m-5'-. 
•~m^ 
H-2.4,6/H-5' 
Finnic 2. Mole ratio plot of eheinieat shift ehanae for H-5' lASi^^) of fi-CD 
cluriii!^ titration with enalapril maleate 
figure .). 21) ROESY spectriun (400 MHz) oj mi.mue oj li-CD (Hj and 
enalapril maleate jGI (IHI/IGI=0.H07). The marked cross peaks support 
.structure for 1:2 fi-CD enalapril maleate complex 
ROESY" spectrum (Figure 3) was recorded for a mixture of 
enalapril maleate and P-CD (H/G=0.807) to study the mode of 
penetration of two guest molecules into a P-CD cavitv 
Intermolecular cross peaks observed between the aromatic 
protons of the guest and W-5' of P-CD and no cross peaks 
observed between the aromatic protons and H-3' confirm the 
shallow penetration of the aromatic ring into the p-CD cavit\ 
from narrower rim side". Moreover, Cross peak between H-19 
and H-2, 4, 6 of enalapril maleate confirmed that aromatic ring 
of one guest molecule and 5-nicmbered ring of another molecule 
share the same p-CD cavity which is in agreement with the 1:2 
host:guest stoichiomctry of the complex. Cross peak between 
H-17 (18) and H-3' was also observed which confirms thai .^  
membered ring enters the p-CD cavity from wider rim side. Fi-
gure 4 shows an expanded region of the ROESY spectrum 
containing cross peaks between the P-CD and enalapril maleaio 
protons. The proposed structure for the I ;2 P-CD-enalapnl 
maleate complex is shown in Figure ."5. 
It is important to mention here that though the cis-trans ratio 
for enalapril maleale, as determined I'rom the integration ol 14-
CH, doublet, reinained alinosi unchanged, in the presence ol P-
CD, in four samples. However, there was a significant change 
observed in one of the sample (Table 2). This can only be explaincil 
in terms of catalysis by the P-CD. However, this needs further 
investigation. 
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H-18/H-5-
H-I7(l8)/H-3-
H-l8/lt-!9 
H-2,4,6/H-i- H-2,4.6/H-19 
H-3,S/H-5- ^ «=/ 
1 1 1 -—1 r 
4 
I 1 ( 1 
fii^lire 4. ExpauMun of pan 2D ROESY speclntin xhuwinf; cro.sspcakx hctwee 
I'lialapiH inalcan' and [3-CD 
fij^iirc 5. frapoM'tt \[ru( ILitc for 1:2 l}-cvclotle\lrin-c'iiulapril mali'Mte 
ininpl<'\ 
CONCLUSION 
Enabpril maleale, which exists in two geometrical forms in 
solution, forms a I: 2 host-guest inclusion complex with P-CD in 
the concentration range studied. The aromatic ring of one guest 
molecule enters the (3-CD cavity from narrower rim side while .5-
membered ring penetrates through wider rim side as evidenced by 
ROESY spectrum. The structure for the complex has been proposed. 
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Abstract The inclusion complexes of fi-CD and parec-
oxib [PRB] in aqueous solution were investigated using ' H 
NMR spectroscopic study revealed the existence of four 
different equilibria for 1:1 inclusion complexes in which 
both the aromatic rings of the guest are tightly held by the 
host cavity. The NMR spectra of the PRB studied in the 
presence of ^-CD are fully assigned and interpreted by 
means of COSY spectrum for the unambiguous assignment 
of guest aromatic ring protons. The parallel interpretation 
of fi-CD chemical shift changes and dipolar contacts, with 
the aid of 2D ROESY, allows the mode of binding to be 
established for four possible structures of 1:1 PRB-/3-CD 
inclusion complexes. 
Keywords /i-cyclodextrin • Parecoxib • Host-guest 
interaction • NMR spectroscopy 
Introduction 
Traditionally oral non-steroidal anti-inflammatory drugs 
(NSAIDs) are used to treat mild to moderate acute pain. 
This is problematic, however, when the patients are unable 
to take oral medication or are nauseous and vomiting. 
Parecoxib (parecoxib sodium, PRB), a non-steroidal anti-
inflammatory drug, is the first selective cyciooxygenase-2 
inhibitor administered as an intramuscular or intravenous 
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injection for short-term management of post-operative 
pain. It is an attractive alternative to parenteral ketorolac 
because of the fewer gastrointestinal events [1], 
The solubility of poorly water-soluble drugs can be al-
tered in many ways, such as modification of drug crystal 
forms or addition of co-solvents, surfactants and cyclo-
dextrins (CDs), etc. CDs are of great interest in the area of 
pharmaceuticals because complexation of a pharmaceutical 
compound with CDs results in, besides improved water 
solubility [2], various altered desirable properties like in-
creased stability [3], dissolution rate [4] and bioavailability 
[5] and reduced volatility and masking of some undesirable 
properties of the drug like unpleasant odor and taste [6], 
That stimulated a great deal of research towards the syn-
thesis and characterization of CD inclusion complexes. 
CDs can be visualized as toroidal, hollow, truncated 
cones, containing a relatively hydrophobic central cavity 
and hydrophilic outer surface. Due to their characteristic 
architecture, CDs have an ability to recognize and embrace 
a variety of molecules into their cavity to form host-guest 
complexes [7]. The hydrophobic guest or the hydrophobic 
part of the guest molecule is held by the CD-cavity by non-
covalent interactions while the polar part of the guest 
protrudes outside the cavity. The guest generally enters the 
cavity from wider side of the rim and the size and shape of 
the host cavity, in combination with the size of the guest, 
are major determinants for the formation of the CD-
inclusion complexes [7, 8]. 
A variety of techniques are available to observe host/ 
guest interactions depending on the applications envisaged 
for the complex [9]. NMR spectroscopy is, however, one of 
the most reliable techniques for studying the CD inclusion 
complexes [10]. Evidence for incorporation of guest into 
the CD-hydrophobic cavity is easily obtained by simple ' H 
NMR experiments. ' H NMR spectra of mixtures of CD and 
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guest molecule exhibit chemical shift changes for both CD 
as well as guest protons [11], Changes in the chemical shift 
of CD cavity protons, H-3' and H-5', are indicative of 
internalization of the guest or part of the guest molecule 
into the CD cavity thus confirming the formation of an 
inclusion complex [12, 13]. A deeper insight into the ste-
reochemical features of the inclusion complex can be ob-
tained by means of 2D ROESY spectroscopy. The 
observability of intermolecular NOEs between inner cavity 
protons (H-3' and H-5') of [i~CD and guest molecules give 
a direct evidence that the guest has entered inside the 
cavity of the CD [14] since NOE cross peaks are observed 
between the protons that are closer than 0.4 nm in space in 
ROESY spectrum. The relative intensities of these cross 
peaks depend on the spaces between the corresponding 
protons. 
In continuation of our work on the preparation and 
characterization of CD inclusion complexes of pharma-
ceutical compounds in aqueous solution [15, 16], we report 
here our results on the complexation behavior of parecoxib 
with /?-CD using ' H N M R ( ' H , COSY and ROESY) 
spectroscopy. 
Experimental 
' H NMR spectra were recorded on a Bruker 400 MHz 
instrument while COSY and ROESY experiments were 
performed on a Bruker 800 MHz instrument for a mixture 
of parecoxib and [1-CD ([/i-CD]/[PRB] = 0.625). All the 
spectra were recorded in D2O at room temperature without 
adding any external reference and the chemical shift values 
{()) are reported in ppm. HDO proton signal at 4.790 was 
used as an internal reference throughout this work. To 
determine the stoichiometry and the overall binding con-
stant, ' H NMR spectra of four mixtures of parecoxib and /?-
CD, were recorded by keeping the concentration of PRB 
constant at 8.4 mM while the concentration of /?-CD was 
varied from 3.9 to 11.7 mM. The molar ratios ([/i-CD]/ 
[PRB]), ranging from 0.42-1.15 were calculated by direct 
integration of appropriate signals. No distinct peaks were 
observed for bound and free form of PRB and /?-CD 
indicating a fast equilibrium on the NMR time scale. 
Results and discussion 
'H NMR spectrum of pure parecoxib exhibited a pair of 
interacting doublets at 7.721 (,/= 8.5 Hz) and 7.274 
(,/ = 9.0 Hz), each integrating for two protons, which were 
assigned to H-3, 5 and H-4, 6 of p-substituted aromatic 
ring, respectively. The signal for H-10 of phenyl ring 
ohscrvcil as a nuilliplel al 7.403 (1H, ni, H-10) while 
signals for remaining phenyl ring protons appeared merged 
in the region 7.303-7.400. A singlet at 2.387, for three 
protons, was due to methyl group of the heterocyclic ring 
(H-7). The ethyl group protons were observed as a quartet 
at 2.089 (2H, J = 7.5 Hz, CH2) and a triplet at 0.911 (3H, 
J = 8.0 Hz, CH3). Distinction between the signals for two 
aromatic rings of PRB could be determined with the help of 
COSY experiment. Figure 1 showing a pair of cross con-
nections for two separate doublets at 7.332 and 7.859 were 
confirmed for disubstituted aromatic ring. Whereas, the 
remaining cross peaks were determined for phenyl ring 
protons but due to some ambiguity their assignments could 
not be made (Fig. 1). 
Prominent changes in the nature and position of signals 
for most of the protons of parecoxib were observed in the 
presence of ^-CD, which increased with the increasing 
concentration of [i-CD. The signals for the protons of both 
the phenyl and p-substituted aromatic rings exhibited 
downfield shift changes. The chemical shift changes for 
aliphatic protons were also observed but these were found 
not to be affected by the change in the concentration of /J-
CD. Part of spectra exhibiting aromatic proton signals of 
parecoxib, in the absence as well as in the presence of ft-
CD, are shown in Fig. 2, while chemical shift change (AS) 
data for parecoxib protons is given in Table 1. 
All the [S-CD protons displayed chemical shift changes 
in the presence of parecoxib. The Fig. 3 shows the spectral 
region containing j8-CD protons for pure /?-CD as well as 
mixture of ^-CD and PRB. Significant chemical shift 
t 
^ 
H-3,5/H-4,6 
0 t 
7.i 7.6 7.5 7.4 
-7.8 
D, 
7.3 -
Fig. 1 A partial 800 MHz COSY .spectrum of parecoxib-/i-CD H/l-
CD1/[PRB1 = 0.62.S) inclusion complex in DjO at 25 °C showing 
distinction between the cross peaks of two aromatic ring protons ot 
the parecoxib 
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H-Ph 
l ^ H - 4 , 6 
[P-CD]/[PRB]=1.10 
[P-CD]/[PRB]=0.88 
[P-CD]/[PRB]=0.42 
[PRB] H-3,5 
7,7 1^ 7.5 
1 ^ 
7.4 7.3 
Fig. 2 Partial 400 MHz 'H NMR spectra for parecoxib in the 
absence and presence of /i-cyclodextrin, in D2O at 25 °C 
changes for the proton.s po.sitioned inside the cavity, 
namely H-3' and H-5', and the protons located near the 
narrow rim (H-6') were observed in the presence of PRB. 
The protons situated near the wider rim, H-2' and H-4', 
showed only insignificant chemical shift changes in the 
presence of PRB. Moreover, the chemical shift change for 
H-5' was more pronounced compared to H-3'. 
/i-CD is a truncated right cylindrical cone shaped mole-
cule, 7.9 X 10"* cm high, with a hollow tapered cavity 
whose top and bottom dimensions are 6.5 x 10"* and 
6.8 X 10"* cm [7]. On internalization of a guest, ^-CD 
cavity protons show upfield chemical shift changes. On the 
other hand, all the guest protons generally experience 
downfield shift changes. The.se shift changes are attributed 
to the anisotropic ring current effect of the aromatic guest. 
H-2' H-4V 
P!W\ 
4.0 3.9 3.8 3.7 3.6 
[P-CD]/[PRB]=l.iO 
H-3' 
4.0 IV 3.8 3.7 3.6 
Fig. 3 A part of 'H NMR spectra of /i-cyclodextrin (400 MHz), 
showing the changes in chemical shift for -^cyclodextrin protons on 
interaction with parecoxib 
Moreover, information regarding the mode of penetration of 
the guest into the cavity, i.e. from narrower or wider rim 
side, can be obtained from these shift changes. A typical 
interference is that Af^ n-s- > AS^^.y if the guest enters the 
cavity from narrower side and vice versa [11] but there are 
exceptions and these conclusions can only be drawn when 
only one complex is formed while in cases where multiple 
equilibria exist these shift changes can only be used as an 
evidence for the formation of inclusion complexes. The 
observed shift changes in the /J-CD cavity protons, and the 
concomitant chemical shift changes in the PRB proton sig-
nals, in the spectra of mixtures of ^-CD and PRB, compared 
to pure components, is a clear indication of inclusion of 
some part of the guest into the ^-CD cavity and thus con-
firming the formation of/9-CD-PRB inclusion complex/es. 
The determination of stoichiometry of the complex is 
the first step for any structural studies of the inclusion 
Tabic 1 'H NMR (400 MHz) chemical shift (d, ppm) data for parecoxib and chemical shift change (A(5) values for the studied protons of 
parecoxib in the presence of /i-cyclodextrin in D2O at 25 °C 
Protons [PRB] [/i-CD]/[PRB] =1.15 [/(-CD]/[PRB] = 1.10 
0.110 
0.071 
0.046 
0.049 
0.060 
0.055 
[/(-CD]/[PRB] 
0.100 
0.068 
0.050 
0,049 
0.062 
0.056 
= 0.88 [/(-CD]/[PRB] 
0.076 
0.034 
0.003 
0.023 
0.067 
0.060 
:0 ,42 
H-3,5 
H-iO 
11-4,6 
H-7 
H-2 
HI 
7,721 
7.403 
7.274 
2,3S7 
2,089 
0,911 
0,116 
0.071 
0.043 
0,048 
0,063 
0,058 
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complexes, which was achieved by Hanna-Ashbaugh 
method [17-19]. 
1/A.5 = l / ( / faA5max[H]o) + 1/A.5„,ax 
In the Hanna-Ashbaugh equation A5 is the observed 
chemical shift difference for a given [H]o concentration, 
Ai^ max is the chemical shift difference between a pure 
sample of complex and the free component, K^ is the 
binding constant and [H]o is the initial concentration of the 
host. ' H N M R spectra of several mixtures of PRB and ^-
CD were recorded by keeping the concentration of PRB 
constant and varying the concentration of fl-CD. The ' H 
NMR chemical shift change data was obtained for PRB. 
The double reciprocal plot was obtained for H-3, 5 by 
plotting A<5H.:I,5 against [H]o in the form of 1/A<5 versus 1/ 
[H]o which gave a straight line, with a slope l/K.^A5mM = 
26.50938 mM ppm"' and intercept l/AS^^^^ = 6.30737 ppm"' 
(Fig. 4), confirming the 1:1 stoichiometry for the PRB-
/i-CD complex. The overall binding constant (A!„) of the 
complex/es was determined to be 238 M' ' . The binding 
constant was also calculated by Scott's method which 
comes out to be 252 M' ' . 
To ascertain the involvement of two aromatic rings in 
the complexation, a ROESY experiment was performed on 
a mixture of ji-CD and PRB. A set of cross peaks connects 
both the H-5' and H-3' of jS-CD to both the aromatic ring 
protons (Fig. 5), taking into account the 1:1 stoichiometry 
of the complex, indicates that four different equilibria may 
exist in solution (Scheme 1). The presence of strong cross 
peaks between /i-CD inner cavity protons with both the 
guest aromatic ring protons confirmed that both the rings 
are involved in complexation. The presence of multiple 
equilibria for PRB-/i-CD inclusion complexes in solution 
has been suggested due to the significant intermolecular 
14.0-
13.OH 
12.0-
11.0-
10.0-
9.00-
8.00' 
CO 
<3 
H-3.5 
0.08 0.12 
~[—'—\—' r-
0.16 0.20 0.24 
l/[H]omM"' 
Fig. 4 lllustiation of the Bencsi-Hildebraiid data ucatment gives 
A", = 23iS M"' for 1:1 parecoxib-/i-CD complex 
H-I 
H-3,5 
H-6'-
(ppm) v\V"-^  "-^ . w 
H-5' 
/H-2 ' 
>H-4-
Fig. 5 A partial 800 MHz 2D ROESY spectrum of parecoxib-/y-CD 
([/(-CD]/[PRB] = 0.625) inclusion complex in D2O at 25 °C with 
mixing time of 500 ms, indicating the dipolar contacts between 
protons of the parecoxib and protons of -^CD 
interactions between both the aromatic rings with [i-CD 
inner cavity protons (H-3', H-5' and H-6') (Fig. 5). Several 
topologies may arise for each aromatic ring because entry 
may occur through either the wider or narrower rim of ft-
CD and penetration may be either shallow or deep. NOE 
peaks confirm four binding Modes of PRB with host cavity 
in which the mono- and di-substituted guest aromatic rings 
may enter either from primary or secondary hydroxyl side 
and penetrate deep. Therefore, four possible modes of 
inclusion equilibria have been suggested on the basis of our 
findings i.e. cross peaks with all of ^-CD cavity protons. A 
schematic representation of the inclusion equilibria is 
showing plausible structure of all the four 1:1 PRB-/J-CD 
inclusion complexes (Scheme 1). 
Conclusions 
The detailed ' H NMR spectro.scopy .study of parecoxib in 
the presence as well absence of fi-CD in solution confirmed 
multi-equilibria as the formation of four 1:1 inclusion 
complex, resulting by the penetration of both the aromatic 
ring into the fl-CD cavity from narrow as well as .secondary 
rim side, as evidenced by ROESY spectrum. The complexes 
including aromatic ring of the guest and CDs are general ly 
formed by the penetration of the guest from wider rim side 
[10] but there are cases reported where guest enters the 
cavity from both the sides [20, 21 ], which has been found in 
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J IncI Phenoin Macrocycl Chem 
Scheme 1 Supposed 
representation of all the four 
possible mode of penetrations 
for 1:1 inclusion complexes 
fonned between PRB and /(-CD 
system in solution 
1 2 I «^ / 
l]C HjC C NSO,—f 
Mode-ll Mode-IV ?"' 
the case of parec()xib-/i-CD complexes. The association 
constant (K.J of the complex was determined to be 238 M~'. 
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